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Executive Summary 
Background  
Supplementary prescribing was introduced in 2003 for nurses and pharmacists (and more recently for 
other health professionals). It allows suitably trained professionals to prescribe for patients in 
accordance with a Clinical Management Plan (CMP) following initial diagnosis by an independent 
medical prescriber and with the patient’s agreement. 
Aims 
This research aimed to explore how supplementary prescribing in nursing and pharmacy was working in 
practice in England. The objectives of the project were to evaluate barriers and facilitators to the 
implementation of supplementary prescribing, patient and professional experiences, prescribing 
practices and issues around the safety and costs of supplementary prescribing. 
Method 
The research consisted of 3 stages: in stage 1, a thematic review of published and ‘grey’ literatures, and 
interviews with key stakeholders involved in supplementary prescribing were undertaken; stage 2 
comprised an analysis of community and primary care nurse and pharmacist prescribing using PACT 
data (2004 – 2007) and a postal questionnaire survey of nurse (n=518) and pharmacist (n=411) 
supplementary prescribers; in stage 3, ten detailed case studies of supplementary prescribing practice 
in various settings were conducted, utilising observations, interviews and prescribing data. Research 
was undertaken from 2006 to 2008.   
Key findings  
Literature review: The literature review identified predominantly positive views and experiences of those 
involved in supplementary prescribing, although doctors and patients were perceived to lack awareness 
of supplementary prescribing. Implementation barrier included inadequate funding for training and 
support in practice, accessing medical records and information technology and difficulties using CMPs.  
Stakeholder interviews: Stakeholders broadly welcomed supplementary prescribing, identifying benefits 
for both patients and healthcare professionals, whilst also highlighting similar implementation barriers to 
those in the literature review. The safety of supplementary prescribing was not considered problematic. 
PACT analysis: Between 2004 to 2007 the volume (and cost) of nurse prescribing increased from 3.5 
million items (£52 million) in 2004 to 9.3 million items (£108 million) in 2007; for pharmacists, it 
increased from 2706 items (£25,000) in 2004 to 64,883 items (£637,000) in 2007. Nurse and pharmacist 
prescribing remains a small proportion of all community and primary care prescribing (1.2% for nurses, 
0.008% for pharmacists in 2007).  Dressings and appliance prescribing constituted the main area of 
nurse prescribing and pharmacist prescribing was predominantly for cardiovascular medicines.  
Questionnaire surveys: Reported current use of supplementary prescribing varied considerably between 
the two professions. Of nurses surveyed, 28% reported using supplementary prescribing, in community, 
GP practice and hospital settings, whilst 89% reported using independent prescribing. Of pharmacists 
surveyed, 51% reported using supplementary prescribing, in GP practice and hospital settings far more 
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than the community; in relation to independent prescribing, only 11% were trained but 33% were 
training and 52% intended to train. Prescribed items varied across the two professions although the 
reported volume of prescribing was similar for both. The majority of pharmacists prescribed 
cardiovascular medicines (60%), worked as supplementary prescribers for an average of 4 hours a 
week, saw an average of 15 patients on a recurring basis and issued an average of 4 prescriptions per 
week. Infections constituted the largest category for nurse supplementary prescribing (46%) and nurses 
worked as supplementary prescribers for an average of 10 hours a week, saw an average of 20 patients 
on a recurring basis and issued on average 6 prescriptions a week as supplementary prescribers. 
Nurses’ consultations lasted an average of 20 minutes, compared to an average of 18 minutes for 
pharmacists.  Prescribing training was viewed positively overall, but training needs varied between 
professions, contributing to mixed views about inter-professional courses; the period of learning in 
practice and designated medical practitioners (DMPs) were especially praised. Prescribing confidence 
and perceived competence were high in both professions, with least confidence being expressed about 
prescribing for patients with co-morbidities. Nurses and pharmacists reported requests by patients and 
colleagues to prescribe outside of their area of competence. Nurses and pharmacists were positive 
about the safety climate and culture in which they worked. Prescribing costs per patient consultation 
were similar for both professions (£7.02 for pharmacists, £6.50 for nurses), but costs for reviewing 
prescribing were significantly less for nurses (£2.87 and £6.65 per session respectively).  
Case Studies: Patients’ experiences of supplementary prescribing were positive overall, with nurses and 
pharmacists considered easier to talk to than doctors whilst also offering longer consultations. Patients 
lacked awareness and understanding of what supplementary prescribing and Clinical Management 
Plans (CMPs) entailed. Doctors’ experiences of supplementary prescribing were also positive, 
confirming their expectations that non-medical prescribing should be used in clinical niches, using what 
they referred to as ‘protocols’. They were more cautious about nurses and pharmacists undertaking a 
diagnostic role. Nurses and pharmacists were positive about their prescribing role, although some had 
reservations about CMPs and their supplementary prescribing training. Supplementary prescribing 
represented an innovation in working practice for many pharmacists but tended to formalise nurses’ 
existing practices. Analysis and observation of CMPs revealed differences in application and content: 
some CMPs were non-patient specific and some were signed retrospectively by doctors. Analysis of 
consultations revealed variations in length and the number of questions asked by both prescriber and 
patient. Doctors’ continued involvement in patient care was still evident with examples where 
prescribers sought the doctors' advice during consultations or referred patients on to doctors. Some 
prescribers could not offer patients signed prescriptions whilst others had to hand-write them, leading to 
delays in patients receiving prescriptions.  Assessment of the prescribing safety of 71 prescribed 
medicines revealed no prescribing errors, three assessments of inappropriate prescribing – two of which 
were for use of branded medicines - and transgressions involving CMPs in six case study sites, based 
on the majority view of assessors.  
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Lay Summary 
Supplementary prescribing means that health care staff other than doctors can now write prescriptions 
for patients. Before they can prescribe, health care staff have to do a training course and a doctor 
reviews their prescribing to make sure it is safe. Supplementary prescribers use something called a 
clinical management plan, which guides what medicines and treatments they give. This guide has to be 
agreed by a doctor and the patient needs to agree to this arrangement.  
Supplementary prescribing started in 2003 with nurses and pharmacists and now other health care staff 
can also prescribe as well.  It was introduced by the government to make it easier to get medicines and 
treatments and to better use the skills that health care staff have. Because supplementary prescribing is 
a new thing, the government asked for some research to be done to make sure it was working properly. 
This research looked at supplementary prescribing by nurses and pharmacists only, in England.  
Overall, the research found that nurses and pharmacists were generally happy with supplementary 
prescribing, although some found it hard to get started with prescribing. A lot of the nurses had now 
moved on to a new form of prescribing called independent prescribing and many pharmacists also 
wanted to do this. There were also some problems with computers and the technology used.  
Nurses' and pharmacists' prescribing was increasing, but was still very small compared to all the 
prescribing done in England mainly by doctors. Many nurses were prescribing things like dressings. 
Both nurses and pharmacists were prescribing for only a small part of the day usually. Both nurses and 
pharmacist said they had longer appointment times with patients and that patients generally liked this. 
Doctors were generally happy with nurses and pharmacists doing supplementary prescribing but 
weren’t sure about them going on to do independent prescribing, which means nurses and pharmacists 
can diagnose illness. The research also found that the guides that supplementary prescribers were 
supposed to be using were being used in slightly different ways than were intended, but overall, there 
were very few cases where they thought there were safety problems with what nurses and pharmacists 
were prescribing. The researchers found that patients were quite happy with nurses and pharmacists 
doing supplementary prescribing, but they didn’t know much about it. Looking over the work that they 
had done, the research team made some recommendations to improve how supplementary prescribing 
worked. These included making everyone more aware of nurse and pharmacist supplementary 
prescribing, reviewing the guidelines to make sure they are working properly and involving doctors more 
in the training of supplementary prescribers. We also recommended that more should be done to help 
supplementary prescribers make their own prescriptions and we think that a review is needed of some 
aspects of the prescribing training of nurses and pharmacists. Finally, although we found no problems 
with prescribing safety in this research, we think that research is needed to confirm this. 
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1 Introduction 
 
The delivery of medicines to patients through prescribing represents an integral aspect of modern 
healthcare, offering significant benefits in reducing morbidity and mortality, although at increasing cost 
to the healthcare budget. Throughout most of the twentieth century, doctors in the UK retained their 
status (alongside dentists) as the primary authorities able to prescribe. However, in response to 
demands to enhance access to medicines and to better utilise the skills of the health workforce, 
legislative changes were introduced to confer prescribing privileges upon professionals other than 
doctors, both in the UK and in other countries (Emmerton et al 2005). In the UK, this involved National 
Health Service (NHS) district nurse and health visitor prescribing from a limited list of medicines and 
appliances. More recently, suitably trained nurses, pharmacists and other allied health professionals1 
have been able to prescribe for patients from a wider list of medicines. The introduction of two key 
prescribing models have facilitated these changes in prescribing privileges and these are the 
introduction of supplementary prescribing in 2003 and nurse and pharmacist independent prescribing in 
2006 (Department of Health 2005, 2006).  
 
Supplementary prescribing represents a tripartite model of prescribing between doctor, prescriber and 
patient, with the doctor providing the initial diagnosis and the prescriber being given authority through a 
patient-specific clinical management plan (CMP), to prescribe medicines for that patient. Independent 
prescribing permits assessment and diagnosis of patients by non-medical prescribers, without a clinical 
management plan. Key to both forms of prescribing is the requirement that healthcare professionals 
must be suitably trained and prescribing within their clinical competencies. 
 
Whilst independent prescribing is presently permitted for only nurses and pharmacists, supplementary 
prescribing has been introduced for nurses, pharmacists and some allied health professionals and 
optometrists, and shares similarities with international models of prescribing, (sometimes referred to as 
collaborative or dependent prescribing) such as those in the USA (Emmerton et al 2005). It may be 
particularly suited to managing patients with chronic, long-term conditions and promises benefits 
including faster access to medicines for patients and better use of the skills of prescribers and doctors. 
Supplementary prescribing represents an innovative policy development in the NHS and may be 
expected to impact upon the UK healthcare system in terms of healthcare professionals and service 
users (Cooper et al In press), as well as other areas such as the cost and type of prescribing and issues 
such as salary and consultation times. The importance of patient safety in relation to medicines and 
prescribing also extends to supplementary prescribing.  
                                         
1 Chiropodists/podiatrists, radiographers, physiotherapists, optometrists 
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 Given the innovative nature of supplementary prescribing and the perceived impact that it may have, 
the Department of Health commissioned this study to evaluate supplementary prescribing in England by 
the two main professional groups who are presently prescribing - nurses and pharmacists - in relation to 
its implementation, practice and future challenges.  
 
The specific objectives of this study were to: 
 
§ Thematically review the literature relating to supplementary prescribing  
§ Explore the experiences and perceptions of key stakeholders about supplementary prescribing 
practice and training. 
§ Evaluate the overall prescribing of nurses and pharmacists in the primary care setting using 
PACT data. 
§ Evaluate the safety of nurse and pharmacist supplementary prescribing, by assessing 
prescribing safety (in relation to errors and violations), appropriateness and safety climate.  
§ Evaluate the cost of supplementary prescribing in relation to consultation times, salaries and 
training. 
§ Explore nurse and pharmacist prescribing consultations with patients. 
 
In the next chapter, the methods of the study are described, followed by further chapters describing the 
results of the study. Discussion and recommendation chapters then follow, with a glossary, references 
and appendices providing additional information. 
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2 Methods 
 
Based upon the objectives identified, this study was conceptually and logistically divided into three 
distinct but linked research stages. In the first stage, a thematic review of relevant supplementary 
prescribing literature was undertaken, together with interviews with key supplementary prescribing 
stakeholders, to explore current experiences and perceptions of supplementary prescribing and also to 
inform other aspects of the study such as questionnaires and interview schedules. In the second stage, 
two distinct areas of research were undertaken: an analysis of PACT data from 2004 to 2007, and two 
questionnaire surveys, of nurse and pharmacist supplementary prescribers respectively. In the third and 
final stage, a series of case studies was undertaken, to observe supplementary prescribing practice, 
interview prescribers, doctors and patients and collect data relating to actual prescribing, and to assess 
safety and cost factors. In the remainder of this chapter, details of the methods for each stage are 
provided.  
 
2.1 Stage One: Literature reviews and stakeholder scoping study 
 
2.1.1 Literature search 
A thematic literature review was undertaken to explore both empirical pharmacist and nurse 
supplementary prescribing research and also opinion and commentary and the grey literature relating to 
supplementary prescribing. The reason for including such potentially diverse literatures was due mainly 
to supplementary prescribing being a relatively recent development with an associated lack of empirical 
research, as other reviews have identified in relation to pharmacy (Tonna et al 2007) and nurse non-
medical prescribing (Latter and Courtenay 2004). Hence, a thematic rather than systematic review was 
considered most appropriate and including grey literature offered the opportunity not only of identifying 
research that would not otherwise be found (such as from conferences, non-peer reviewed publications 
and commissioned and policy documents) but also of considering more broadly how supplementary 
prescribing is perceived from the perspectives of the nursing, pharmacy and medical professions. 
Searches were made of that literature from 1997 to 2007 using combinations of the following keywords: 
‘supplementary prescriber’, ‘supplementary prescribing’, ‘nurs* and prescrib*’, ‘pharmac* and prescrib*’.  
These search criteria were used to allow for the inclusion of papers on non-medical prescribing more 
generally if these were relevant to supplementary prescribing, especially since the IESP status of many 
UK nurses means that research may have been undertaken using such nurse samples without specific 
reference to supplementary prescribing. Although supplementary prescribing was only introduced in 
2003, the earlier search date was used to allow for early consultation or policy documents or reflection 
on the proposed use of supplementary prescribing. Exclusion criteria included papers relating to specific 
but non-supplementary forms of prescribing, such as patient group directions and independent 
prescribing (e.g. Harris et al 2004). The following electronic databases were searched: MEDLINE, 
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EMBASE, CINAHL, ISI Web of Knowledge and Zetoc. In addition, on-line searches of The 
Pharmaceutical Journal, International Journal of Pharmacy Practice, Journal of Clinical Nursing, Journal 
of Advanced Nursing, Nurse Prescriber, Nursing Times and Department of Health websites were made.  
 
2.1.2 Stakeholder Scoping Study 
In order to scope the range of issues pertinent to the implementation of supplementary prescribing in 
nursing and pharmacy, interviews with key stakeholders were conducted. Using purposive sampling, 52 
individuals or organisations were initially approached to reflect key stakeholder groups and from these, 
43 individual stakeholders were subsequently interviewed during 2006 (appendix B). These 
stakeholders were identified primary through contacts of the authors, in terms of their involvement 
currently or previously in the training, research, practice and implementation of supplementary 
prescribing in both primary (community and general medical practice) and secondary (hospital) care 
settings. Insights from patient groups and the nursing, pharmacy and medical professions were also 
considered desirable, and recruitment of stakeholders from appropriate organisations was also 
undertaken, again using contacts of the authors. In several cases, stakeholders were no longer directly 
involved in supplementary prescribing, but were recruited based upon their previous experience of 
supplementary prescribing. Qualitative, semi-structured interviews were undertaken mainly by 
telephone, as this overcame the problems of interviewing a relatively large number of interviewees 
across many locations in the UK, in the relatively short time-scale permitted.  Although such interviews 
may lead to less interaction and rapport, this was not considered an issue in this research. A small 
number of interviews, however, were conducted in person. An interview guide was developed, based 
upon the thematic literature review undertaken and discussions amongst the authors (Appendix B). 
Interviews varied in duration from 21 to 82 minutes with a mean of 42 minutes. 
 
One of the research team undertook framework analysis (King 1998) of transcribed interviews initially, 
using a coding frame based upon broad categories such as education, implementation, safety and cost. 
This method was used in part because of the relatively large number of participants involved and to 
make the initial stages of coding more manageable, yet open to refinement and revision (King 1998). A 
second researcher undertook additional open and axial coding, together with the process of constant 
comparison, with transcripts being re-read until all emergent themes had been coded.   
 
2.2 Stage Two: PACT analysis & survey of supplementary prescribers 
 
2.2.1 Analysis of PACT data for community and primary care prescribing 
Prescribing analysis and cost (PACT) data are routinely collected by the NHS Business Services 
Authority, Prescription Pricing Division (NHS BSA PPD) for all prescribers working in community and 
primary care in England. Data are collected at the level of individual prescribers and are aggregated to 
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provide information at a practice, SHA and national level. PACT data can provide information at the 
level of individual drugs through to therapeutic areas which broadly map to BNF chapters. PACT data 
were collected retrospectively from 2003 until December 2007. Data were provided at regional and 
national (England) level. The regional data correspond to Strategic Health Authority boundaries and the 
data supplied reflected boundaries changes in 2006. Data were also provided within therapeutic areas 
which broadly map to BNF chapter and subchapter level. Data on both the number of items prescribed 
(volume) and the net ingredient cost (NIC) of items were supplied. Supplemental data and statistical 
analysis was also obtained from the Prescribing Support Unit and NHS Business Services Authority 
reports and from the Royal Pharmaceutical Society of Great Britain (RPSGB). 
 
2.2.2 Questionnaire Survey of Nurse and Pharmacist supplementary prescribers 
A survey of nurse and pharmacist prescribers was undertaken in 2007 to explore issues relating to the 
demographic and role characteristics of supplementary prescribers, their prescribing practices and their 
views and experiences of supplementary prescribing. Data on costs and patient safety were also 
collected. A postal questionnaire was used for the survey (with minor modifications for each profession 
based on differences in qualifications between nurses and pharmacy). The design of the questionnaires 
was informed by findings from the scoping study and the literature reviews. The questionnaire included 
structured and semi-structured questions and an existing validated data collection tool, the Teamwork 
and Safety Climate Survey (University of Texas). The questionnaire was piloted with nurse and 
pharmacist colleagues and modified where necessary (see Appendix C). 
The method used to recruit respondents to the survey differed between nurses and pharmacists. For 
pharmacists, the Royal Pharmaceutical Society of Great Britain (RPSGB) provided labels with the 
names and contact details of all pharmacists registered with them as supplementary prescribers. The 
questionnaires were sent out in April 2007 with a covering letter, freepost envelope and information 
sheet. A follow up questionnaire was distributed to non-responders three weeks later.  
In relation to recruiting nurses, we initially sought (and received) approval to access the Nursing and 
Midwifery Council (NMC) register. This was subsequently withdrawn by the NMC because of data 
protection issues relating to their registration process. Accessing nurses through the employing Trust or 
PCT was considered, however this would have necessitated separate research governance applications 
for each participating Trust, which was considered likely to result in unacceptable delays to the project. 
Therefore, a decision was made to sample supplementary prescribing trained nurses via Higher 
Education Institutions (HEIs) where prescribing training was offered. All HEIs that had provided 
supplementary prescribing training courses for nurses were contacted and asked either if they would be 
prepared to distribute a questionnaire to nurses who had completed their supplementary prescriber 
training or if they would provide contact details. Approaches to HEIs were made via telephone, email 
and letter and any administration costs relating to recruitment and distribution were met. Where HEIs 
were willing to distribute questionnaires, they were sent a stamped envelope containing a letter, 
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information sheet, questionnaire and freepost envelope and they distributed them themselves. Ethical 
approval for the study, including a substantial amendment relating to the method of distribution of the 
nurse questionnaire, was obtained from Central Manchester MREC.  
 
Data from returned questionnaires were entered into SPSS 14 (quantitative) or Word (qualitative). 
Descriptive and inferential statistics were conducted using SPSS. c2 tests and Mann Whitney U Tests 
were carried out to test for the null hypothesis that there was no association between the professional 
group (nurse or pharmacist) and a number of key variables.  
 
Costs associated with supplementary prescribing were calculated per consultation (i.e. patient) and for 
prescribing review per session using nurses' and pharmacists' self-reported estimations in the survey 
and standard salary data from the Personal Social Services Research Unit Database (Curtis 2007). The 
data for the cost analysis were analysed using parametric (mean and standard deviation) and non-
parametric (median and IQ range) statistical methods. Due to the non-normal distribution of the data, 
non-parametric methods only (the Mann-Whitney U test) were used to assess for statistically significant 
differences in key cost variables between pharmacists and nurses. 
  
Qualitative questionnaire data were initially analysed separately for each profession. Open coding of all 
responses was performed and coding refined until all data were represented in coding categories. 
Codes and themes were then compared between professions to generate axial codes. Tabulation of 
qualitative responses was also undertaken to estimate the frequency of responses in order to 
complement but not replace the qualitative analysis and help identify key themes (Silverman 2001). 
 
2.3 Stage Three: Case studies  
 
2.3.1 Setting up case studies and recruitment  
Recruitment of supplementary prescribers 
Nurses and pharmacists who had completed questionnaires in the second stage of the study were 
asked to indicate whether they were interested in participating in case studies and, if so, to provide 
contact details. Nurses and pharmacists were then contacted by telephone to confirm prescribing status 
and volume of prescribing (both to ensure they were prescribing as supplementary rather than 
independent prescribers and that they were prescribing in sufficient volume to make the case study 
practically feasible). Employer information was collected to facilitate research governance approval to 
be sought. Snowball sampling was also used to recruit case study participants, whereby participating 
nurses and pharmacists were asked if they knew of other supplementary prescribers who may be 
interested in participating. Ethical review for this and all other aspects of the case studies was obtained 
from Leeds East MREC. 
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Recruitment of patients 
Supplementary prescribers identified patients attending a specific clinic or appointments on the day(s) 
that the case study was being undertaken. Letters, information sheets and consent forms were sent to 
these patients in advance, explaining that there would be a researcher present during their consultation, 
that the consultation would be recorded, that anonymised details of Clinical Management Plans (CMPs) 
and any medicines that were prescribed would be recorded and that they would be invited to complete a 
questionnaire which would also invite them to take part in a telephone interview. Patients could either 
return the consent form in advance or on the day of the consultation.  
 
Recruitment of independent prescribers 
Supplementary prescribers were asked to identify independent medical prescribers with whom they 
worked and forward a letter of invitation, information sheet and consent form asking them if they would 
consider participating in an interview.  
 
2.3.2 Data collection  
Observation of consultations 
Where patients consented, the attending researcher maintained detailed field notes of the consultations 
between supplementary prescribers and their patients. Full details of prescribed medicines were 
recorded, along with information relating to other current prescribed medicines and a copy of the CMP. 
On some occasions it was possible to visually inspect the actual prescription but to prevent delays and 
intrusions into the actual consultation, verbatim prescribing details were often collected post hoc. On 
several occasions, it was not possible to obtain a copy of the CMP, due to the electronic format of 
some, the lack of printing facilities or the use of ‘generic CMPs’ that were not patient specific in some 
sites. These issues are described in detail in the case study results chapter. 
 
Interviews with supplementary prescribers 
These were mainly undertaken face to face during the case study and after observing consultations, but 
a minority were subsequent telephone interviews. Interviews allowed the researcher to explore issues 
surrounding supplementary prescribing in more detail, to allow the researcher to question the prescriber 
about aspects of the observations and also to collect data for the analysis of costs. An interview 
question schedule was developed following discussion with the research team, and was informed by the 
literature review, the stakeholder study and the questionnaire data.  
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Interviews with independent prescribers 
Interviews were conducted either by telephone or at the case study site, again using an interview 
schedule that was informed by the literature and data collected in the study.  Questions sought to 
explore experiences and perceptions of supplementary, but also other forms of non-medical prescribing.  
 
Questionnaires and interviews with patients  
A questionnaire was developed to elicit information about patients’ experiences and perceptions of 
supplementary prescribing together with measures of their medicine adherence and information 
provision (the Medication Adherence Report Scale (University of Brighton) and the Satisfaction with 
Information about Medicines Scale (Horne 2001) respectively). Patients were also invited to provide 
contact details if they were willing to participate in an interview. The questionnaire was piloted and 
reviewed by several nurse and pharmacist prescribers. Patients received the questionnaire at the end of 
the observation and completed it at their convenience (a freepost envelope was provided). Patients 
willing to be interviewed were subsequently contacted and a telephone interview arranged and 
conducted. An interview schedule was developed following discussion and was again informed by the 
literature and data previously collected. In some case studies, it was also possible to interview patients 
after the consultation, with their consent. All interviews were recorded and consent was gained.  
 
2.3.3 Data analysis  
Analysis of prescribing safety and appropriateness 
Although prescribing safety is now widely recognised as an important policy and research concern 
(Barber 1995, Kohn et al 2000, Leap 1997, Wilson and Sheikh 2002), no explicit measure of the safety 
of prescribing has yet been developed. Following Reason's influential analysis as applied to healthcare 
(Reason 1990, 2000), a broader interpretation of safety that embraces prescribing culture, errors and 
intentional violations was utilised. Prescribing culture was addressed in the questionnaire survey, using 
the Texas instrument, whilst for errors, a definition advanced by Dean et al (2000) was used as a 
standard by which to analyse actual prescribing – this definition having being recognised in official 
publications relating to patient safety and prescribing (Department of Health 2003). Violations arise in 
different forms (Parker and Lawton 2006) but given the lack of an explicit measure in the literature, it 
was decided to focus upon transgressions relating to the CMP. Specifically, and based upon analysis of 
the stakeholder interviews and questionnaire survey data, transgressions relating to deviation from the 
standards required for CMPs were measured, in terms of whether a specific CMP had been developed 
for an individual patient and whether the prescribing was in accordance with the CMP.  
 
Prescribing appropriateness was assessed using the nine questions included in the Prescribing 
Appropriateness Index (PAI) measure developed by Cantrill, Sibbald and Buetow (1998). This was 
chosen over the Medication Appropriateness Index (MAI) developed by Hanlon et al (1992) since the 
 17 
PAI has been validated in the context of UK prescribing and also for long-term conditions, which 
supplementary prescribing would be expected to include. The prescribing data collected during case 
studies were entered onto specially designed spreadsheets to record exact details of the medicine 
prescribed, the dose, quantity and form. Details of other current medication were also recorded, as was 
additional information provided by the prescriber about their prescribing (following recognition that 
prescribing should include not merely pharmacological but social and personal factors, too (Cribb and 
Barber 1999). Analysis of prescribing was undertaken by an expert group consisting of four assessors 
from differing professional backgrounds (general practitioner/academia, pharmacology/nurse 
prescribing course lecturer, clinical pharmacy and community pharmacy). Each assessor was provided 
with details of all prescribing from the case studies, the CMP if available and any additional information 
observed in the consultations or provided by the supplementary prescriber. They were provided with 
assessment instructions and a checklist form (see Appendix D) which asked them to apply the PAI 
questions and assess whether any errors or CMP transgressions had occurred. For each act of 
prescribing, individual assessments based upon error, violation and appropriateness were obtained 
from each assessor. Assessors then discussed the cases to clarify individual assessments and report 
observations and a majority view (three or more assessors) on each prescribed medicine was reported. 
Prescribing appropriateness was assessed using nine indicators, with a negative assessment of any 
one indicator leading to an overall inappropriate score for that prescribed medicine.  
 
Analysis of consultations 
For each case study, a sample of consultations observed were transcribed verbatim. Using these 
transcripts and associated field notes, an overview of each of the case studies was developed. In 
addition, simple quantification of the numbers of questions asked by prescriber and patient respectively 
were undertaken. Furthermore, framework analysis of consultations was undertaken using modified 
indicators of the success of consultations developed by Barry et al (2001). 
 
Analysis of prescriber, doctor and patient interviews 
All interviews were fully transcribed and analysis of the interviews was undertaken separately in relation 
to the three interviewee groups. One of the researchers analysed the transcripts, by repeatedly reading 
them and first generating a set of descriptive themes - initial experiences, positives and negatives, for 
example - which were all fully open coded. Transcripts were then re-read to consider any broader 
themes and the process of constant comparison also used to consider any links between themes, 
interviewees and issues such as setting and profession, for example, and additional axial codes 
generated. Discussion of the emergent themes and coding was undertaken by the researcher with two 
other team members, who also read the transcripts. In particular, any disagreement or additional 
themes were discussed and the overall coding refined as a result. 
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Analysis of the costs of supplementary prescribing  
This component considered the costs of supplementary prescribing to the NHS focusing upon initial set-
up costs and additional costs such as indemnity insurance and salary changes - the costs of 
supplementary prescribing consultations and reviews having been derived from the survey data. All 
resource use and costs data were analysed using the statistical package SPSS version 15.0. Unit costs 
were based upon the 2006-2007 financial year. 
 
The initial set-up costs incorporated the costs required to provide the relevant training for either a nurse 
or pharmacist. The initial set-up costs also focus upon the time taken to develop and agree clinical 
management plans. Resource use data relating to the time taken to develop a clinical management plan 
for all patients and for each patient were obtained through interviews with supplementary prescribers 
and costed using national unit costs from the Personal Social Services Research Unit Database (Curtis 
2007). An average cost of training courses was developed using information about the cost of training 
courses from academic institutions that form the main sources of training. The final category described 
the costs of any additional ongoing training to prescribing nurses or pharmacists. These training costs 
were obtained via interviews with supplementary prescribers. 
 
As well as the three main categories, several additional costs were considered relevant. Interviews with 
supplementary prescribers were also used to estimate whether they had received any increase in salary 
as a result of becoming a supplementary prescriber; whether they had to meet the costs of any levies 
incurred as a result of registering as a supplementary prescriber and if so, how much these levies cost. 
In addition, information about whether supplementary prescribers had to pay insurance as a result of 
their prescribing role and if they did have to pay insurance, how much this was, was also collected.  
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3 Results - Thematic Literature Review 
 
Using search criteria described in the methods chapter, 35 empirical research papers relating to 
supplementary prescribing in nursing and pharmacy were identified2. A further 25 nurse supplementary 
prescribing papers and 5 pharmacist supplementary prescribing papers were identified which described 
anecdotal opinions and experiences of supplementary prescribing practice. One book was identified and 
20 key policy documents, plus a number of anonymous reports on supplementary prescribing in 
publications such as The Pharmaceutical Journal and Nursing Times (Cooper et al 2008). These 
findings are now presented according to the type of literature identified and key emergent themes.  
 
3.1 Empirical Studies 
The empirical studies most frequently focused upon experiences and perceptions of supplementary 
prescribing practitioners, but also those of other healthcare professionals, patients and public. Studies 
indicated that supplementary prescribing pharmacists saw clear benefits in terms of increased 
confidence, job satisfaction and independence, together with a perception that patients were more 
satisfied and better managed by supplementary prescribing (George et al 2006). Weiss et al (2006) 
reported similar findings alongside a perception that pharmacists could offer more medicines 
information and enjoyed more time with patients as compared to care provided by a doctor. Studies 
indicated that nurses’ experiences of supplementary prescribing were largely positive and suggested 
that they felt confident about prescribing (Courtenay et al 2006). However, several studies revealed that 
having a supplementary prescribing qualification did not necessarily result in actual supplementary 
prescribing practice (Candlish 2006, George et al 2007). 
The views of other health-care professionals - doctors particularly - revealed a more qualified 
assessment of supplementary prescribing. An over-riding theme was their lack of awareness of 
supplementary prescribing (George et al 2006, Hughes and McCann 2003, Lloyd, McHenry and Hughes 
2005, Weiss et al 2006), and although broadly positive about supplementary prescribing, doctors had a 
number of reservations relating to, for example, the erosion of doctors' traditional roles and professional 
hierarchies. Pre-existing relationships between doctor and supplementary prescriber were considered 
important in facilitating supplementary prescribing (Avery et al 2004). 
Very little research appeared to have involved patients although Weiss et al (2006) reported that 
patients struggled to identify benefits in pharmacist supplementary prescribing but suggested potentially 
reduced GP workloads; pharmacist supplementary prescribing hypertension clinic patients reported 
greater involvement and understanding in relation to their treatment or condition (Smalley 2006). 
Relationships between professions were highlighted in some studies, and, in a study looking at the 
perceived inter-professional barriers between GPs and community pharmacists, concerns emerged 
                                         
2 Of note was that several publications reported different aspects of one overall study and data set. 
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about pharmacists’ ‘shopkeeper’ image and subordination to doctors (Hughes and McCann 2003) plus 
medical practitioners’ reservations about non medical prescribing and preference for protocol, rather 
than independent prescribing (Buckley et al 2006). Amongst nurses, Jones (2006) reported a paradox of 
supplementary prescribing helping ‘police’ junior doctors, whilst maintaining consultants’ dominance. 
 
3.2 Anecdotal Literature 
A significant body of anecdotal literature was identified that reported experiences of supplementary 
prescribing, often in nursing. Echoing the empirical studies, the anecdotal literature reflected positive 
attitudes about supplementary prescribing but identified clear barriers to successful practice. Ignorance 
about nurse supplementary prescribing on the part of medical practitioners was reported (Baird 2004), 
as was the view that supplementary prescribing merely formalised previous informal mechanisms where 
pharmacists all but made prescribing decisions for doctors (Tomlin 2005).  Supplementary prescribing 
appeared to have been used in many clinical settings, including mental health, renal services, 
rheumatology, dermatology, epilepsy, substance misuse and diabetes (Cooper et al 2008). 
 
3.3 Barriers and facilitators 
The implementation of supplementary prescribing was a recurrent theme. Facilitators included a good 
pharmacist-doctor relationship linked to mutual trust (Lloyd and Hughes 2007) and effective 
communication and support from peers, doctors and employing organisations. Barriers were often 
antonymic to facilitators and a lack of communication was identified (Hay et al 2004) along with time and 
financial limitations, no primary care strategy or funding, difficulty in accessing patients' medical records 
and a perceived lack of awareness of supplementary prescribing amongst other healthcare 
professionals, patients and public. Additional barriers - often referred to in the anecdotal literature - were 
identified in the minutiae of practice, including problems obtaining prescription pads after qualification, 
inadequate IT to print prescriptions, poor administrative support and delays between training and actual 
prescribing. The CMP was often criticised for its encumbering, time-consuming and restrictive nature. 
 
3.4 Independent Prescribing 
Several comparisons between supplementary prescribing and independent prescribing were identified. 
Lloyd and Hughes (2007) reported many pharmacists’ belief that independent prescribing was a natural 
extension of supplementary prescribing but doubted their skills, whilst doctors’ viewed independent 
prescribing more negatively. Warchal et al (2006) reported pharmacists’ intentions to become 
independent prescribers, but also concerns about medical acceptability. In the nurse palliative care 
setting, Kinley et al (2004) argued that supplementary prescribing may be a retrograde step compared 
to independent prescribing as it retained links to medical paternalism, precluding nurse responsibility. 
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3.5 Education and training 
The adequacy or otherwise of non-medical prescribing education was a theme in several studies, 
particularly in terms of the content of the courses undertaken by nurses and pharmacists. Several 
studies reported a perception amongst stakeholders that the skills of nurses and pharmacists were 
different and that additional and profession-specific training was needed, despite several universities 
offering courses that admitted students from different professions and taught them together. Buckley et 
al (2006), for example, observed that stakeholders perceived nurses as having a lack of necessary 
pharmacological knowledge and pharmacists, a lack of closeness and knowledge of the patient. 
Dawoud et al (2004) noted that an early cohort of pharmacists undertaking supplementary prescribing 
training felt they were competent in pharmacology and pharmacokinetics and hence wanted less of this 
in a course but more training involving the physical examination of patients and counselling. Hobson 
and Sewell [42] reported several PCT and chief pharmacists' views that the lack of clinical assessment 
of nurse prescribing trainees was a concern, but not for pharmacists. Although much of the nurse 
prescribing education literature identified was not specific to supplementary prescribing, two studies 
referred specifically to this prescribing model. Bradley et al (2006) focused upon the implementation of 
supplementary prescribing on existing nurse prescribing courses at four institutions and interviewed 
lecturers, identifying themes surrounding recruitment concerns, time limitations, the CMP and a lack of 
pharmacological knowledge amongst student nurses. Skingsley et al (2006) focused on 
neuropharmacology training requirements for mental health nurse prescribers generally and reported 
that nurses found it rewarding but challenging, especially in relation to aspects of theory and scientific 
terminology. The authors noted, however, that the addition of supplementary prescribing training might 
lead to increased nurse cohorts from more varied clinical settings and questioned whether the courses 
could cope with this increased demand and variety. 
 
3.6 Grey literature 
Three types of grey literature were identified. Firstly, there were publications from official bodies 
providing formal and often detailed information about how supplementary prescribing would be 
implemented and controlled. Examples included formal documents relating to the implementation of 
supplementary prescribing (Department of Health 2005), non-medical prescribing summaries, 
educational requirements, competency frameworks and resources for assessing supplementary 
prescribing practice (NPC 2004). RPSGB publications included briefing papers (Weiss et al 2006), 
commissioned research and a conference report on the early progress of pharmacist supplementary 
prescribing (Royal Pharmaceutical Society 2006) which highlighted many of the issues described in this 
review. The National Prescribing Centre reported on two studies: one a scoping study which 
recommended that IT access was important and that CMPs should be relatively quick and simple to 
develop and implement (NPC 2005), the other a questionnaire survey of non-medical prescribers which 
identified numerous support and training needs for supplementary prescribing (NPC 2006). Secondly, 
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there were several reports of supplementary prescribing in the nurse and pharmacy press such as the 
Nursing Times and the Pharmaceutical Journal and these were often either positive in tone or simply 
offered journalistic reportage on supplementary prescribing developments. Thirdly, several more critical 
articles were identified in the medical and general press. The medical practitioner publication Pulse, for 
example, although reserving most criticism for independent prescribing, referred to supplementary 
prescribing as a 'controversial plan' that ignored doctors' concerns about increased workload, safety and 
funding (Anon 2002).  Avery and Pringle (2005), noted that non-medical prescribing and especially 
independent prescribing could be valuable initiatives only if training and information technology access 
safeguards were in place. Horton (2002) argued that nurse prescribing could offer valuable benefits but 
the pace of nurse prescribing was, he argued, 'reckless' and amounted to an 'dangerous uncontrolled 
experiment,' echoing other arguments about cost and labour savings (McCartney et al (1999). 
 
3.7 Summary 
Increasing body of literature emerging, with predominantly qualitative and survey data from empirical 
research revealing generally positive views amongst those involved in supplementary prescribing. 
 However, more critical tone identified amongst some doctors in opinion pieces and some publications, 
although it is worth noting that doctors are the group with the least awareness of non medical 
prescribing. 
Supplementary prescribing identified in many clinical areas although empirical and anecdotal literature 
indicate continuing implementation barriers and perceived lack of awareness of supplementary 
prescribing by some doctors and patients. 
Lack of research exploring cost issues of supplementary prescribing and views of patients neglected. 
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4 Results - Stakeholder Scoping Study  
 
Analysis of interviews with 43 supplementary prescribing stakeholders revealed several broad themes 
which, due to the relatively structured nature of the interviews, corresponded closely to the questions 
asked. Stakeholders’ background and expertise appeared to affect their responses and, for example, 
those involved in research, teaching or policy tended to consider supplementary prescribing in terms of 
training and competency, whereas practitioners focused more upon barriers and problems in practice. In 
other respects, however, the views of different stakeholders were broadly similar, such as perceptions 
of professional competencies, for example. The key emergent themes are now presented in turn. 
 
4.1 Training and Education 
Supplementary prescribing training was generally viewed positively and it was argued that it adequately 
prepared students for prescribing, and also offered flexible study and inter-professional learning 
opportunities. Negative aspects of training concerned the limited timescale and some aspects of course 
content, such as the absence of training in clinical specialities. Perceived variation between courses 
was also identified. Many stakeholders commented on key professional differences in relation to training 
needs: nurses were perceived to lack pharmacology/therapeutics knowledge, whilst pharmacists lacked 
the necessary counselling and clinical diagnostic skills: 
"Nurses have the consultancy skills already and just need to learn the pharmacology and 
the importance of prescribing whereas pharmacists, from what I have seen, [have] a lot 
more concerns about how to meet the patients, how to weigh up the patients […] So 
combined courses can confuse me somewhat."  (Primary care SP pharmacist) 
Hence, joint supplementary prescribing courses were seen as inherently problematic by some 
stakeholders, although others considered such courses advantageous in offering inter-professional 
insights and support. Academic stakeholders warned that early student cohorts may be 
unrepresentative of their professions overall and were concerned about the competency and motivation 
of later prescribing cohorts.  Doctors' mentoring roles (as DMPs) were often praised, although students 
and course providers reported isolated examples of dilatory supervision. Doctors' lack of remuneration 
and busy workloads were recognised in relation to the DMP role. Many stakeholders were also 
concerned that continuing professional development (CPD) training for prescribers was limited and not 
inter-professional. 
 
4.2 Supplementary Prescribing Implementation and Practice 
Reducing doctors' workloads and encouraging interaction and understanding between different 
healthcare professions were perceived to be benefits accruing from supplementary prescribing. There 
was also a perception that patients were generally positive about supplementary prescribing, valued 
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potentially enhanced access to medicines and that supplementary prescribing resulted in quicker 
appointment times: 
“I get the feeling that the patients have certainly had access to their medicines more 
quickly […] It has been a much more direct kind of route for them getting what they need, 
and that has been particularly useful for people with chronic problems.” 
 (supplementary prescribing course lecturer) 
 Patients' lack of awareness of supplementary prescribing was also reported as a concern. Specific 
benefits of CMPs were identified, including encouraging inter-professional interaction, differentiating 
different prescribing models and encouraging reviews of current treatment guidelines. Other 
stakeholders, however, felt there were significant practical difficulties in designing and implementing 
CMPs. 
 
4.3 Facilitators and Barriers to the Implementation of Supplementary Prescribing 
Stakeholders identified several factors that they felt might affect how supplementary prescribing was 
introduced in practice. Adequate support was considered necessary, both formally in terms of 
employers' and commissioning bodies' support, and informally from work colleagues and prescriber 
networks. Access to appropriate information technology (IT) and facilities and a good pre-existing 
working relationship between supplementary prescriber and doctor were also cited. An enthusiastic 
approach was also required by supplementary prescribers, to encourage peers to become prescribers 
and manage any implementation barriers. Delays between training and practice were cited, as was a 
perceived pressure on prescribers to return to existing tasks (like pharmacists to dispensing) after 
qualifying: 
“There are still some people out there, in hospital in particular, that have qualified and 
can’t get practising because they are being dragged back to their dispensary.”  
(Clinical lead) 
 Poor IT infrastructure was noted in terms of software that could not accommodate supplementary 
prescribing and lack of access to patients’ medical records.  
 
4.4 Professional relationships and boundary encroachment  
Views varied as to the impact of supplementary prescribing on inter-professional relationships. Some 
argued that supplementary prescribing might enhance inter-professional relationships, by offering an 
opportunity for increased interaction and potentially facilitating trust between professions. Other 
stakeholders argued that some doctors might feel threatened by supplementary prescribing, with one 
doctor highlighting a ‘certain amount of suspicion and sometimes antipathy’ towards supplementary 
prescribing from other doctors. It was also noted that supplementary prescribing might be a less 
threatening model of non-medical prescribing (as compared to independent prescribing) because it did 
not involve making an initial diagnosis, thus maintaining medical authority in this domain.  Occasional 
inter- and intra-professional tensions were identified, including an example of pharmacists encroaching 
on nurses' clinics, and concern about resentment of non-medical prescribers by non-prescribing peers: 
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“I think it has raised some issues with some professional jealousies where some nurses 
in particular have found that some of their peers don’t like it really  (the fact that they are 
prescribing) and [their peers] would sooner go to the GP rather than ask the nurse 
prescriber about things.” (Clinical lead) 
 
4.5 Safety 
Issues associated with the safety of supplementary prescribing were frequently cited. Comparisons 
between supplementary prescribing and independent prescribing were often made and supplementary 
prescribing was considered by some to be relatively safe, due to the existence of the CMP which guided 
prescribing decisions and because of less complex patients presenting. Safe prescribing was argued to 
require adequate training, auditing and practice reviews, but inappropriate IT and record access were 
considered possible safety threats. Several stakeholders remarked that pharmacists’ understanding of 
pharmacology might lead to safer prescribing, but others argued that nurses’ diagnostic training offered 
an additional safety check. 
 
4.6 Costs of supplementary prescribing 
Several cost issues emerged concerning salaries, prescribing and indirect costs, both as cost-saving 
but also burdens. It was argued that supplementary prescribing might reduce costs since nurses or 
pharmacists cost less than medical practitioners and would be undertaking routine prescribing: 
“It is cost-cutting and that was fully intentional and that was the only reason they would 
allow nurses to expand their role is to get cheaper labour basically.” (Hospital 
supplementary prescribing nurse) 
Conversely, some argued costs might rise since non-medical prescribers might demand higher salaries. 
Direct prescribing costs were identified, including concerns about the prescribing patterns of nurses and 
pharmacists and concerns that more prescribers would mean increased prescribing and hence 
increased costs. Indirect costs were referred to in terms of training prescribers initially and the effects of 
longer consultation times for non-medical prescribers generally.  
 
4.7 Independent prescribing 
Whilst not the main focus of the scoping exercise, many stakeholders referred to independent 
prescribing, with independent prescribing being perceived as a more flexible model of prescribing. This 
view was justified on the grounds that it did not require a CMP, would further improve access to 
medicines and represented a more prestigious and autonomous prescribing model.  Concerns emerged 
that independent prescribing might pose a greater threat to medical authority, that independent 
prescribing might not suit less confident non-medical prescribers, that independent prescribing might 
increase prescribing costs, that independent prescribing could lead to prescribing beyond nurses’ and 
pharmacists’ competencies and that their diagnostic skills might be inadequate for some presenting 
conditions. 
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4.8 Future challenges  
Although some stakeholders believed supplementary prescribing would become an integral part of 
nurses’ and pharmacists’ roles and their undergraduate training, others argued that it might be 
superseded by independent prescribing. A minority of stakeholders' comments suggested that nurse 
and pharmacist prescribing had been introduced too rapidly and that further developments should be 
more conservative and informed by research. Key challenges were perceived to be increasing 
awareness of supplementary prescribing, introducing local strategies for implementing supplementary 
prescribing more effectively, addressing deficiencies in CPD and training and addressing access to 
patients’ medical records generally. 
4.9  
4.10 Limitations 
Stakeholders' views may not necessarily be representative of their peers and, for example, 
supplementary prescribers interviewed were from early cohorts and medical stakeholders were those 
who had direct experience of supplementary prescribing. The study also relied upon stakeholders' 
perceptions of supplementary prescribing and this may differ from actual practice: it was evident from 
the analysis that some stakeholders appeared to espouse received wisdom or offered responses that 
reflected what they had read in the literature – especially those not actively involved in practice. 
 
4.11 Summary 
 
Supplementary prescribing appeared to be broadly welcomed by stakeholders and perceived to offer a 
number of benefits for patients and healthcare professionals. 
Several perceived ongoing implementation barriers and challenges were identified and these, along with 
the emergence of several differences and tensions may be relevant to the success of supplementary 
prescribing. 
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5 Results - Analysis of PACT data 
 
The aim of the analysis of PACT data was to explore the volume, costs and trends of nurse and 
pharmacist prescribing in community and primary care, examining data at a regional and national level, 
both overall and at therapeutic chapter and subchapter level from 2004-20073. Data on all prescribing in 
community and primary care (including doctors’) were also compared with nurse and pharmacist 
prescribing. It is worth noting at this stage that the figures for 2004-2006 reflect pharmacist 
supplementary prescribing only and from 2007 onwards, supplementary and independent prescribing. 
 
5.1 Overall level 
 
5.1.1 Comparison of medical and non medical prescribing 
The volume and cost of all nurse and pharmacist prescribing represented a small proportion of the 
overall prescribing in primary care and the community (Table 5.1)  
Table 5-1 Prescribing 2004 and 2007 
Year Profession Volume Net Ingredient Cost % of all prescribing 
Nurse 3,539,159 £52,167,484 0.52% 
Pharmacist 2,706 £25,348 0.0004% 
2004 
All 686,138,900 £8,079,566,994 100% 
Nurse 9,366,309 £107,736,871 1.2% 
Pharmacist 64,883 £637,907 0.008% 
2007 
All 786,145,690 £8,169,170,609 100% 
 
5.1.2 Nurse prescribing 
The total number of items prescribed by nurses in community and primary care increased from 3.5 
million in 2004 to 4 million in 2005, 6.3 million in 2006 and 9.4 million in 2007. There was a 14.3% 
increase in the number of items prescribed between 2004 and 2005, a 55.9% increase in the number of 
items prescribed between 2005 and 2006 and a 48.5% increase in the number of items prescribed 
between 2006 and 2007. These trends can be seen in Figure 5.1. The net ingredient cost of items 
prescribed by nurses in community and primary care increased from £52.2 million in 2004 to £58.9 
million in 2005, £79.3 million in 2006 and £107.7 million in 2007. There was a 12.9% increase in the 
cost of items prescribed between 2004 and 2005, a 34.7% increase in the number of items prescribed 
between 2005 and 2006 and a 35.8% increase in the number of items prescribed between 2006 and 
2007.  The volume of nurse prescribing has increased month on month with the exception of two 
months (decrease in volume of 1% or less). The largest percentage increase in volume of items 
prescribed was in June 2006, which saw a 22.7% increase. These increases are also reflected in the 
net ingredient cost which, in the same month, saw a 14.9% increase.   
                                         
3 For analysis and further discussion of pharmacist PACT data from 2004-2006, see Guillaume et al 2008 
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5.1.3 Pharmacist prescribing 
The total number of items prescribed by pharmacists in community and primary care increased from 
2,706 in 2004 to 11,458 in 2005, 31,052 in 2006 and 64,883 in 2007. There was a 323% increase in the 
number of items prescribed between 2004 and 2005, a 170% increase in the number of items 
prescribed between 2005 and 2006 and a 109% increase in the number of items prescribed between 
2006 and 2007. These trends can be seen in Figure 5.2.  The net ingredient cost of items prescribed by 
pharmacists in community and primary care increased from £25,348 in 2004 to £96,846 in 2005, 
£278,634 in 2006 and £637,907.37 in 2007. There was a 282% increase in the cost of items prescribed 
between 2004 and 2005, a 187% increase in the cost of items prescribed between 2005 and 2006 and 
a 128.9% increase in the cost of items prescribed between 2006 and 2007. The volume of pharmacist 
prescribing has increased every month since 2004, with one exception, a 0.2% fall in March 2005. The 
largest monthly percentage increase was 50.8% (1839 to 2774 items) in June 2005. The largest 
percentage increase in costs was in September 2006 (55.7%, £79,501 to £105,424).  
 
Figure 5-1 Nurse prescribing trends 2004-07 Figure 5-2 Pharmacist prescribing trends 2004-2007 
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5.2 Therapeutic ‘chapter’ level 
 
5.2.1 Trends in all prescribing in community and primary care 
Between 2004 and 2007, the largest single therapeutic area prescribed in was cardiovascular, which 
constituted 31.8% of all prescribing in community and primary care in 2007. The largest chapters by 
volume for all prescribing in community and primary care have remained the same between 2004 and 
2007 and are as follows, in order: cardiovascular system, central nervous system, endocrine system, 
gastro-intestinal system, respiratory system and infections.  
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5.2.2 Trends in nurse prescribing 
The therapeutic area with the largest volume of nurse prescribing in all years from 2004 to 2007 was 
dressings. However, the percentage of the total volume of nurse prescribing that dressings constitutes 
has fallen from 56.5% in 2004 to 21.6% in 2007. The chapter with the second highest volume in all 
years between 2004 and 2007 is skin. Examining chapters which contain drug items only, the highest 
volume of nurse prescribing in 2007 is in the infections chapter. The chapter which has seen the largest 
growth in volume of prescribing between 2004 and 2007 is malignant disease and immunosuppression 
(from 24 to 9413 items) followed by cardiovascular (from 7019 items to 789,152 items). Figure 5.3 
shows the five drug chapters with the largest volume of nurse prescribing in 2007.  
 
Figure 5-3 Nurse prescribing by chapter (containing drug items) in 2007 
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5.2.3 Trends in pharmacist prescribing 
The therapeutic area with the largest volume of pharmacist prescribing in all years from 2004 to 2007 
was cardiovascular, which formed a significant, but decreasing percentage of all pharmacist prescribing. 
In 2004, cardiovascular constituted 66.1% of all pharmacist prescribing whereas in 2007, cardiovascular 
constituted 48.3% of all pharmacist prescribing but was still the highest volume chapter (Figure 5.4) 
Figure 5-4 Pharmacist prescribing by chapter in 
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5.3 Subchapter level 
 
5.3.1 Nurse prescribing 
At subchapter level, the developing role of nurses in infectious disease management, health promotion 
and the management of long-term conditions was evident. For example, in the infections therapeutic 
area the majority of prescribing was for antibacterials (93% in 2007). Health promotion activities were 
represented by the prescribing of contraceptives (84% of the obstetrics, gynaecology and urinary tract 
disorders prescription items in 2007) and drugs used in substance dependence (30% of central nervous 
system prescription items in 2007). Management of long-term conditions was apparent for 
cardiovascular drugs where a wide range of different types of drug were prescribed including anti-
hypertensives and cholesterol lowering medications. There  was also evidence of substantial increases 
in prescriptions for drugs used in diabetes, which constituted 53% of endocrine prescription items in 
2007. However, as with all PACT data, it was not clear whether these have been prescribed using 
supplementary prescribing.  
 
5.3.2 Pharmacist prescribing 
Closer examination of pharmacist prescribing at subchapter level revealed several patterns. The 
dominant chapter was the cardiovascular therapeutic area and the dominant subchapter was 
hypertension and heart failure (29% in 2007), including angiotension converting enzyme (ACE) 
inhibitors. This was then followed by three subchapters, within which prescribing appeared to be 
relatively equally spread (diuretics, nitrates, calcium channel blockers and other anti-anginal drugs and 
lipid-regulating drugs). In the central nervous system chapter, drugs used in substance dependence, 
analgesics and hypnotics & anxiolytics were the largest subchapters. In the respiratory chapter, 
bronchodilators and corticosteroids constituted 88% of the chapter and diabetes medicines constituted 
over 50% of the endocrine chapter 
 
5.4 Regional level 
 
The North West had the highest number of prescriptions issued by nurses in comparison with the other 
strategic health authorities, with 1,743,017 items prescribed in 2007. The next highest Strategic Health 
Authority by volume of items prescribed was Yorkshire and the Humber (1,230,741). The percentage of 
all nurse prescribing by SHA varied from 19.4% (North West) to 3.5% (South Central).  The area with 
the highest volume of pharmacist prescribing was also the North West, which had 16,371 items 
prescribed by pharmacists in 2007. This was followed by the West Midlands with 14,152 items. This 
area experienced the largest percentage increase with 0 items prescribed in 2004 and 2005. The 
percentage of all prescribing by SHA varies from 25.2% (North West) to 1.8% (South East Coast). As 
Figures 5.5 and 5.6 highlight, there is a much greater variation by region in the volume of pharmacist 
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prescribing as compared with nurse prescribing. Horner (2007) reported that, in the year to September 
2007, pharmacy prescriptions had been received from 53.9% of PCTs (82 out of 152). 
 
Figure 5-5 Nurse prescribing by region in 2007 
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Figure 5-6 Pharmacist prescribing by region in 2007 
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5.5 Limitations 
This data only reflects primary care and community prescribing and not prescribing in the hospital 
setting so does not give a complete reflection of overall nurse and pharmacist prescribing. It also only 
related to prescribing in England and included all forms of non-medical prescribing. Finally, prescriber 
level data was not provided, so it was not possible to comment upon individual variations prescribing. 
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5.6 Summary 
 
Nurse and pharmacist prescribing increased between 2004 and 2007 as a proportion of all prescribing, 
from 0.52% to 1.2% for nurses and 0.0004% to 0.008% for pharmacists. 
Small overall contribution makes it difficult to compare data and trends more thoroughly.  
It is not possible to assess whether non-medical prescribing led to an increase in overall prescribing or 
represented substitute prescribing with no resultant rise in NHS costs. 
The historical legacy of district nurse and health visitor prescribing was observed in the patterns of 
nurses prescribing dressing and appliances, however medicines prescribing rising.  
Pharmacist prescribing was predominantly in the cardiovascular chapter. 
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6 Results - Survey of Qualified Nurse and Pharmacist Supplementary Prescribers 
 
The results of the postal questionnaire surveys of qualified supplementary prescribing nurses and 
pharmacists are arranged into sections and both qualitative and quantitative data relating to both 
professions are presented within these sections. A copy of the questionnaire may be found in Appendix 
C. Whilst the questions regarding demographics and training were answered by all respondents, only 
the responses of pharmacists and nurses currently prescribing are reported for brevity after section 6.2.  
 
6.1 Response rates 
The pharmacist survey was a census of all the supplementary prescribing qualified pharmacists in 
England as of April 2007. A total of 808 questionnaires were distributed. Four hundred and eleven 
(51%) were returned after one follow-up to non-responders. Of these 411, 36 pharmacists (8.7%) 
returned the questionnaire incomplete and 375 (91.3%) completed the questionnaire.  
In relation to the nurse survey, 13 HEIs (of a possible 39) agreed to participate. A total of 1628 
questionnaires were distributed between July and December 2007 and 518 were returned, which 
represents 32% of those distributed. Of these 518, 110 (21.2%) nurses returned the questionnaire 
incomplete and 408 (78.8%) completed the questionnaire.   
 
6.2 Supplementary prescribing status 
There was a significant association between profession and prescribing (χ2 =43.742, d.f. =1, p=0.000) 
(Figure 6.1). The majority of trained nurse supplementary prescribers (71.9%, n=294) were not 
prescribing as supplementary prescribers, whereas just over half of pharmacists (n=193, 51.0%) were.  
Figure 6-1Supplementary prescribing status by profession 
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Tests for association were undertaken between all prescribers and non-prescribers in relation to gender, 
attitudes to training and year for qualification as supplementary prescriber. There was significant 
association between pharmacist but not nurse prescribing status and qualification as a supplementary 
 34 
prescriber - 70.7% (53/75) of pharmacists qualifying in 2004 reported current prescribing, of those 
qualifying in 2005, 55.6% (60/108) and of those qualifying in 2006, 44% (53/120) reported current 
prescribing ((χ2 = 14.35, d.f. =1, p=0.002) There was significant association between attitude to training 
and prescribing status for nurses but not pharmacists - 94% (105/112) of currently prescribing nurses 
agreed/strongly agreed that their prescribing training was useful, compared to 77% (177/230) of non-
prescribers (χ2 = 15.476, d.f. =1, p=0.000). 
 
6.3 Demographics 
Key information regarding the demographic characteristics of nurses and pharmacist supplementary 
prescribers is included in the following table: 
Table 6-1 Demographic characteristics 
Variable Categories Nurse  Pharmacist  
Male 15 (13.0%) 58 (30.2%) Gender 
Female 100 (87.0%) 134 (69.8%) 
20-29 3 (2.6%) 22 (6.1%) 
30-39 17 (14.8%) 143 (39.5%) 
40-49 68 (59.1%) 129 (35.6%) 
50-59 27 (23.5%) 62 (17.1%) 
60-65 0 (0.0%) 3 (0.8%) 
Age 
66 + 0 (0.0%) 3 (0.8%) 
 
There was a significant association between gender and professional group, with pharmacists being 
significantly more likely to be male (χ2 =10.764, d.f. =1, p=0.001). There was no significant association 
between profession and age.  
 
6.4 Education 
The educational qualifications held by nurses and pharmacists are presented in Table 6.2.  
Table 6-2 Educational characteristics 
Variable Categories Nurse Pharmacist 
BPharm N/A 110 (57.0%) 
MPharm N/A 18 (9.3%) 
Pre registration 30 (26.0%) N/A 
Advanced Diploma 32 (27.8%) N/A 
Bachelors 55 (47.8%) 65 (33.7%) 
PG Diploma/Masters 14 (12.2%) 122 (63.2%) 
Doctoral  0 (0.0%) 9 (4.7%) 
Qualification 
Other 22 (19.1%) 16 (8.3%) 
1 47 (52.8%) 61 (32.3%) 
2 27 (30.3%) 122 (64.5%) 
Qualifications (n) 
3 15 (16.9%) 6 (3.2%) 
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In the case of the variable ‘qualification’, as nurses and pharmacists may have had more than one 
qualification, the percentage figure refers to the percentage of respondents with that qualification. Whilst 
direct comparisons between nurses and pharmacists were not possible due to different qualifications, it 
was apparent that less than half of the nurse respondents had a degree but that many pharmacists had 
a degree, and post-graduate qualification such as clinical pharmacy. 
 
6.5 Role characteristics 
Descriptive statistics relating to the roles of nurse and pharmacist supplementary prescribers are 
presented in Table 6.3. There was no association between work location and profession save nurses 
being significantly more likely than pharmacists to be working in the community (χ2 = 51.2, d.f. =1, 
p=0.000). Of note is that only 7.3% of pharmacists reported working in the largest pharmacy sector - the 
community.  Supplementary prescribing qualified nurses and pharmacists did not appear to be working 
in more specialised areas. Nurses and pharmacists may have worked in more than one location, 
therefore the figure for ‘location of work’, refers to the percentage of respondents in each location.  
 
Table 6-3 Job role characteristics 
Variable Categories Nurse Pharmacist 
Range 8-60 2-60 
Median (interquartile range) 37.5 (7.8) 37.5 (7.5) 
Overall hours worked 
Exactly 37.5 hours a week 56 (49.1%) 77 (40%) 
Less than £20,000 9 (12.3%) 8 (4.3%) 
£21,000-£30,000 43 (37.3%) 19 (10.2%) 
£31,000-£40,000 54 (74.0%) 64 (34.2%) 
£41,000-£50,000 6 (8.2%) 65 (34.8%) 
£51,000-£60,000 0 (0%) 21 (11.2%) 
Salary Band (per annum) 
More than £60,000 1 (1.4%) 10 (5.3%) 
Hospital 40 (34.8%) 78 (40.4%) 
General Practice 42 (36.5%) 102 (52.9%) 
Community 48 (41.7%) 14 (7.3%) 
Walk in centre 3 (2.6%) 2 (1.0%) 
Care Home 4 (3.4%) 3 (1.6%) 
Prison 0 (0.0%) 2 (1.0%) 
Location of work 
Other 0 (0.0%) 7 (3.6%) 
1 89 (79.4%) 170 (91.9%) 
2 21 (18.8%) 15 (8.1%) 
Number of locations 
worked in  
3 2 (1.8%) 0 (0.0%) 
 
Mann-Whitney U Tests showed that there was no significant association between hours worked and 
profession. Chi squared tests indicated an association between profession and salary (χ2 = 73.8, d.f. =5, 
p=0.000) - most pharmacists earned over, and most nurses earned under, £40,000 per annum.  
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6.6 Training 
As Figure 6.2 indicates, pharmacists were positive about the training that they received. The highest 
level of disagreement was in relation to whether training provided the knowledge (n=43, 22.9% 
disagreed) and skills (n=32, 17.1% disagreed) that they required to practice as a supplementary 
prescriber. The majority of pharmacists (n=122, 67.4%) believed that the training that they received 
allowed them to formalise the practice that they were undertaking before they trained. Pharmacists 
frequently referred to the period of learning in practice (LIP) and the involvement of their DMP as the 
most useful aspects of training. Legal aspects of prescribing, consultation and examination skills were 
also considered valuable parts of supplementary prescribing training. Negative aspects included 
unnecessary pharmacology training and aspects of course delivery such as excessive paperwork, 
documenting and demonstrating competencies and reflective practice. Some pharmacists valued 
training with other professionals, but others considered it inappropriate to teach professions with 
different needs. Several pharmacists believed no improvements to courses were necessary but others 
suggested more course content focusing on examination, consultation, clinical skills, and diagnosis. 
 
Figure 6-2 Pharmacist attitudes to training 
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Current nurse prescribers’ views were similar to those of pharmacist prescribers, with the majority 
agreeing that their training was useful (Figure 6.3). Training met the needs of supplementary prescribers 
in terms of their knowledge and skills. The majority of nurses (n=78, 73.6%) believed that the training 
that they received allowed them to formalise pre-prescribing work practices. 
Nurses' open responses to training questions revealed both positive and negative comments about 
training and suggested improvements. Positively, nurses valued the pharmacology training offered, 
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offering them a 'better understanding of medicines.' Practical course content that could be applied 
directly to prescribing practice was also praised, including designing and using CMPs, using prescribing 
software, writing prescriptions and using the BNF. Like pharmacists, nurses also cited legal aspects of 
prescribing as being useful. Nurses' previous education and knowledge appeared to vary since some 
nurses reflected that such content was merely an opportunity to 'revisit', 'revise', 'enhance' and 'update' 
existing knowledge. Nurses also praised opportunities for inter-professional interaction. Negative course 
aspects included their generic nature and neglect of specific clinical areas and occasional references to 
poor teaching standards, assessment and lack of time to undertake courses. Several nurses - usually 
those using independent prescribing in practice - questioned why supplementary prescribing was being 
taught at all, as they did not expect to use this type of prescribing once qualified. Suggested course 
improvements included more pharmacology and law training, using CMPs and how to manage issues 
such as ‘GP politics’ and ‘barriers to prescribing’. 
 
Figure 6-3 Nurse attitudes to training 
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Comparing nurses and pharmacists attitudes to training, nurses were significantly more likely to agree 
that their supplementary prescribing training provided the knowledge they needed to prescribe (χ2 = 
14.2, d.f. =1, p=0.000) and the skills that they needed to prescribe (χ2 = 8.827, d.f. =1, p=0.003).  
 
6.7 Support and Prescribing Review 
Key characteristics relating to the support that nurses and pharmacists receive in their prescribing role 
are included in Table 6.4. No associations were found between support and prescribing role and 
profession. There was a significant association between length of sessions to review practice and 
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profession with nurses having shorter sessions (Mann Whitney U Test =1992.5, Z= -3.277, p=0.001), 
and between profession and frequency of sessions to review prescribing practice (p<0.002).  
Formal and informal review mechanisms for pharmacist prescribing were identified. Formally, these 
involved existing multi-disciplinary team meetings, or in secondary care, ward rounds or weekly patient 
reviews. Audits and performance reviews were also considered to be forms of review. Informal review of 
supplementary prescribing appeared to require pharmacists to initiate them, as 'ad hoc' discussions with 
doctors or when 'interesting or difficult cases' arose - this raising the possibility that prescribing problems 
might not be identified and addressed if they were not recognised by the pharmacist.  A small number of 
open response comments referred to a complete lack of pharmacist prescribing review. 
Table 6-4 Support and prescribing review 
Variable Categories Nurse Pharmacist 
Satisfied with support 
regarding prescribing decisions Agree 85 (80.2%) 144 (81.4%) 
Satisfied with support 
regarding prescribing role Agree 72 (68.6%) 114 (64.4%) 
Prescribing decisions are 
regularly monitored Agree 52 (48.6%) 81 (46.5%) 
Independent prescriber 
available to discuss patients Agree 87 (87.9%) 166 (91.2%) 
Once a week 14 (12.2%) 41 (21.2%) 
Once a fortnight 7 (6.1) 11 (5.7) 
Once a month 10 (8.7) 29 (15.0) 
Once every 3 months 12 (10.4) 26 (13.5) 
Once every 6 months 10 (8.7) 4 (2.1) 
Once a year  6 (5.2) 21 (10.9) 
Frequency of sessions to 
review prescribing practice* 
Never 37 (32.2) 34 (17.6) 
Range 0-45 0-90 Length of sessions to review 
prescribing practice (iminutes)^ Median (interquartile range) 1 (18) 12 (29) 
* p<0.002  ^ p<0.001 
 
Nurses also identified several prescribing review mechanisms and informal reviews were common, 
although several stated that no reviews of their prescribing occurred. Formal, regular reviews of 
prescribing were reported after supervision or appraisal meeting, or commonly during case review 
sessions. Nurses noted regular case review sessions attended by several healthcare professionals and, 
like pharmacists, many examples were identified of ‘ad hoc’, ‘opportunistic’ reviews for nurses’ 
prescribing, often nurse initiated. Some nurses used reflective practice to review their prescribing. 
 
6.8 Prescribing 
Nurses and pharmacists varied in relation to different aspects of their prescribing, as indicated in Table 
6.5, which presents the prescribing practices of nurses and pharmacists with reference to their self-
reported hours worked, prescriptions issued, patients prescribed for and appointment and review times. 
On average, nurses report spending a greater proportion of their working time as a supplementary 
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prescriber (a mean of 15 hours per week for a nurse and 6 hours per week for a pharmacist; median of 
10 hours per week for a nurse and 4 hours per week for a pharmacist) and these differences are 
statistically significant (p<0.001). In contrast pharmacists report that they spend a greater proportion of 
time reviewing their supplementary prescribing practice per session (mean 17 mins; median 15 mins) 
than do nurses (mean 9 mins; median 1 min and these differences are also statistically significant 
(p=0.002). Nurses tend to prescribe for a greater number of patients per year on a recurring basis and 
issue more prescriptions per week on average than do pharmacists although it is important to note that 
the range for the question relating to ‘how many prescriptions per week are issued’ for pharmacists is 
much higher than for nurses (0-700 relative to 0-150) indicating that a proportion of pharmacists are 
prescribing much more frequently than nurses. Nurses reported that they tend to spend slightly longer 
on average with each patient for whom they are a supplementary prescriber (mean 21 minutes relative 
to 18 minutes; median 20 minutes relative to 18 minutes) but these were not statistically significant. 
Table 6-5 Prescribing practice 
Question  Pharmacists Nurses 
N 168 84 
Mean (SD) 5.92 (5.75) 15.31 (13.83) 
Median (IQ Range) 4.00 (2.00-8.00) 10.00 (2.00-29.75) 
Min 0 0 
Max 30 40 
How many hours worked as a 
supplementary prescriber? * 
Sig. p<0.001 p<0.001 
N 107 54 
Mean (SD) 16.95 (17.39) 9.48 (13.76) 
Median (IQ Range) 15.00 (1.00-30.00) 1.00 (1.00-19.00) 
Min 0 0 
Max 90 45 
How long do you spend reviewing 
your supplementary prescribing 
practice per session? * 
Sig. p=0.002 p=0.002 
N 156 80 
Mean (SD) 53.94 (202.18) 170.92 (910.20) 
Median (IQ Range) 15 (4-50) 20 (3-50) 
Min 0 0 
Max 2400 8000 
On average how many patients 
do you prescribe for on a  
recurring basis? 
Sig p=0.993 p=0.993 
N 175 99 
Mean (SD) 11.69 (54.29) 13.78 (19.57) 
Median (IQ Range) 4 (2-10) 6 (3-20) 
Min 0 0 
Max 700 150 
On average how many 
prescriptions do you 
issue per week? * 
Sig. p<0.001 p<0.001 
N 179 94 
Mean (SD) 17.56 (8.26) 21.15 (13.67) 
Median (IQ Range) 18 (15-20) 20 15-30) 
Min 0 1 
Max 45 60 
On average how long do you 
spend with each patient for whom 
you are a supplementary 
prescriber? (minutes) 
Sig. p=0.113 p=0.113 
* statistically significant difference between means 
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The predominant chapter in which pharmacists were prescribing was cardiovascular, followed by gastro-
intestinal (table 6.6). The majority of pharmacists prescribed in fewer than five BNF chapters, with 
34.2% (n=66) prescribing in one chapter only. In contrast, almost 40% of nurses were prescribing in 
more than five chapters, with 22.6% (n=26) prescribing in one chapter only. Nurse prescribing was more 
evenly split between the top four chapters than pharmacist prescribing. 
Table 6-6 BNF sections 
Variable Nurse Pharmacist 
Infections  51 (46.4%) Cardiovascular 115 (59.9%) 
Respiratory 47 (43.0%) Gastro-intestinal 50 (26.0%) 
Skin 45 (40.9%) Respiratory 42 (21.9%) 
Sections in which most 
frequently prescribed 
Minor ailments 41 (37.3%) Central Nervous System 39 (20.3% 
1 26 (22.6%) 61 (61.0%) Number of sections 
prescribed in  <5 66 (34.2%) 130 (90.9%) 
 
6.9 Costs 
Costs associated with supplementary prescribing were calculated for the time spent with patients and 
for reviewing supplementary prescribing practice based upon nurses' and pharmacists' self-reports of 
practice (Table 6.5) and standard salary data (Curtis 2007) and these are presented in Table 6.7. 
Table 6-7 Costs associated with supplementary prescribing 
  Pharmacist Nurse 
Mean (SD) ₤6.65 (₤7.34) ₤2.87 (₤4.31) 
Median (IQ Range) 5.00 (0.48-9.75) 0.38 (0.26-3.75) 
Min 0 0 
Max 34 16 
Cost of reviewing supplementary 
prescribing practice per session.* 
Sig. P<0.001 p<0.001 
Mean (SD) ₤7.02 (₤3.71) ₤6.50 (₤4.68) 
Median (IQ Range) ₤6.33 (₤0.48-₤8.33) ₤5.75 (₤2.92-₤9.50) 
Min ₤0.00 ₤0.28 
Max ₤18.75 ₤20.67 
Cost of time spent with each 
supplementary prescribing patient. 
Sig. P=0.170 p=0.170 
* statistically significant difference between means 
 
 There were statistically significant differences in the costs of reviewing supplementary prescribing 
practice per session (mean ₤6.65 for pharmacists and ₤2.87 for nurses; median ₤5.00 for pharmacists 
and ₤0.38 for nurses) reflecting the differences in the time spent reviewing with nurses reporting much 
shorter reviewing times on average than pharmacists. Finally the average cost of time spent with each 
patient was found to be broadly similar between the two professions (mean ₤7.02 for pharmacists and 
₤6.50 for nurses; median ₤6.33 for pharmacists and ₤5.75 for nurses) and these differences were not 
found to be statistically significant (p=0.170).      
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6.10 Colleagues and Relationships 
Table 6.8 compares nurses and pharmacists in terms of their views about independent (medical 
prescribers). There were no significant differences between the two professional groups.  
 
Table 6-8 Views on independent (medical) prescribing 
Variable Categories Nurse Pharmacist 
Patients receive better care from supplementary 
prescribers 
Agree 29 (27.9%) 58 (32.2%) 
Patients have longer consultation times with 
supplementary prescribers 
Agree 56 (53.8%) 138 (76.2%) 
Supplementary prescribing is instead of an independent 
(medical) prescriber 
Agree 31 (37.9%) 60 (33.5%) 
 
Pharmacists perceived supplementary prescribing to have improved relationships with others generally, 
but this was particularly so with respect to doctors, who appeared to be pharmacists' key reference 
group. This had resulted in more 'respect' and increased their 'profile and status' amongst doctors.  
Improved relationships and 'much more respect' were reported in relation to their pharmacist peers, too, 
although several pharmacists reported no changes or a worsening of peer relationships. For these 
pharmacists, supplementary prescribing appeared to have resulted in a sense of difference - a 'slight 
alienation' - and jealously between them and non-prescribing pharmacists. Several pharmacists also 
perceived nurse resentment at pharmacists' prescribing role, and that there was 'competition from 
nurses', 'professional jealousy', and 'some tension [and] demarcation issues.'   
Nurses' open responses revealed a perception of enhanced respect for some following prescribing. 
Positive relationships with doctors were reported but some nurses reported worsening of relationships 
with other nurses after becoming prescribers - being 'resented' the object of 'immense professional 
jealousy.' Several nurses reported no relationship changes. 
 
6.11 Confidence and competence 
As Table 6.9 indicates, pharmacists and nurses felt confident in their roles as supplementary 
prescribers and there were no significant differences between nurses and pharmacists. 
 
Table 6-9 Confidence in supplementary prescribing practice 
Variable Categories Nurse Pharmacist 
Confident to prescribe the appropriate treatment Agree 107 (98.1%) 184 (100%) 
Confident to prescribe the correct dosage Agree 107 (98.1%) 183 (99.5%) 
Confident to identify drug related problems Agree 104 (95.4%) 182 (98.9%) 
Confident to identify drug interactions Agree 100 (92.6%) 181 (99.5%) 
Confident to prescribe for patients with co-morbidities Agree 71 (67.0%) 160 (87.5%) 
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6.12 Safety 
Pharmacists reported that they had sufficient knowledge of pharmacology and therapeutics to prescribe 
safely (n=183, 100%). With reference to prescribing for patients with co-morbidities, 34 (18.7%) had 
concerns. A smaller percentage of 89.8% of nurses (n=97) agreed that they had sufficient knowledge of 
pharmacology and therapeutics to prescribe safely. Thirty-one nurses (30.4%) had concerns about 
prescribing for patients with co-morbidities.  
 
Figure 6-4 Requests to prescribe outside area of competence 
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As Figure 6.4 highlights, a number of nurses and pharmacists were asked to prescribe in areas that 
they perceived to be outside their competence by patients and colleagues. Pharmacists were more 
likely to be asked to prescribe outside their area of competence by patients than nurses (χ2 = 8.103, d.f. 
=1, p=0.004).  However, only 2.2% (n=4) of pharmacists and 2.9% of nurses (n=3) agreed that they had 
concerns that they were prescribing outside their area of competence. 
 
6.13 Safety climate 
Pharmacists and nurses reported that they were generally positive about the safety climate in which 
they worked. Therefore it was decided to look at only negative and neutral responses to questions to 
examine perceptions of the safety climate in which they worked. In the case of pharmacists, the highest 
level of disagreement was around whether staff received appropriate feedback about their performance 
(29.8%, n=54 were neutral and 23.7%, n=43 disagreed). This was followed by whether levels of staffing 
in their area of the organisation were sufficient to handle the number of patients (17.7%, n=32 
disagreed, 21.1%, n=38 neutral). The questions to which there was least disagreement were whether 
pharmacists knew the proper channels to which they should direct questions regarding patient safety 
(2.8%, n=5 neutral and 0.6%, n=1 disagreed). In the case of nurse supplementary prescribers, the 
strongest disagreement was around whether their organisation was doing more for patient safety than it 
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was doing one year ago (50.0%, n=52 neutral and 11.5%, n=12 disagreed). This was followed by 
whether levels of staffing were sufficient to handle the number of patients (21.2%, n=22 neutral and 
36.5%, n=38 disagreed). The question with the least disagreement was whether nurses knew the proper 
channels to direct questions regarding patient safety (4.8%, n=5 neutral, 2.9%, n=3 disagreed).  
 
6.14 Impact of supplementary prescribing  
Table 6.10 compares nurses and pharmacists views on the impact and benefits of becoming a 
supplementary prescriber. For both professions, improved job satisfaction was cited by a large 
percentage, alongside greater autonomy. However, less than a third of nurses and pharmacists felt they 
had a higher status as a result of their prescribing role. There were no significant associations between 
profession and benefits of supplementary prescribing. 
 
Table 6-10 Perceived benefits of supplementary prescribing 
Variable Categories Nurse Pharmacist 
Greater autonomy  Agree 78 (91.6%) 135 (73.8%) 
Higher status  Agree 27 (25.2%) 59 (32.4%) 
Improved job satisfaction Agree 95 (88.8%) 159 (86.9%) 
 
Open responses reinforced this, with several positive aspects relating to becoming supplementary 
prescribers emerging, especially in terms of personal benefits: increased job satisfaction and a sense of 
acceptance were reported by some, along with more independence and control over their work. By 
contrast, others felt supplementary prescribing provided security and 'clear boundaries' due to the 
doctors' initial diagnosis, with the CMP acting as a 'safeguard.'  In relation to others, several 
pharmacists commented that doctors would have lower workloads, and that patients were given more 
information and advice about medicines and treatments. These, and also improved clinical outcomes, 
were attributed by some pharmacists to their pharmacological expertise and longer consultation times 
compared to doctors. 
Negative aspects of supplementary prescribing practice included CMP problems, procedural difficulties 
in setting-up adequate patient referrals to supplementary prescribers, problems accessing patients' 
notes, delays in obtaining prescription pads and logistical issues running clinics. The CMP in particular 
was singled out for criticism, being variously described as 'restrictive', 'cumbersome' and 'time-
consuming.'  Obtaining the doctor's approval for a CMP was often difficult, pharmacists noted, and 
others reported being frustrated due to not being able to prescribe simple medicines not included in 
CMPs. Some pharmacists reported reverting back to simply asking doctors to sign prescriptions for 
them, to save time and patient inconvenience. CMPs were also considered unsuitable in settings such 
as paperless GP practices, and on acute hospital wards. Problems with inadequate information 
technology and especially computer prescribing software were frequently mentioned, leading to either 
hand-written prescriptions or unsigned prescriptions for doctors to sign. Some medical resistance and 
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antipathy to pharmacist prescribing and a lack of understanding of supplementary prescribing were also 
reported. Pharmacists reported 'doctors' resistance to accept changing roles' and a perception that 
prescribing was 'still seen as [the] domain of doctors.' Temporal problems emerged in terms of 
prescribing delays due to CMPs, lack of time to practice supplementary prescribing due to other work 
commitments and delays obtaining prescription pads. 
Nurses open responses revealed positive and negative aspects of supplementary prescribing. Positive 
aspects included time benefits, enhanced autonomy and improved relationships, increased continuity of 
care and less work for doctors.  Nurses reported, like pharmacists, not only perceived time savings and 
quicker access to medicines and services for patients but also having more time to spend with them - 
beneficial 'continuity of care' was frequently mentioned. Unlike pharmacists, nurses seldom cited 
professional acceptance or improved relationships. 
Nurses identified a number of negative issues that were also raised by pharmacists: use of CMPs, lack 
of support and understanding and inadequate remuneration, doctors, resistance and various logistical 
and practical issues. There was a perception amongst some nurses that supplementary prescribing was 
not only less practical than independent prescribing but also inferior. CMP criticism arose in terms of 
difficulties and delays in completing them and finding doctors to agree to and sign them. Such problems 
led some nurses to argue that the CMP meant that supplementary prescribing was used less than 
independent prescribing. Several nurses commented that CMPs were not being used in practice, 
Doctors were frequently identified in relation to negative aspects of supplementary prescribing and were 
criticised not only for their lack of understanding of supplementary prescribing and reluctance to sign 
and complete CMPs but also in terms of their resistance overall to nurse prescribing - nurses perceived 
that 'some feel you are after their job.'  Some nurses commented that doctors and other staff had made 
active attempts to prevent supplementary prescribing being implemented.  Like pharmacists, several 
nurses commented on significant - from three months to one year - delays in obtaining prescription 
pads, and information technology problems involving poor patient record access and an inability to print 
prescriptions. However, several nurses did not consider there to be any negative aspects of 
supplementary prescribing.  
 
6.15 Patients  
Table 6-11 Patients and supplementary prescribing 
Variable Categories Nurse Pharmacist 
Patients are aware of what supplementary 
prescribing entails 
Agree 43 (42.2%) 87 (47.8%) 
Patients are provided with information about 
supplementary prescribing 
Agree 99 (67.0%) 138 (75.8%) 
Supplementary prescribing has improved 
relationships with patients 
Agree 74 (70.5%) 148 (81.4%) 
Supplementary prescribing has improved 
patients compliance 
Agree 64 (61.0%) 117 (65.0%) 
Patients are included in prescribing decisions Agree 104 (99.0%) 165 (90.7%) 
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Patient awareness of supplementary prescribing was perceived to be low, but both nurses and 
pharmacists reported that they included patients in prescribing decisions and the majority provided them 
with information (Table 6.11).  
 
6.16 Independent Prescribing 
A much higher percentage of nurse supplementary prescribers were prescribing independently 
compared with pharmacists, almost only a small minority of pharmacists did not intend to become 
independent prescribers (figure 7.5). Many pharmacists compared supplementary prescribing to 
independent prescribing and there was a strong belief that supplementary prescribing represented a 
'stepping stone' or introductory prescribing model, prior to becoming an independent prescriber. It was 
apparent that pharmacists viewed supplementary prescribing positively in this sense, as a useful 'first 
step', as further training towards eventual independent prescribing and as 'a safety net', allowing 
pharmacists to gain confidence, experience, competence and clinical skills. Other pharmacists 
expressed distain for supplementary prescribing in comparison to independent prescribing, with 
supplementary prescribing being described as a 'bureaucratic hindrance' and 'a half way house between 
nothing at all and full independent prescribing i.e. a compromise.' Critics of supplementary prescribing 
also argued that independent prescribing would allow greater flexibility, encourage other pharmacists to 
become prescribers, allow pharmacists to perform their prescribing role in 'a much more efficient and 
satisfactory way' and was ''the only practical option long-term' according to one pharmacist. 
 
Figure 6-5 Independent Prescribing 
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Two different opinions emerged amongst nurses in relation to independent and supplementary 
prescribing from the open response questions. Firstly, several nurses commented that supplementary 
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prescribing had been beneficial for their practice and supplementary prescribing was viewed as being 
'valuable', had resulted in 'greater knowledge and confidence', and 'allowed a much higher standard of 
care.' By contrast, whilst some nurses merely commented that independent prescribing and not 
supplementary prescribing was being used in practice, others held strong opinions and variously noted 
that independent prescribing had 'been more useful' than supplementary prescribing, that independent 
prescribing had 'superseded' supplementary prescribing and that supplementary prescribing was, in 
comparison, 'inappropriate' in some settings, 'unnecessarily restrictive and time consuming.' This led 
several nurses to question why a survey of supplementary prescribing was necessary. 
 
6.17 Limitations 
Survey limitations exist in terms of the representativeness of the samples of both pharmacists and 
nurses, since information about non-responders was not available. For pharmacists, this was due to 
time constraints but for nurses was due mainly to difficulties in obtaining overall response rates from 
HEIs who distributed questionnaires to nurses. Furthermore, some nurse responses involved details of 
prescribing that would be expected from an independent prescriber, as part of a diagnostic role, such as 
antibiotics, for example. This raises the possibility that nurses, in particular, may have completed parts 
of the questionnaire based in part upon their experiences of independent prescribing. However, it is also 
possible that this prescribing may have been incorporated in a CMP in, for example, a patient with 
asthma having antibiotics for a potential chest infection included following agreement with a doctor. 
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6.18 Summary 
A large majority of trained nurses were using independent, not supplementary prescribing. 
Just over half of pharmacists were using supplementary prescribing, but the majority were currently 
prescribing, undertaking training in or intended to use independent prescribing. 
Nurses reported longer consultation times than pharmacists (21mins and 18mins respectively).  
The cost of supplementary prescribing consultations was similar (£7.02 for pharmacists and £6.50 for 
nurses) but nurses' costs for reviewing their supplementary prescribing were less than for pharmacists 
(£2.87 and £6.65 per session respectively). 
Nurses and pharmacists were positive about the safety climate and culture where they worked in 
relation to prescribing but reported being asked by patients and colleagues to prescribe beyond their 
clinical competence, although few reported acceding to such requests. 
Supplementary prescribing qualified nurses were evenly represented in hospitals, GP practices and 
community but pharmacists were significantly underrepresented in the community. 
Both professions were positive overall about prescribing training and favoured combined independent 
and supplementary courses. Training allowed their prior practice to be formalised. 
Prescribing constituted a small proportion of nurses' and pharmacists' roles. 
Majority of pharmacists were prescribing cardiovascular medicines, issuing five or fewer prescriptions 
per week and had appointment times that ranged from 1 to 45 minutes 
The majority of nurses were prescribing in the infections chapter, issuing four or fewer prescriptions a 
week (as supplementary prescribers). Appointment times range: 1-60 minutes. 
Confidence and perceived competence were high in both professions, with least confidence being 
expressed about prescribing for patients with co-morbidities 
Supplementary prescribing led to increased autonomy and job satisfaction, more than pay or status 
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7 Results - Case Studies 
 
A series of 10 case studies (6 pharmacists and 4 nurses) were undertaken in order to explore in depth 
key issues relating to the prescribing practices of supplementary prescribing nurses and pharmacists. 
The case studies facilitated an exploration of how supplementary prescribing was working in practice 
and also elicited data on the safety of supplementary prescribing, the costs of supplementary 
prescribing (in conjunction with questionnaire data), styles of consultation and the views and 
experiences of supplementary prescribers, doctors and patients. Full details of the method and analysis 
are included in Chapter Two. The results of the case studies are arranged into sections on the 
characteristics of participants, safety of supplementary prescribing, costs of supplementary prescribing, 
an analysis of consultations, an analysis of CMPs, views of supplementary prescribers, views of doctors 
and views of patients (interviews and questionnaires) 
 
7.1 Case study characteristics 
Table 7.1 provides an overview of the case study participants, presented so as to protect their 
anonymity. More details about the data collected in each of the case studies is included in Appendix D. 
Pseudonyms are used throughout the chapter.  
 
Table 7-1 Overview of case study participants 
Variable Categories Number 
Male 2 Gender 
Female 8 
Nurse 4 Profession 
Pharmacist 6 
Primary Care 6 Location of work 
Secondary Care 4 
General 1 
Cardiovascular disease 3 
Endocrine (thyroid disease) 1 
Oncology 1 
Dermatology 1 
Substance misuse 2 
Clinical area  
(These represent main clinical 
areas. Some prescribers, 
classified as general, also 
reported other clinical 
competencies e.g. chronic 
obstructive pulmonary disease 
and osteoporosis) ADHD 1 
 
7.2 Safety of supplementary prescribing 
Across the 77 consultations observed, 71 prescribed medicines were used for an assessment of the 
safety of prescribing by nurse and pharmacists in relation to errors and appropriateness. These data 
were collated from nine of the ten case studies (in one case study it was not possible to collect detailed 
prescribing information - see Appendix D). The volume of prescribing varied considerably according to 
the case study site and was most frequent in the primary care settings. Methadone was the most 
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frequently prescribed medicine (n=16), reflecting the inclusion of two substance misuse case studies, 
whilst two sites involving hypertension and cardiovascular medicine in GP surgeries led to the 
prescribing of 15 and 14 items respectively over two days’ observations. 
 
As described in Chapter Two, in order to assess errors and appropriateness, four assessors used an 
assessment tool developed from the literature and subsequent group discussion (see Appendix D). No 
errors were identified across the 71 prescribed medicines assessed, although there were three 
prescriptions which were assessed as being inappropriate overall (based upon the majority view of the 
assessors). Two of these involved prescribing of branded rather than generic medicines by nurses and 
the other by a pharmacist involving the prescribing of a medicine considered more expensive than 
others in its class. In addition, 11 prescriptions were assessed as being inappropriate by two of the four 
assessors, with the use of branded rather than generic medicines being the most commonly identified 
indicator of inappropriateness (although in one case study, the brand was cheaper than the generic).4  
 
It was also noted in two of the secondary care hospital case studies and the two substance misuse sites 
that information about other prescribed medicines that the patient might be taking were either not 
recorded or were hard to access in paper-based patient notes. Furthermore, in several case studies it 
was observed that the supplementary prescriber made no attempt to ask about other current medication 
use or did not attempt to refer to the patient's notes. In one site, there was an assumption that the 
independent prescribing consultant would have done this in their initial consultation but no attempt was 
made to check this or update medicine use.  
 
7.3 Set-up and additional costs of supplementary prescribing 
This component of the study considered additional costs associated with supplementary prescribing in 
relation to initial set-up, salary and indemnity insurance, and complements the costs associated with 
consultations and reviews for nurses and pharmacists based upon the survey and reported in chapter 6. 
 
Table 7-2 Supplementary prescribing set-up costs 
  Nurse: n=4 
Mean (SD) 
Pharmacist: n=6 
Mean (SD) 
Time taken to develop initial CMPs (minutes) 230 (329) 90 (60) 
Cost of developing CMP for all patients (£) 93 (131) 55 (38) 
Time taken to develop CMP for each patient (minutes) 35 (57) 4 (2) 
Cost of developing CMP for each patient (£) 20 (28) 2 (1) 
Cost of supplementary prescribing training course (£) 1300 (0) 1300 (0) 
TOTAL (£) 1408 (127) 1339 (41) 
                                         
4 Confirmed with reference to the Drug Tariff and the manufacturer of the medicine in the UK 
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The initial set-up costs incorporate the costs required to provide the relevant training and to set up the 
CMP for patients for whom supplementary prescribers are prescribing. Table 8.2 indicates that the 
average set up costs of supplementary prescribing were slightly higher for nurses at £1408 compared to 
£1339 for Pharmacists. Interviews with supplementary prescribers were also used to estimate whether 
they had received any increase in salary as a result of becoming a supplementary prescriber. However 
none of the individuals indicated that they had received any increase in salary as a consequence of 
taking on this role. Some of the individuals (n=6) indicated that they had to meet the costs of levies 
incurred as a result of registering as a supplementary prescriber and these levies varied within a range 
from a minimum of £25 to a maximum of £76 respectively. 
 
7.4 Analysis of consultations 
An in-depth analysis was undertaken on 30 consultations between supplementary prescribers and 
patients (3 per case study) looking at the length of consultations and the questions asked. An additional 
analysis was undertaken to identify emergent and common themes within the consultations.  
 
In all but one of the case studies, the supplementary prescriber did not have their own room in which to 
undertake the consultations. This varied from prescribers who were able to use the same room for an 
entire clinic session to those who changed rooms between consultations. In five of the consultations 
observed there were additional people present: parents of young children (3 consultations), an adult 
child of an older parent (1 consultation), a spouse (1 consultation) and a doctor (1 consultation).  
 
There was no significant difference between nurses and pharmacists in the length of consultations; 
however the mean length of consultation for nurses was 14.3 minutes (standard deviation 9.68 minutes) 
with a range of 7.5 to 44 minutes. The mean length of consultation for pharmacists was 18.1 minutes 
(standard deviation 8.42 minutes) with a range of 7-43 minutes.  
 
The number of questions asked by supplementary prescribers and by patients was assessed. Clearly, 
the length of the consultation might influence the number of questions that could be potentially asked by 
both the prescriber and the patient. The number of prescriber questions varied from 55 (in a 44 minute 
consultation by a pharmacist) to 5 (in a seven minute consultation, also by a pharmacist). The number 
of patient questions varied from 28 (in the same 44 minute consultation) to 0 (four consultations, all with 
children).  There were only three consultations in which the patient asked more questions that the 
prescriber. In the four consultations where there were no questions asked by the patient, the patient 
was either a teenager or a child. In three of these cases, the parent of the child was also present and 
asked questions about the child’s treatment and medication.  
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7.5 Observation of consultations 
The nature of the introduction to the consultation depended upon whether the supplementary prescriber 
had assessed the patient previously. It was evident from a number of sites that the prescriber had an 
existing relationship with the patient; in contrast some patients were consulting the supplementary 
prescriber for the first time. Description of their role was often described in relation to a doctor: 
 “I’m working with [doctor S] in the clinic”  
“I’m Kim, I’m a pharmacist that works alongside the doctors and nurses here at the surgery and 
I’ve been trained to allow me to prescribe for patients with high blood pressure”. 
 There were no examples of patients questioning the authority of the supplementary prescriber. There 
was only one site where the supplementary prescriber referred to the clinical management plan.  In this 
site the prescriber also told the patient that they could return to see the doctor instead if they preferred. 
Physical examinations played a role in the majority of the consultations analysed. These varied from 
blood pressure and pulse readings, to examination of injection sites and examination of feet. Whilst 
most of the examinations were undertaken in the consultation room, in one case the nurse took patient 
height and weight measurements in an adjacent room and in another, weight and blood pressure 
measurements were undertaken by a healthcare assistant. In one consultation, a blood sample was 
taken from a patient.  
 
The format in which the patient received their prescription varied. In five cases, the supplementary 
prescriber printed out the prescription and signed it themselves. In one case the prescription was 
printed out and the patient was asked to take their prescription to reception in order for a doctor to sign 
it, as the computer software would not permit non medical prescribing. In one case study it was 
observed that the prescriber could not access prescription printing and patient test results on the same 
computer. Therefore in one observed session the prescriber hand-wrote prescriptions in order to access 
test results, whereas in a different session, prescriptions were electronically printed. In five cases, 
prescriptions were handwritten and signed by the supplementary prescriber. There were also examples 
in two case study sites of supplementary prescribers printing out repeat prescriptions for patients to take 
to the reception to get the doctor to sign.  In two cases, prescribing for the patients was undertaken by 
their GP through a hospital repeat prescription service, so the supplementary prescribing consultation 
was to review this prescribing and one site involved changes to medication doses (for hypertension 
following blood pressure monitoring) that led to changes to the patients' records and subsequent repeat 
prescription. One pharmacist described their prescription: 
 “That prescription is just like any doctors prescription although I’ve signed it”.  
 
Medicines were described in a number of different ways by both patients and supplementary 
prescribers.  Most were described as the name of the drug, but there were examples of medicines being 
described more colloquially: “the sickness pill” or “the green capsules” or “the water tablet” by both 
supplementary prescribers and patients. There were numerous examples of advice being given on how 
 52 
to take medicines e.g. statins and steroid inhalers that had been prescribed for patients by doctors.  It 
was also apparent that, supplementary prescribers discussed wider health and social issues with 
patients during the consultations. There were examples of smoking cessation advice, dietary advice and 
vaccination information being given to patients, although written information was only given to patients 
in one site. There were also some examples of negotiation taking place in the consultations, particularly 
in the substance misuse sites, where patients had specific ideas of the medicine (and dose) that they 
wanted to take. Other examples of negotiations in the consultations include a patient being encouraged 
to wear a 24 hour blood pressure monitor when they were reluctant to do so.  
 
Explicit references to doctors and their continued input into care were made during many of the 
consultations. These varied from supplementary prescribers asking a doctor to come and speak to the 
patient during the consultation, to a supplementary prescriber leaving the room to speak to a doctor who 
was on site (in both primary and secondary care settings) as well as cases where patients were referred 
back to the doctor. One referral back to the doctor was made by a supplementary prescriber who was 
also qualified as an independent prescriber: “this is the stage where I would actually ask you to see one 
of the doctors”. In one case, the supplementary prescriber was asked a question about a condition 
which they did not have knowledge of, and answered the question “I’m not a doctor and I couldn’t 
possibly tell you”.  
 
7.6 Analysis of Clinical Management Plans (CMPs) 
As part of the overall case study assessment, copies of CMPs were obtained to both explore how they 
were being used in practice and also to assist in the assessment of prescribing safety. Safety 
assessments were made by the expert assessors whereas more general observations were made by 
the researchers. It was evident that CMPs were being used differently and fell into 5 broad types, 
varying in terms of whether they were present or missing, paper based or electronic, generic or patient-
specific, signed by doctors before or after prescribing had occurred, and used by supplementary 
prescribers only or those with independent and supplementary prescribing qualifications (Appendix D).  
 
Considering the range of types in more detail, the first type was identified in two case study sites, where 
CMP documents were identified but were not used for individual patients or attached to patients' 
records. In one case, this was a single CMP which contained a large number of indications - which 
assessors in the safety and appropriateness study described as a 'generic CMP [that] provides no 
useful information' with 'no details of dosing [or] follow-up'.  In the other case, four generic CMPs had 
been developed which corresponded to the four medicines that the nurse prescriber used, and these 
were supplemented with further documentation about the medicines (such as manufacturers product 
leaflets) and associated diagnostic tests and referral procedures. However, in both these sites, the 
prescriber was also qualified as an independent prescriber and therefore a CMP was not strictly legally 
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required for the prescribing. Of significance, however, was the observation that both prescribed 
medicines independently during the observations that were not included in CMPs. 
 
The next two types of CMP identified in case studies were physical copies that the prescriber usually 
developed for the particular patient prior to the consultation and either printed out so that they could be 
signed and stored in the patients' paper notes (or electronic notes if scanned), or attached electronically 
and involving electronic signatures for patient, doctor and supplementary prescriber agreement. Two 
types of such CMPs were identified since some were not signed or agreed by the doctor until after 
prescribing had occurred, and this was observed in three case study sites for some of the CMPs. In one 
case study - where controlled drugs were prescribed - this was the standard practice and the prescriber 
noted that the doctor would usually sign them as a batch when time permitted.  
 
A fourth type of CMP was identified in one site where controlled drugs were prescribed, and this 
involved a generic CMP being developed and attached to individual patients' electronic records, with an 
electronic record of the doctor's, prescriber's and patient's agreement being added, although the 
prescriber noted that not all doctors conformed to this system of attaching the generic CMP to patient's 
records prior to a supplementary prescribing consultation occurring. 
 
The fifth type involved one observed instance of a CMP that was missing from a patients' record, 
although the prescriber believed one had originally been developed and believed a receptionists may 
have failed to update the patients' record despite being given the paper CMP initially. 
 
In relation to the actual content of CMPs, there was also variation: in some sites, specific drugs were 
referred to, along with detailed referral criteria, but in others quite general references were made only to 
therapeutic classes of drugs. Assessors in the safety and appropriateness study noted that in the area 
of cardiovascular disease, a cholesterol lowering medicine or aspirin had been prescribed but these 
either were not specifically included in the CMP as permitted medicines, or they did appear but were not 
accounted for in terms of conditions to be treated (namely, either primary/secondary prevention of 
cardiovascular risk or hypercholesterolaemia). 
 
Based on these above observations, the assessors identified transgressions in six case studies, namely 
where doctors' signatures were obtained following prescribing, where generic CMPs were used or 
where a CMP was missing. 
 
7.7 Views of supplementary prescribers 
Ten interviews were conducted with pharmacists and nurses participating in the case studies, although 
at one site it was not possible to conduct an interview with the pharmacist and, in another, a pharmacist 
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was interviewed but subsequently withdrew from the research (as they became an independent 
prescriber). The interviews revealed a similar range of themes to those identified in the two 
questionnaire surveys described in chapter seven, including experiences of training, views on CMPs, 
doctors, independent prescribing and positive and negative aspects. Overall, the interviews showed that 
supplementary prescribing had been a positive experience, with both pharmacists and nurses 
commenting that it had been rewarding, had increased job satisfaction and allowed them to utilise their 
clinical abilities and enabled them to be more involved in, and have more time to devote to, patients and  
their care: 
"For me it's been a complete positive experience and a long time coming […]I absolutely 
love it, it's the highlight of my week. I would do it full-time. I mean I qualified a couple of 
years ago and I never had the chance to do it because, you know, for whatever reason, it 
wasn't set-up or was difficult for the trust to set-up […]" (Nurse primary care, substance 
misuse) 
 Negative comments were few but included: isolated experiences of patients stating that they preferred 
to see a doctor; several nurses and pharmacists commenting upon the poor quality of the prescribing 
courses they undertook and problems with use of CMPs. Where training courses were criticised, this 
was based on a perception that they did not adequately prepare them for prescribing practice because 
they were either too general or because the training was considered of poor quality. CMPs were 
considered to be problematic in practice, due to them being time-consuming to set up and with 
attendant difficulties in some case study sites in having a doctor agree to them: 
"like ridiculous situations where […] someone had said […] to see [the supplementary 
prescriber] at the next appointment and she will sort out your clinical management plan and 
then you haven’t got anybody here to do one so you know you are overstepping the law 
aren’t you, you are breaking the law by doing it but clearly the spirit of it is there." (Nurse, 
substance misuse) 
 On the other hand, one nurse was more positive and considered the CMP to be important in defining 
her area of prescribing and used a generic CMP and associated medication literature at the same time 
as being independently qualified. One nurse prescriber remarked that becoming a prescriber had 
resulted in what she considered to be inappropriate requests to prescribe (from other nurse colleagues).  
 
A number of examples of intra and inter-professional conflicts emerged, and these could be grouped 
into those between nurse prescribers and other nurses, and between pharmacist prescribers and 
nurses. The former involved a sense of rivalry within the nursing profession about those with a 
prescribing role and a perception that existing nursing roles were being neglected, whilst the latter 
seemed to reflect a form of boundary encroachment: 
"The ones that I had the problem with were the basic nurses and I still have actually.  I 
have got a lot of problem.  They just don’t think it is right that a pharmacist is taking over 
their role and feel quite vulnerable about it whereas the nurse practitioners see us as an 
add on to them so that we can do it together" (Pharmacist, primary care) 
 Echoing a theme identified in doctors' interviews, several nurses and pharmacists commented upon the 
role of doctors in encouraging prescribing training and acting as DMPs.  Several pharmacists 
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commented upon certain skills that they perceived pharmacists to have which nurses lacked which 
made them more suited for a prescribing role. These included a 'broader' degree training, and greater 
expertise in medicines, pharmacology and concordance. Of note were several pharmacists' comments 
that, in their experience, nurse prescribers lacked confidence and linked this to an inability to take 
responsibility for their prescribing. A number of comparisons - as opposed to conflicts - were also 
reported between supplementary prescribers and doctors. Some centred on perceptions that doctors 
might resent the additional time that supplementary prescribers had for their consultations, although it 
was recognised that there was an associated need to justify this time by undertaking additional tasks 
depending upon the clinical area, such as education, health promotion, compliance advice, diagnostic 
checks, health assessments and medicines use reviews. Isolated comments included a perception of 
different standards, such as one nurse's belief that if a prescribing error occurred, she would be dealt 
with more severely than a doctor, and a pharmacists' conviction that poor time management by a doctor 
would be tolerated, but not for a pharmacist. Confirming the views of patients in interviews, nurses and 
pharmacists reflected that they might be less threatening to patients than doctors and hence more 
approachable.  
 
Although the views and experiences of nurses and pharmacists were broadly similar, some differences 
were apparent.  Firstly, supplementary prescribing appeared to be a consolidation of existing practices 
for three of the nurses, but was an innovation for most pharmacists and appeared to have transformed 
their roles. That the three nurses for whom supplementary prescribing consolidated existing practices 
worked in secondary care may also be relevant, but they described previously making prescribing 
decisions - often following their assessments or tests - and having a doctor write a prescription:  
"I was doing the nurse led clinic and […] it was becoming logistically a nightmare in terms 
of medication because in the nature of the condition, things change - I need to change 
doses, I need to change drugs completely if they have put weight on and it took me so 
much time to do a consultation and then me say 'well I think you need to change 
medication so what I am going to do now is send you home, find a doctor, tell them what to 
write, get a prescription and post it out to you and I can only do that second class so you 
might get it in a week’s time' and they’re tearing their hair out now and so I decided to do it 
[the prescribing course] because it would change my practice"  Nurse, secondary care 
 For pharmacists, there appeared to be more of a change to working practices - in the primary care 
setting, for example, several pharmacists described an explicit change from previous PCT practice 
support or ‘surveillance' roles to that of prescriber directly involved in patients' care. Secondly, 
pharmacists appeared to validate or demonstrate their clinical and prescribing acumen in interviews 
through the use of (often extremely detailed) examples of prescribing decisions that had been significant 
for patients. A third difference concerned pharmacists' attitudes towards independent prescribing, which 
was identified as an imperative. Such pharmacists shared, however, the same views as nurses who 
currently used supplementary prescribing, with independent prescribing being considered to offer 
pragmatic benefits in relation to more flexible practice and an end to mandatory CMPs. 
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All interviewees shared a pragmatic and developmental approach to role enhancement in relation to 
prescribing. For example, substance misuse nurses eagerly awaited proposed legislative changes to 
allow simplified controlled drug prescribing independently. In addition, several nurses and pharmacists 
discussed expanding into different clinical areas, although these were usually still niche areas and 
linked to existing clinical competencies. As well as expansion in other clinical areas, there was a desire 
amongst those who were not using prescribing full-time to expand prescribing in terms of more patients 
and increase their workload, reflecting their awareness of the limited scale of their present prescribing. 
 
7.8 Views of independent prescribers 
All the independent prescribers who were interviewed were either GPs or consultants and had direct 
experience of supplementary prescribing, either in relation to developing or signing CMPs, acting as a 
DMP or through referring patients to supplementary prescribers. Overall, their impression of 
supplementary prescribing was very positive, with few negative aspects reported. It was also apparent 
that many doctors lacked a full understanding of supplementary prescribing conceptually and 
procedurally, with many using the term 'protocol' rather than CMP, together with ignorance about the 
need for patients' and doctors' agreement to patient specific individual plans before prescribing, for 
example. Positively, doctors perceived supplementary prescribing to have benefits for patients, doctors 
and also the supplementary prescriber. For patients, doctors variously cited increased safety, improved 
quality of service, longer consultation times, enhanced disease control, greater continuity of care and 
reduced delays. Doctors' workloads were frequently cited, with several arguing that they had decreased. 
Others, however, noted that the scale of supplementary prescribing was too small for any changes to be 
noticed, whilst some also commented that because more patients were being seen as a result of 
supplementary prescribing, this inevitably resulted in eventual presentations to doctors at some stage. 
Several doctors also commented that supplementary prescribing - especially from pharmacists in 
primary care - had led them to reflect more on their clinical knowledge and prescribing patterns. 
Supplementary prescribing also appeared to contribute positively to meeting targets and QOF and was 
considered 'cost effective' by several. 
 
Few negative aspects emerged, with occasional comments about isolated patient concerns about being 
referred to a non-medical prescriber, the administrative problems of signing CMPs, losing contact with 
patients and being referred more difficult and complex patients. There were comments by some doctors 
that supplementary prescribers enjoyed 'the luxury' of longer consultations. 
 
Doctors were asked to describe their experiences of supplementary prescribing, in terms of their on-
going involvement and also setting-up, and also non-medical prescribing more generally. Most doctors 
knew the nurse or pharmacist prior to their supplementary prescribing role, and hence supplementary 
prescribing represented part of an on-going relationship, although one doctor commented that 
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supplementary prescribing had changed his perception of pharmacists. It was apparent that many had 
experienced non-medical prescribing in the form of independent nurse prescribing in primary care prior 
to supplementary prescribing, although the former was often cited negatively, as being often 
problematic, leading to increased workloads, safety concerns and issues around nurse competency and 
responsibility. As noted, supplementary prescribing elicited few negative responses in comparison but 
an emergent theme was doctors' perception of supplementary prescribing as being 'protocol' prescribing 
in a 'narrow' clinical area, and, normatively, a lesser task than other medical activities, such as diagnosis 
in particular. Doctors variously referred to prescribing as being a ‘bread and butter' activity that involved 
merely the 'start, stop, increase and decrease' of medicines and one reflected: 
"[The supplementary prescriber] prescribes well known drugs…a few well known drugs, 
according to protocol and she can increase or decrease it and start it or stop it. So it's 
almost not like de novo prescribing, it's continuing prescribing […]."  Dermatology registrar 
Doctors also referred to some tasks associated with supplementary prescribing, such as titrating 
medicines doses in clinical areas such a substance misuse and hypertension or responding to 
cholesterol tests, as tasks that wasted doctors' time. A key distinction was made in this respect between 
supplementary prescribing and the overall work of doctors, especially in relation to diagnosis, which was 
argued to be a more skilled, uncertain and difficult task. Supplementary prescribing was not considered 
by any of the doctors interviewed to be a threat to their own professional work, although several 
questioned the viability of a full diagnostic role (as in IP) and how doctors' roles would then be any 
different from an independent nurse or pharmacist prescriber. Other doctors, however, believed that a 
diagnostic role was possible and was part of taking full responsibility for patients, although a recurrent 
theme was that this might only work in specific clinical areas where nurses and pharmacists had 
particular expertise. A key contrast was made between doctors' broad range of experience and 
knowledge of many conditions and the more limited understanding of nurses and pharmacists. Indeed, 
the indeterminate and extensive nature of doctors' training and experience appeared to be important in 
defending some doctors' roles and contributed to a perception that medical authority was being 
maintained. Other aspects of interviews also supported medical authority included the distinction that 
prescribing per se was a lesser task than 'de novo' diagnosis and doctors' accounts of becoming 
involved in non-medical prescribing. For example, several commented that they would only act as 
DMPs for nurses or pharmacists that they trusted and had refused to assist those not known to them. 
Furthermore, several examples were provided of doctors being able to control prescribing activities - 
especially in the case of nurse practitioners in primary care - in terms of stopping prescribing or not 
encouraging training: 
"I am completely confident that the right people will be selected because ultimately we 
are selecting them […] and if we thought it was generally pointless and we didn't see 
any value to the practice then we would say’ no’." Jack, GP, thirties. 
 There was a perception that in the secondary care setting, however, this may be more difficult to 
influence. 
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Another group of issues to emerge involved perceptions about occupational attributes and comparisons, 
amongst supplementary prescribers and doctors. A key one, in addition to the distinction mentioned 
above about broader clinical knowledge, concerned issues of doctors' unique training and experience, 
and also intellectual ability, especially in comparison to nurses. The latter were reported by several 
doctors to be - by inference - intellectually inferior, non-degree educated and even perceived to be more 
influenced by pharmaceutical companies. Pharmacists were not viewed as critically and several doctors 
commented upon pharmacists’ superior knowledge of pharmacology, evidence-based medicine and 
drug costs. However, it was apparent that doctors considered nurses and pharmacists to be well suited 
to roles such as supplementary prescribing, because of their record and time-keeping skills, and 
tendency to follow guidelines and protocols (as compared to doctors). Several doctors believed 
pharmacists rather than nurses to be more suited to a prescriber role, based upon their knowledge, 
although it was recognised that nurses had important clinical skills which pharmacists lacked. This led 
one doctor to argue that a teamwork approach was best, to allow the respective skills of all professions 
to contribute to the well-being of patients, although other doctors recognised inherent differences 
between doctors and supplementary prescribers: 
"I think with a supplementary prescriber, there is a temptation to feel able to over-rule a 
decision whereas with another doctor, you at least have to negotiate." (GP, thirties) 
One GP distinguished between his experience of pharmacists qua prescribers and those in the 
community, who were viewed as being 'separate' and less appropriate for the necessary 'team 
approach' of prescribing and managing many conditions. 
Doctors also identified several attributes that they believed contributed to a good prescriber, such as 
taking responsibility and being confident but more importantly, having insights into their clinical 
limitations - 'knowing what they don't know' - and also asking for help. Asking for help was typified in 
terms of a repeated comment that supplementary prescribers should be able to 'knock on the door' of 
the doctor, and appeared not to be resented as an intrusion or a conflict with the need for professional 
responsibility. Indeed, there was a sense that several doctors encouraged such advice seeking: 
"Our plan was to give him relatively straightforward people with hypertension but he is 
expanding his role into looking at other aspects of cardiovascular medicine so he is not 
scared to knock on the door and say, you know, "this is where I am with this person, 
what do I do next?" and I would worry that the danger would be sometimes that people 
would muddle on without you know feeling that they could offload and share with the 
doctor who was attached to them." (GP, fifties) 
However, a theme identified amongst several doctors was that of self-deprecation and insights into their 
own professions' variable standards, where 'arrogance' amongst colleagues was claimed to possibly 
hamper non-medical prescribing initiatives, together with poor clinical and prescribing standards 
amongst some doctors.  
 
Doctors were also asked about their broader understanding of why supplementary prescribing and other 
non medical prescribing initiatives had been introduced and they perceived a range of factors to be 
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relevant, but frequently considered themselves somewhat 'cynical''. They identified financial saving in 
relation to nurses and pharmacists being cheaper, some PCTs offering supplementary prescribing 
services at no cost to GP surgeries, increasing workload and patients, a shortage of doctors and 
especially GPs, the need to meet target and general comments about governmental policy. Indeed, the 
latter was frequently viewed not only cynically but also as inevitable and, in contrast to the theme of 
doctors' continued medical authority identified above. 
 
7.9 Views of patients 
Twenty-eight patients were interviewed, the majority of whom were recruited from primary care settings 
and interviews lasted from 5 to 30 minutes overall.  Interviews with patients revealed positive 
experiences in relation supplementary prescribing, and insights relating to patients’ attitudes towards 
doctors, nurses and pharmacists, patients’ understanding of illnesses and treatment, non-medical 
prescribing generally and the reasons for its introduction. Some patients had experienced 
supplementary prescribing on a number of occasions, whilst for others, the case study observation was 
their first experience. Patients identified a range of positive aspects, including a perception that they had 
more time during consultations with the supplementary prescriber compared to normal care and a 
concomitant sense of not being ‘rushed’ or ‘kept waiting’; supplementary prescribers were often praised 
for being more approachable (than their experience of normal care) and one patient noted that having 
another person involved in their care provided extra re-assurance. Being approachable was often 
contrasted with patients’ perception of doctors and although none of the patients interviewed felt there 
was a marked difference in the style of the respective consultations, doctors were perceived as being 
more intimidating and hurried: 
“I wouldn’t say that she [the supplementary prescriber] is lesser, it is just that a doctor is 
a little bit of a higher person and I feel a bit small around them if you know what I mean 
whereas if it was a nurse I suppose you are more or less on the same level if you know 
what I mean.” (Male substance misuse patient, twenties) 
Patients did not spontaneously mention any negative aspects of supplementary prescribing and only in 
very occasional asides did anything amounting to criticism of supplementary prescribing emerge: one 
patient was inconvenienced by their pharmacist prescriber not being able to sign prescriptions (they left 
consultations with a computer-printed prescription that the doctor still needed to sign – leading to delays 
in receiving their medication); another patient felt too much information about their medication was 
provided by a supplementary prescribing pharmacist, whilst another patient felt too little had been given 
by a supplementary prescribing nurse regarding side effects.  
 
First experiences of supplementary prescribing varied in terms of how patients were referred (although 
not surprisingly it was almost always the doctor who initiated the referral). Indeed, doctors appeared to 
be involved in some form of legitimation of the supplementary prescriber’s role for the patient: 
"Doctor S sent me to the pharmacist and I went with his confidence really and I had no 
reason to doubt he was wrong you know. I don't think he was wrong and if he sent me 
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to the nurse I would have the same confidence but I wouldn't have the confidence to 
select my own nurse." (hypertensive patient, seventies, primary care) 
However, there appeared to be some degree of uncertainty as to whom the patient would actually be 
seeing, with some doctors not mentioning the type of professional the patient would be seeing. This led 
to patient assumptions or confusion about the supplementary prescriber, with some falsely believing 
they were seeing a doctor, whilst others thought pharmacists were actually nurses (two patients’ 
observed however that the supplementary prescribers’ inability to sign prescriptions challenged their 
assumption of a medical encounter) and one thought the nurse would ‘only take blood’. These first 
encounters were also revealing in that they were often associated with a certain ‘suspicion’, ‘concern’ or 
‘apprehension’ about whom they would be seeing, although patients reported that these concerns were 
allayed following their meeting with the supplementary prescriber: 
 "I was a little bit apprehensive I suppose because I thought I would be seeing a proper 
doctor you know but when I met him [the supplementary prescriber] he was very 
pleasant "  (Hypertensive patient, sixties, primary care) 
Patients were asked about their knowledge of supplementary and other forms of non-medical 
prescribing and asked to comment on why they perceived these initiatives to have been introduced. 
Two sets of accounts emerged: the first centred around those who appeared to be informed of health 
care policy generally and who reported having a knowledge of pharmacist and particularly nurse 
prescribing, the other set of accounts was comprised of those who were less aware and for whom the 
supplementary prescribing consultations were their first experience of non-medical prescribing. What 
both groups had in common was a perception that such prescribing had been introduced to reduce the 
workload of doctors, who were perceived to be subject to the pressures of seeing increasing numbers of 
patients in a limited time. Cost savings were also cited, with nurses in particular being regarded as 
'cheaper’ than doctors, although one patient argued that this led to reduced expectations.  
 
Many patients were also candid about their own illnesses and perceived their long-term conditions to be 
almost a burden for doctors and the NHS more generally. Patients’ knowledge of supplementary 
prescribing also appeared to be grounded in an understanding that this occurred in the narrow clinical 
specialty of the nurse or pharmacist and many patients drew a clear distinction between this and the 
more general clinical knowledge and work of doctors, especially in the primary care setting. However, 
this understanding of a clinical niche for supplementary prescribing appeared to be a positive and 
several patients perceived such prescribers to have superior knowledge to GPs and these clinical 
niches provided patients with confidence about the competency of the prescriber. Linked to patients’ 
insights into their illnesses was also a common distinction between their present chronic condition (such 
as hypertension in many of the primary care case studies) and more acute illness, where it was clearly 
stated that the doctor would still be consulted. Indeed, several examples were provided where patients 
either had asked the nurse or pharmacist about an acute illness or had been referred to their doctor, or 
where patients had made separate appointments. The referral mechanism back to their doctor was a 
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frequently cited one and was argued to be a necessary attribute of the supplementary prescriber, 
although several patients commented that they rarely saw their doctor and the supplementary 
prescribing encounter was their only current experience: 
"The doctor more or less said because he was so busy that in future I would be seeing 
this person but she was well qualified but if I wasn't happy at all that I could go back to 
him […] I am not afraid of [the supplementary prescriber] like I am the doctor. In awe 
really - not afraid - in awe."  (Hypertensive patients, seventies, primary care) 
 Patients also provided further comments on the attributes of nurse and pharmacist prescribers and, 
related to referrals, noted that understanding the limits of their own clinical competency was important, 
together with the ability to communicate and be up-to-date about their clinical area. 
 
Another theme concerned comparisons between doctors and nurse and pharmacist supplementary 
prescribers and several have already been considered, such as their respective approachability, clinical 
knowledge and sense of urgency and workload.  Doctors’ greater length and breadth of training and 
experience were apparent for many, and there was a perception that supplementary prescribing was a 
recent initiative and hence nurses and pharmacists had been more recently trained than compared to 
doctors. For some patients, a distinct hierarchy was present, with the doctor being considered ultimately 
the best person to prescribe, as the previous quotation indicated, and as another patient noted: 
" Well, you know, it's your health, isn't it? You want the best you can get kind of thing, 
you know what I mean, and then they start putting you down to a labourer… you know 
you need a word. You know what I mean? I'm not degrading him you know what I mean, 
and then you think well I'd rather see the specialist kind of thing, the doctor" (Male 
hypertensive patients, forties, primary care). 
 For other patients, however, doctors were viewed as being fallible like nurses and pharmacists as were 
viewed more as providers of information, from which the patient could then make an autonomous 
choice. This also represented the final emergent theme, namely patients who appeared to be active and 
those who were more passive. For the former, the supplementary prescriber was no different from the 
doctor and could be challenged –although one patient conceded they might be slightly less likely to 
challenge a doctor – and they felt they were in control of their treatment and indeed felt a certain 
pressure in such autonomy. For other patients, however, there was a more passive approach, of ‘giving 
things a go’ and a presumption that all NHS changes were for the good and should be accepted. One 
patient appeared to be passive in being disappointed by the advice given by the supplementary 
prescriber, yet did not feel she could demand to see the doctor again. 
 
7.10 Patient questionnaires 
Questionnaires were returned from nine of the ten case study sites. A total of 44 questionnaires were 
returned. Fewer questionnaires were returned by patients prescribed for by nurses (n=11) as compared 
to pharmacists (n=33). Also fewer questionnaires were returned from patients prescribed for by hospital 
supplementary prescribers (n=5) as opposed to primary care supplementary prescribers (n=39). 
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Therefore the dataset cannot be analysed in sub groups. Tables which summarise questionnaire 
responses can be found in Appendix D.  
 
Patients were generally very positive about being prescribed for by supplementary prescribers with 40 
agreeing that they had confidence in their supplementary prescriber and 41 that they had a good 
relationship with their supplementary prescriber.  Higher levels of disagreement were found around 
CMPs, as Table 7.3 indicates. Over half of the patients responding to the questionnaire disagreed or 
were not aware that they had a CMP, although 14 patients said that they had signed their CMP, which 
links in with the findings of the interviews and observation.  
 
Table 7-3 Patient views about the CMP and information  
Variable Agree Disagree Don’t know 
I have been given written information about having a 
supplementary prescriber 
22 14 4 
I have a written plan for my treatment by the 
supplementary prescriber 
15 15 6 
I was involved in designing my written plan for my 
treatment by the supplementary prescriber 
14 18 2 
I understand my written plan for my treatment by the 
supplementary prescriber 
16 14 4 
I signed my written plan for my treatment by the 
supplementary prescriber 
14 15 6 
 
Use of the MARS scale showed that the patients of supplementary prescribers did not engage in non 
adherent behaviour, with only a very small number of patients  answering that they often (1 response) or 
sometimes (8 responses) engaged in behaviour which was non adherent.  With reference to the SIMS 
scale, patients were assessed on their satisfaction about receiving information related to their medicines 
use. Within this group there were high levels of satisfaction with information received, with patients who 
answered “about right” being the most frequently chosen group for each statement. 
 
Qualitative responses to the question “What do you consider is the best thing about having a pharmacist 
supplementary prescriber” resulted in responses from 33 patients. The comments that they made were 
in line with the findings presented in section XXXX. Patients viewed supplementary prescribers as 
knowing more about medication and having more time to spend with patients. Positive comments 
related to ease of getting an appointment with a supplementary prescriber, confidence in the 
supplementary prescriber, a more informal level of conversation and being easier to talk to. Other 
benefits that they identified included freeing up of doctors time to deal with acute conditions. Patients 
also commented that they received excellent care from both supplementary prescribers and doctors.  
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7.11 Summary 
 
No prescribing errors and three assessments of inappropriate prescribing (including two for use of a 
branded rather than generic medicine) were identified from 71 supplementary prescribed medicines; 
CMP transgressions were identified in six case studies, all based on the majority view of a panel of 
assessors. 
Costs for setting-up supplementary prescribing slightly higher per nurse (£1408) than per pharmacist 
(£1339); no salary increases identified but often increased insurance costs. 
Analysis of CMPs revealed five different types in use, varying in terms of whether they were paper or 
electronic, used by supplementary prescribers only or those with an independent prescribing 
qualification, generic or patient-specific and signed before, during or after prescribing had occurred;  
some variation and ambiguity identified in terms of CMP content. 
Patients' experiences of supplementary prescribing were positive, with longer consultation times valued, 
nurses and pharmacists considered easier to talk to and perceived as experts in their clinical areas; 
perceiving time/workload saving for doctors also recognised. 
Several patients were initially apprehensive of supplementary prescribing, although doctors' roles in 
initially referring patients legitimised supplementary prescribing. 
Doctors still considered accessible by patients and ultimately responsible for their care, despite 
supplementary prescribing; several patients ideally wanted to see a doctor for all consultations. 
Although some patients were aware of non-medical prescribing generally, most lacked any detailed 
understanding of supplementary prescribing and clinical management plans. 
Doctors appeared to lack understanding of supplementary prescribing both conceptually and practically 
often referring to 'protocol' prescribing and displaying some ignorance or confusion over the use of 
CMPs and medical and patient agreement. 
Doctors identified benefits for patients and themselves from supplementary prescribing, in terms of 
lesser workloads, increased reflection on their own prescribing and meeting targets. 
Doctors favoured nurse and pharmacist prescribing using 'protocol's in specific clinical areas and 
considered a general diagnostic role best suited to doctors. 
Doctors expected supplementary prescribers to recognise their clinical limitations and seek doctors' 
help, together with taking responsibility for prescribing and clinical decisions. 
Supplementary prescribing consultations varied in length and complexity. Supplementary prescribers 
who had not met patients before introduced themselves. There were frequent references to doctors, 
including prescribers seeking doctors' help during consultations and referring patients on to doctors. 
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8 Discussion 
 
The aim in this chapter is to reflect upon key results from various aspects of the evaluation and discuss 
these in the light of published literatures.   
 
8.1 Training issues for supplementary prescribers 
This study identified several issues in relation to training for supplementary prescribers. Common to 
many problems identified with the training is a fundamental difference in previous training and existing 
competencies and skills that means offering a single prescribing course risks not addressing the 
learning needs of each profession. Benefits of increased understanding of different professions and 
improved communication and collaboration are all aims of inter-professional learning. These could have 
benefits not only in training but also in subsequent practice, reflecting a more fundamental socialization 
process that can occur in healthcare training (Elston 2004). However, the need to provide each  
profession with potentially differing sets of knowledge and skills may be difficult to accommodate in 
practice. This is no more evident than in the case of pharmacological knowledge, where a clear theme 
emerged in this study whereby pharmacists considered themselves to be already competent in this 
respect, echoing previous research (Dawoud et al 2004), whereas nurses reported the pharmacology 
content of courses to be helpful and required. The use of approved, or accreditation of prior learning 
may be relevant in this respect. Furthermore, this research only collected data relating to pharmacists 
self-reports and perceptions of pharmacological competency and further empirical research may be 
needed to explore this, as has occurred within the nursing profession (Banning 2004, Bradley et al 
2006, Offredy et al 2007). A further issue concerns the integration of prescribing training into the 
undergraduate curriculum, as has been proposed (RPSGB 2003) and this study raises questions about 
such a proposal. In particular, how will undergraduate students' lack of clinical experience affect the 
success of such courses and will it be possible to incorporate the period of learning in practice and time 
with a DMP that pharmacists so valued into an undergraduate course? Such concerns have emerged in 
other research (Warchal et al 2006) but further research will be needed to assess these developments. 
 
8.2 Supplementary prescribing practices & implementation issues 
The analysis of PACT data (see Section 2.2) revealed relatively modest levels of prescribing by both 
nurses and pharmacists. This was subsequently confirmed both in our surveys of practice, and most 
clearly in the case studies. As can be seen from the survey, prescribing volumes were generally of the 
order of between 2-10 items per week, for both of the professions. The difficulties that were experienced 
recruiting case study sites resulted from the low reported level of prescription items dispensed (typically 
below 10 items per week). Therefore, triangulating across the various data sources, it was clear that 
nurses or pharmacists were undertaking relatively modest levels of supplementary prescribing.  
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Again, triangulating across the data sources, it was apparent that nurses and pharmacists were 
experiencing a number of implementation difficulties in relation to the practice of supplementary 
prescribing. Several factors appeared to be pertinent here. Firstly, several case study sites were using 
prescribing software which could not generate printed prescriptions with the required information in 
order to enable the pharmacist to physically sign the prescription. In one case, this resulted in the 
pharmacist prescriber signing no actual prescriptions at all but issuing unsigned prescriptions for 
doctors to sign. In two others, this resulted in lengthy delays as prescriptions were hand-written. Whilst 
similar implementation problems have emerged in previous research (Courtenay et al 2007, George et 
al 2007, Weiss et al 2006), this research confirms that such information technology issues have not 
been entirely overcome. Secondly, it was clear from our observational work that policies encouraging 
primary care prescribing were observed in several of the secondary care hospital settings. In such 
examples, prescribing by the patient's GP was encouraged wherever possible, necessarily limiting the 
scope for supplementary prescribing. Thirdly, it was observed that in one site changes to medication 
doses (for hypertension following blood pressure monitoring) led to changes to the patients' notes and 
subsequent medication, but did not result in supplementary prescribing. Hence, the prescribing 
opportunities for nurses and pharmacists did not necessarily lead to actual prescribing and were more 
representative of changes in clinical autonomy. These factors are likely to have an impact on actual 
levels of supplementary prescribing.  
It was also apparent from the survey data that supplementary prescribing by pharmacists was very 
limited in the community setting (7.3% of survey respondents) despite this being the largest area of 
practice for pharmacists in England - around 70% of pharmacists in the UK overall reported active 
employment in the community setting (Hassell et al 2006). Weiss et al (2006) commented upon 
potential problems relating to the use of supplementary prescribing in the community and cited poor 
access to patient records, lack of funding and distant relationships between community pharmacists and 
doctors. Other research also suggests that it is not just community pharmacists' separation from doctors 
but potentially also patients and customers too (Cooper et al In Press) that may be a concern in this 
setting. To such barriers may also be added a perception that community pharmacists are still regarded 
as 'shopkeepers' (Hughes and McCann 2003) rather than health care professionals. Such barriers and 
perceptions are unfortunate given the advantages in accessibility offered by community pharmacists 
and the opportunities they offer in promoting supplementary prescribing.  
 
8.3 Clinical Management Plans 
There were a number of implementation issues arising from the use of CMPs by nurse and pharmacist 
supplementary prescribers identified in this study. Firstly, the case studies and survey responses 
indicated that CMPs were not always being used according to existing guidelines (Department of Health 
2005). For example, in some sites prescribers had both supplementary and independent prescribing 
qualifications. In two sites which involved controlled drugs and three sites that involved supplementary 
(but not independent) prescribers, observed practices did not conform to official guidance. Whilst this 
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use of CMPs was assessed as a transgression (since they appear to involve a form of intentional rule-
breaking, Parker and Lawton 2006), it is not clear whether these can be considered as 'workarounds' in 
response to difficult operating conditions and situations or as situational violations which might impinge 
upon overall safety (Reason 1990, 2000). In some cases, it was clear that the supplementary prescriber 
was accommodating CMPs within a demanding work environment, where both they and doctors were 
busy and the logistics of getting a doctor to sign or agree to a patient specific CMP prior to that patients' 
consultation, was problematic. However, in other sites, CMP use appeared to be congruent with existing 
guidelines. Having said this, there was considerable variation in case study sites which makes 
comparisons difficult, such as different computer software, leading to some sites being able to attach 
electronic signatures to CMPs, for example. One final, but significant point, concerned those prescribers 
with both a supplementary and an independent prescribing qualification, who stated that they used 
supplementary prescribing in their work. In such examples – two occurred in this research – generic 
CMPs had been developed but were not made patient specific or attached to patients’ notes. Of note in 
these two cases were, firstly, that the prescriber still considered themselves to be using supplementary 
prescribing, and secondly, that the CMP (in one case in particular) appeared to provide a level of 
reassurance and guidance for that individuals prescribing practice (a point actually reiterated by several 
nurses in their interviews). This observation may help inform an apparent difference between the 
reported use of supplementary prescribing by nurses in the questionnaire survey in this research and 
that reported elsewhere in the literature (Courtenay and Carey 2008). One possibility is that nurses 
may, like the two cases identified in this research, consider themselves to be still using supplementary 
prescribing, when in fact they could be only using aspects of supplementary prescribing such as a 
generic CMP, if they were also qualified as independent prescribers. These observations could also 
enlighten other research findings, such as for example, a reported inability in accessing a CMP in over 
half the records of mental health patients who had received nurse supplementary prescribing (Norman 
et al 2008). Clearly, however, there was some evidence that CMPs were being used in different ways 
across the study sites.  
 
8.4 Patients’ views and experiences of supplementary prescribing 
There seemed little doubt from this study that patients were generally accepting of a prescribing role by 
nurses and pharmacists. Very few objectives to nurses and pharmacists reviewing and changing 
medication were spontaneously reported in the observational element of the study and similarly very 
few were reported in the qualitative interviews with patients. There appeared to be no difference in this 
finding across primary and secondary care, although further research may be required to reinforce this 
finding. Having said this, patients appeared to recognise that ultimate authority for patient care – and 
therefore medication - remained with the doctor and it may be that there will a greater range of 
objections relating to independent prescribing by nurse and pharmacists. It is interesting that patients 
did not identify particular problems regarding prescribing, given that patient objections have been 
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identified as a problem in other ‘extended role’ studies involving community pharmacists (Salter et al 
2007; Bissell et al 2008). 
On the other hand, patients did not appear to know very much about supplementary prescribing (for 
example, about the roles and responsibilities of doctors, nurses and pharmacists) and this may become 
a problem in the future. As with Weiss et al’s (2006) study of supplementary prescribing by pharmacists, 
it may be that work needs to be done with patient groups to explain in more detail the developing role of 
nurses and pharmacists in prescribing. 
 
8.5 Inter- professional relationships 
Although some literature suggests that non-medical prescribing might be viewed as a possible 
challenge to the medical profession vis-à-vis the exercise of clinical autonomy (Britten 2001), this 
research does not confirm such a view. This was highlighted particularly in the case studies and 
interviews with doctors, where examples were reported (especially in the primary care setting) of 
doctors continuing to be able to support or deny (particularly nurses), an opportunity to become 
prescribers. However, as well as these examples of doctors maintaining control over access to 
prescribing training, an overriding theme emerged from interviews with doctors that non-medical 
prescribing should be of a 'protocol' type – with this phrase being specifically used. Although several 
doctors commented on the need for those prescribing to have full responsibility in relation to prescribing 
- and one doctor championed a fully independent diagnostic nurse/pharmacist prescribing role - doctors 
considered that supplementary prescribing devolved only a limited degree of clinical autonomy to 
nurses and pharmacists, within the remit of the specific ‘protocol’ to prescribe. Doctors' desire for 
supplementary prescribers to be aware of their own clinical limitations, coupled with an acceptance of a 
‘knock on the door’ policy - whereby nurse and pharmacist supplementary prescribers were encouraged 
to seek medical approval - all suggested that medical surveillance was being maintained. This was also 
echoed by several comments from GPs that supplementary prescribing was viewed as another 
government initiative that could be used by doctors in a positive manner to reduce costs and meet 
targets such as reduced waiting lists and times and quality and outcomes framework measures. 
Furthermore, several doctors commented that prescribing had become somewhat routinised as a task 
(with the increasing use of guidelines and protocols such as local formularies and NICE guidelines) and 
they clearly distinguished this from the more indeterminate and skilled task of diagnosis. This reflected 
continued medical surveillance since doctors argued that only they had the necessary unique and broad 
training, experiences and associated skills to undertake this work.   
 
A possible tension was apparent, however, in that whilst doctors appeared to champion 'protocol' 
prescribing in niche clinical areas, supplementary prescribers - and pharmacists in particular - were 
keen to become independent prescribers, at least in part because this eliminated the need to use 
CMPs. Whilst these may appear fundamental differences of opinion, two factors suggest that future 
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nurse and pharmacist independent prescribing may not be incompatible with doctors' preference for 
protocol prescribing. Firstly, when discussing their future plans, nurses and pharmacists said they would 
work in specific clinical areas, in which they had expertise, rather than prescribing generally. This 
supports doctors’ views about limiting prescribing to a specific clinical area according to a protocol. 
Secondly, as noted above, several case studies revealed CMPs still being used - albeit in a generic, 
non-patient specific form – by independent prescribers and this suggests that some form of protocol 
may be helpful to independent prescribing, in documenting prescribing guidelines at practice/trust level. 
 
8.6 Future prescribing by nurses and pharmacists 
Nurses' and pharmacists' plans for future prescribing varied. Several of the participants - particularly 
pharmacists - reflected on independent prescribing offering an opportunity to stop using the CMP due to 
its time consuming nature. However, such pharmacists still intended to work to protocols such as CMPs 
as they represented positive examples of evidence -based practice (e.g. NICE guidelines). This mirrors 
the observations in one nurse secondary care site, where despite having an independent prescribing 
qualification, a generic CMP for prescribed medicines was still in use. Independent prescribing was a 
key feature of many prescribers' future plans but although the survey results suggested that 
pharmacists saw independent prescribing as the next step in their practice- with supplementary 
prescribing being merely a 'stepping stone' - pharmacists in the case studies commented that 
independent prescribing would not lead to major changes to prescribing practice but instead to easier 
practice without CMPs. The experiences of the case studies also reflected pharmacists' independent 
prescribing intentions from the survey, in that two pharmacists gained their independent prescribing 
qualification during the period of the research. In one case, this meant an immediate change to practice, 
which meant they could no longer participate. Some nurses and pharmacists did not intend to expand 
their clinical practice into new areas or to diagnose for patients using independent prescribing. 
 
8.7 Costs of supplementary prescribing 
Several issues emerge from the analysis of costs associated with supplementary prescribing. Firstly, it 
was evident that the costs of supplementary prescribing consultations per patient were not markedly 
different between nurses and pharmacists (mean of £7.02 for pharmacists and £6.50 for nurses, without 
review costs added). In part, this may have resulted from the different consultation lengths identified in 
the surveys - 21 minutes for nurses and 18 minutes for pharmacists - despite pharmacists reporting 
higher salaries on average than nurses. Pharmacists reported longer prescribing review times than 
nurses, making pharmacists more costly than nurses in this respect. Data from the Personal Social 
Services Research Unit Database (Curtis 2007) indicates that GP consultations last 11.7 minutes on 
average and cost £34. Hence, overall nurse and pharmacist supplementary prescribing consultations 
are significantly cheaper than the GP consultations, reflecting the considerably higher salaries of 
doctors. However, whilst this suggests that supplementary prescribing is cost effective, it is also in the 
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case of nurses, almost twice as time-consuming per patient, which may have an impact upon overall 
patient waiting lists, for example. However, as was reported in the case studies, both nurses and 
pharmacists used consultations as opportunities to undertake examinations, conduct health checks, 
measure blood pressure, take blood samples and conduct medicine use reviews, making direct 
comparisons with GPs and doctors more generally somewhat difficult. Exact cost and time comparisons 
are difficult, however, since the costs reported in this research related to all areas of supplementary 
prescribing and not just that in primary care, as per GPs. 
A further cost issue is that doctors' roles as DMPs during the period of learning in practice are not 
remunerated at present, in contrast to the training they offer to medical students, for example. Whilst in 
one respect, this could be viewed as a cost saving in relation to supplementary prescribing, it may also 
argued that it does not provide any incentive for doctors to help in non-medical prescribing training. This 
may impact upon whether more doctors consider becoming DMPs and may need to be addressed if 
supplementary and other forms of prescribing increase and hence lead to demand for more DMPs. 
Finally, the survey and case study results indicated that supplementary prescribing did not lead to salary 
increases and whilst this may again be viewed as being a cost effective aspect of such prescribing, it 
may also act as a disincentive for nurses, pharmacists and AHPs to become prescribers. 
 
8.8 Safety 
No prescribing errors were identified in the case studies of supplementary prescribing. Whilst we would 
argue that there is a strong case for additional research to explore the safety and appropriateness of 
non-medical prescribing, this finding may provide reassurance to those who posed questions about this 
aspect of non-medical prescribing. Certainly, this finding helps to inform the broader debate about the 
safety of non-medical prescribing, by providing empirical evidence that has been argued to be lacking to 
date (Avery and Pringle 2005).  These findings complement other research which provided evidence of 
the quality and safety of nurse independent prescribing in terms of competencies and standards (Latter 
et al 2007). The assessment of appropriate prescribing for most medicines is also a positive finding and 
where inappropriateness was observed, this may have been due more to the validity of the instrument 
since the indicator tool appeared to penalise the use of branded products irrespective of their cost. 
However, as noted in the review of the literature, criticism of non-medical prescribing may be directed 
more at those which involve diagnosis and the findings of this study may not provide all the empirical 
evidence needed to inform debates about all forms of non-medical prescribing. We would argue that 
further research is needed in this area to confirm this finding. 
Finally, the observation that current and authoritative details of patients' medication were not available 
for supplementary prescribers in some case studies raises concerns in relation to prescribing safety. 
However, it should be noted that this was not unique to the supplementary prescribing and from 
observations and discussions with the supplementary prescribers and independent medical prescribers, 
it was apparent that this was the situation for doctors too. 
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9 Glossary 
 
Allied Health Professional (AHP) Member of an ancillary healthcare profession other than medicine, 
nursing, dentistry or pharmacy. AHPs include radiographers, chiropodists, podiatrists, physiotherapists 
and occupational therapists. Regulation is by the Health Professions Council. 
Approved Prior Learning (APL) Mechanism for recognising existing skills or training for students, 
which may be used to exempt students from some aspects of courses or assessments. 
British National Formulary (BNF) Publication that lists, according to therapeutic area, the complete 
range of medicines and products which are available to be prescribed in the UK. Considered 
authoritative, contains information about licensed indications, doses, side effects and issued biannually. 
Clinical management plan (CMP) A written or electronic record of the agreed management of a 
specific patient. Following diagnosis and the agreement of the patient, a CMP allows a supplementary 
prescriber to prescribe medicines appropriate to the patient's conditions included on the CMP. CMPs 
may be developed from generic templates for recognised conditions or may be bespoke. 
Designated medical practitioner (DMP) A registered medical practitioner with three or more recent 
years of clinical experience, who acts as an unremunerated mentor to a supplementary prescribing 
trainee during their training. Presently 12 days of supervised learning in practice with a DMP needed.  
General Practitioner (GP) A personal doctor who provided comprehensive and continuing care for 
patients in the primary care setting (rather than hospital). 
Higher Education Institution (HEI) Institutions such as universities and colleges offering tertiary 
education, often in the form of degrees, whether at undergraduate or postgraduate level. 
Nurse Independent/Supplementary prescriber Qualification now obtained by all nurses who 
undertake prescribing courses, leading to the recording of a V300 prescribing status on the NMC 
register. Permits those qualified to undertake both types of prescribing, where they are competent. 
Independent Prescriber Independent prescriber has two meanings: in relation to supplementary 
prescribing, it is the medical or dental practitioner who made the initial patient diagnosis and who is 
involved with the care of the patient and in the development of the CMP. It also refers to, more broadly, 
a healthcare professional who has a professional responsibility for independent prescribing. 
Independent Prescribing (IP) The Department of Health’s working definition of independent 
prescribing is "prescribing by a practitioner (e.g. doctor, dentist, nurse, pharmacist) responsible and 
accountable for the assessment of patients with undiagnosed or diagnosed conditions and for decisions 
about the clinical management required, including prescribing."(Department of Health 2006) 
Multi-centre Research Ethics Committee (MREC) Committee which considers and approves ethical 
issues relating to research conducted at different sites. 
Nursing and Midwifery Council (NMC) Governing professional body, responsible for regulation and 
registration of nurses, midwives and specialist community public health nurses in the UK. 
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National Health Service (NHS) Organisation responsible for the provision of health care in the UK 
since 1948, offering healthcare largely free at the point of delivery and paid for from direct taxation. 
Nurse Practitioner Specialist nurse, usually working in primary care setting, usually employed by 
medical practice. Involved in roles such as triage, screening, health assessments, reviews. 
Prescribing Analysis and Cost Data (PACT) Data available in relation to prescribing in primary care, 
at the level of individual medical prescribers, practice and PCT. Provides information on actual 
medicines prescribed and costs. Intended to influence prescribing practice and allow comparisons with 
other prescribers but can be distorted due to patient demographics and medical presentations. 
Prescribing Appropriateness Index (PAI) Validated measure of the appropriateness of prescribing 
developed by Cantrill et al (1998). Similar to the Medication Appropriateness Indicator (MAI) developed 
by Hanlon et al (1990) but considered particularly relevant to long-term medication and used in UK 
healthcare setting.  Includes measures of generic prescribing, recognition of standard doses, 
interactions, indications and duration of treatments (see BNF). 
Primary care trust (PCT) Responsible for the health of local populations and involved in the securing of 
health care services for patients and public.  Recent restructure saw dramatic decrease in numbers of 
PCTs in England. 
Prescription Pricing Division (PPD) Formerly Prescription Pricing Authority (PPA). A section of the 
NHS Business Services Authority, responsible for the processing and payment of prescriptions 
dispensed in England. The PPD also provides remuneration for pharmacists & dispensing doctors, 
produces reports on prescribing at various levels (see PACT) and detecting fraud related to dispensing. 
Primary Care Area of healthcare associated with general practitioners and the care given to their 
patients and includes other health care professionals. 
Royal College of Nursing (RCN) Governing professional body for nursing in the UK. 
Royal Pharmaceutical Society of Great Britain (RPSGB) Governing professional body for pharmacy 
in the UK. Currently has regulatory and disciplinary functions, although both are soon to be devolved. 
Secondary Care Specialised health care provided usually in a hospital setting. 
Statistical Package for the Social Sciences (SPSS) Software program designed for the quantitative 
analysis (both descriptive and inferential) of data generated in research, often in the social sciences 
(e.g. survey, attitudinal data). 
Supplementary prescriber An appropriately trained and registered healthcare professional who 
undertakes supplementary prescribing. Currently the following professionals may train and practice as 
supplementary prescribers: nurses, pharmacists, optometrists, physiotherapists, podiatrists and 
radiographers. 
Supplementary prescribing (SP) Defined by the Department of Health as: "a voluntary prescribing 
partnership between an independent prescriber and a supplementary prescriber, to implement an 
agreed patient-specific clinical management plan with the patient's agreement”.  
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11 Appendices 
11.1 Appendix A –Literature Review  
Empirical pharmacy supplementary (or relevant other) prescribing studies (SP=supplementary prescribing) 
AUTHOR(S)  STUDY AIMS/RESULTS METHOD/SAMPLE 
Candlish et al (2005) SP pharmacist and barriers survey. 50% of pharmacists practicing SP. Community a problem 
due to prescription pad delays and IT issues. Most wanted to train and practice IP. Hospital 
argued to be more conducive to SP due to existing relationships, access to medical records 
and pads.  
54 pharmacists who had completed SP training at one university 
returned postal questionnaire from sample of 107 (50%). 
Cassidy et al (2004) Pilot study of pharmacists' and mentors' experiences of SP: relationships, responsibilities 
and professional progression were all emergent issues 
3 focus groups with total of 17 hospital pharmacists and semi-
structured interviews with 11 mentors. 
Child et al (1998) Few doctors or nurses had experienced pharmacist prescribing but positive if training, 
communication skills, resources and liability issues addressed.  
Questionnaire using convenience sample of hospital doctors, 
pharmacists and nurses in 5 UK hospitals. 
Child and Cantrill (1999) Doctors’ perceived barriers to pharmacist prescribing: communication, pharmacists' 
clinical/patient knowledge, doctors' initial prescription-writing and mechanisms for treatment 
review. 
Questionnaire using convenience sample of hospital doctors in 
5 UK hospitals 
Child (2001) Nurses' perceived pharmacist prescribing positively if training, communication skills, 
resources and liability issues addressed. 
115 hospital nurses from 5 UK hospital completed questionnaire 
about pharmacist prescribing 
Dawoud et al (2004) Pharmacists' views after SP training courses: less pharmacology and more examination, 
consultation training needed. 88% perceived themselves already competent. 82% foresaw 
SP problems in co-morbidity, 51% CMP difficulties, and 48% thought pharmacists and not 
nurses most appropriate to prescribe.  
35 self-response questionnaires returned from sample of 
41(85%) first cohort pharmacists from 2 universities 
George et al(2006) SP pharmacists reported benefits as patient management, job satisfaction and self-
confidence but challenges due to lack of: funding, IT support, awareness by others.  
401 questionnaire responses from postal survey of all 488 
(allowing for 30 pilot) UK SP pharmacists (82.2%) 
George et al (2007) Early experiences of SP pharmacists: only half trained SP pharmacists actually practicing,  401 questionnaire responses from postal survey of all 518 (less 
30 pilot) UK SP pharmacists (82.2%) 
Hobson and Sewell 
(2006) 
Implementation of SP in UK: more barriers to SP in primary care SP, whereas secondary 
care SP formalising existing practices. 
Postal survey of pharmacists in PCTs responsible for 
implementing SP (97 secondary, 187 primary care responses) 
Hughes and McCann 
(2003) 
Perceived barriers between pharmacist and GPs: doctors' shopkeeper perception of 
pharmacists and issues of access, hierarchies and lack of SP awareness were all inter-
professional barriers 
6 focus groups involving 22 GPs and 31 pharmacists from three 
areas of Northern Ireland 
Jackson (2003) Baseline survey of implementation of SP in PCTs revealed perceived training issues, greater 
nurse SP due to existing infrastructure and pragmatic uptake. 
192 postal questionnaire returned from sample of all 302 UK 
PCTs (63.5%) 
Jones et al (2004) Pharmacist stakeholders' views on SP. Positive view of SP emerged, but training and GP 
relationships an issue. 
semi-structured interviews with 14 stakeholders: SP trainee 
pharmacists, education providers, policy makers 
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Lloyd and Hughes 
(2007) 
Pharmacists’ and mentors’ views of SP: broadly welcomed by both but issues of deskilling, 
IP threat, boundary encroachment identified. Some pharmacists cautious about competency 
& necessary relationships. 
9 focus groups involving SP pharmacists and 35 semi-structured 
interviews with medical mentors 
Lloyd, McNally and 
Hughes (2005) 
Nurses saw pharmacists as most knowledgeable about medicines but not best for 
prescribing. Pharmacist SP not a threat to nursing but might de-skill doctors  
Questionnaires completed by 205 from sample of 820 randomly 
selected nurses in 11 UK hospitals 
Lloyd, McHenry and 
Hughes (2005) 
Doctors had good relationships with pharmacists, agreed that SP could reduce their 
workload and errors but were unaware of SP and felt doctors best prescribers 
Questionnaire sent to all 516 junior and senior house officers in 
11 UK hospitals. 115 responses. 
Shulman and Jani (2005) SP pharmacists more likely than and doctors to comply with guideline drug dosing for 
haemofiltration 
Retrospective analysis of medication details of 145 ICU patients 
requiring haemofiltration 
Smalley (2006) Patients’ experiences of pharmacist-led SP included: better understanding of their condition, 
better care and involvement in their treatment. 
Convenience sample of patients from one UK SP hypertension 
clinic: 111/127 returned questionnaire.  
Warchal et al (2006) Pharmacists skills, challenge, patient and profession benefits all reasons for taking SP 
course but access to records a barrier. IP an eventual aim and a threat to SP 
38 pharmacists who had completed SP training given postal 
questionnaire and interviewed. 
Weiss et al (2006) Pharmacists positive about SP as challenge and benefit for patient but communication 
issues, clinical examination skills, doctors' and patients' lack of awareness of SP and delays 
in prescribing all concerns  
23 semi-structured pharmacist SP interviews and 5 case studies 
involving interviews with 7 doctors, 5 pharmacists, 3 nurses, 10 
patients and other staff 
While et al (2004) Community pharmacists' views on SP positive in increasing knowledge, job satisfaction, 
patient benefits but time and medical record access concerns. 
127/238 (53.4%) pharmacists from 5 PCT areas responded to 
self-report postal questionnaire Postal questionnaire survey 
 
Empirical nurse supplementary (and relevant other) prescribing studies 
AUTHOR(S)  STUDY DESCRIPTION/RESULTS METHOD 
Avery et al (2004) Doctors’ views on supervision of nurse prescribers: positive impressions but concerns 
about time/remuneration emerged. pre-existing nurse/doctor relationships helped. 
Structured telephone interviews with 6 hospital doctors and 6 GPs  
Bradley et al (2006) Lecturers' experiences of teaching nurse prescribing. Concerns raised about selection 
criteria, pharmacology knowledge and integrating SP to course. Student/lecturer 
feedback needed  
Qualitative semi-structured interviews with 8 lecturers from 4 HEI 
institutions 
Berry et al (2006) Attitudes and informational needs of public in relation to nurse SP. Public had 
confidence of nurse SP but wanted medicines information, esp. side effects.  
Questionnaires completed by convenience sample of 74 members of 
UK public (with no previous experience of nurse prescribing). 
Courtenay et al (2006) Preparing nurse prescribers to prescribe for dermatological conditions:  only 36.7% of 
nurses practicing SP and specialist training considered advantageous 
868/1187 (73%) postal questionnaire responses from convenience 
sample of IESP nurses. 
Courtenay et al (2007) Nurse prescribers confident in mentoring prescribing students. Sample mostly primary 
care IP nurses with degrees and >10 years experience, but few doing SP. 
868/1187 (73%) postal questionnaire responses from convenience 
sample of IESP nurses. 
Courtenay et al (2007) Nurse prescribers practices and factors influencing & inhibiting prescribing: IT access, 
CMP problems and lack of access to continuing professional development 
868/1187 (73%) postal questionnaire responses from convenience 
sample of IESP nurses. 
Gray et a l (2005) Directors positive about nurse SP but questioned training and readiness of mentors. 
Perceived medical acceptance.  
Postal questionnaire involving 45 NHS trust directors of nursing in 
England, focusing upon SP in psychiatric setting 
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Perceived medical acceptance.  England, focusing upon SP in psychiatric setting 
Hay et al (2004) All broadly supportive of nurse SP but confused over roles, implementation and 
disruption to team functioning. Perception Sp formalises existing hospital practices. 
5 Focus groups with 46 clinical teams members: 22 nurses, 8 doctors, 
8 occupational therapists, 6 psychologists and 2 social workers  
Hemingway (2005) Perceptions and demographic details of mental health nurses considering SP training Opportunistic sampling of 89 nurses (from a UK conference and from 
universities providing SP training) 
Hobson and Sewell 
(2006) 
Implementation of SP. Nurse SP slower in secondary care but many involved in 
primary care. No national strategy  
Postal questionnaire of chief pharmacists in 186 primary and 97 
secondary care settings. 
James (2004) SP for hospital diabetic patients led to reduced waiting times, less variability in 
healthcare professional seen by patient. No errors were reported for 51 prescriptions 
Convenience sample of 42 inpatients over 6 months on one ward. 9 
patient, 19 staff questionnaires returned and some clinical glycaemic 
outcome measures recorded  
Jones (2006) Potential reform of hospital psychiatric care using nurse SP: nurses and psychiatrists 
positive about SP but new partnerships and organisational change needed 
6 focus groups involving 19 nurses and 7 psychiatrists from one 
psychiatric hospital unit 
Jones [2006) SP Nurse and psychiatrist relationships: new one needed, based on mutual respect 
and task delegation. Paradoxical nurse policing but medical control perceived with SP. 
6 focus groups involving 19 nurses and 7 psychiatrists from one 
psychiatric hospital unit 
Jones et al (2005) Service users thought nurses listened, gave medicines’ info and allowed focus on 
collaboration; psychiatrics felt less pressure and thought teams more knowledgeable. 
Unspecified interviews to elicit experiences of 11 mental health 
service users, 12 psychiatrists and 11 nurse prescribers regarding SP 
Skingsley et al  (2006) Training mental health nurse prescribers about neuropharmacology led to increased 
understanding and confidence but that prescribing generally needed existing skills 
such as communication and empathy 
Undisclosed method collected feedback from undisclosed number of 
nurses completing prescribing course 
 
Empirical nurse and pharmacist supplementary (and relevant other) prescribing studies 
AUTHOR(S)  STUDY AIMS/RESULTS METHOD 
Buckley et al (2006) Hospital stakeholders’ perspectives on nurse and pharmacist prescribing: all 
broadly supportive but nurses lacking pharmacology skills, pharmacists' diagnostic 
skills/patient knowledge. 
Qualitative semi-structured interviews with 15 stakeholders – doctors, 
nurses, pharmacists, managers, directors - in one NHS trust in the 
secondary care, hospital setting 
Hobson and Sewell 
(2006) 
Pharmacists’ perceived risks and concerns about SP included training needs, 
competencies, responsibilities and positive implementation approach. 
Postal questionnaire of chief pharmacists in primary and secondary care 
settings about nurse and pharmacist SP 
Department of Health 
(2007) research 
conducted by National 
Prescribing Centre. 
CMPs should refer to protocols/guidelines and have to be simple & quick else SP 
not worth the effort. Remote relationships hard and need access to electronic 
records.SP may not work for patients with multiple carer/disease 
Scoping study with undisclosed numbers of pharmacists, nurses and 
doctors given hypothetical cases to develop CMPs 
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11.2 Appendix B – Stakeholder interviews.  
Sample (n=43) 
Nurse Supplementary Prescribers: 
Primary Care (surgery/community)                                                              
Secondary Care (hospital)                                                                             
 
5
3
Pharmacist Supplementary Prescribers: 
Primary Care (doctors’ surgery)                                                                   
Secondary Care (hospital)                                           
 
5
3 
Strategic health authority prescribing lead                                                    
Strategic health authority non-medical prescribing lead                               
PCT non-medical prescribing leads                                                               
Clinical lead       
   (NB two of these stakeholders were former roles)                                                                                          
1
1
2 
1 
Representative of Professional Indemnity Insurance Provider                   1
Patients' Group Representative                                                                    1
Representative of Consumer Organisation                                                  1
Academics (involved in SP research)                                                          2 
Higher Education Institution (university) prescribing course: 
Lecturers 
Course leaders                                                                                                 
 
4 
4
Representatives of nursing organisations                                                        2
Involved in policy:            
Policy stakeholders varied in terms of their role and seniority 
and although specific details cannot be given (to protect 
anonymity), they included a national clinical director, the chair of 
a professional executive committee (involved in primary care 
policy), the chair of a primary care group, a representative from 
the National Prescribing Centre and a regional programs 
manager. Three were also general medical practitioners and 
one had been involved as a designated medical practitioner for 
nurses prescribing training.                                                                              
7 
 
 
Stakeholder interview questions examples 
§ What do you see as the key issues for SP in nursing and pharmacy and non-medical 
prescribing more generally? 
§ What is your overall view of how SP has been implemented? 
§ What is your view on the appropriateness of SP training and on-going support? 
§ How do you think SP has developed over time?  
§ How do you see SP developing in the future?  
§ Do you think SP raises particular issues in relation to safety and if so, what are these? 
§ Do you think SP raises particular issues in relation to multi-disciplinary working and if so, what 
are these? 
§ What impact do you think that SP is going to have or already has had upon prescribing costs? 
§ Do you think that SP might raise issues about professional rivalry or boundary encroachment? 
§ What is your view about the development and use of CMPs? 
§ How might CMPs be improved? 
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11.3 Appendix C – Survey of Nurse and Pharmacist Supplementary Prescribers 
 
Example of Survey Questionnaire 
(Spacing changed for brevity compared to that sent. Nurse questionnaire varied only in 
replacement of 'pharmacist' for 'nurse' throughout.) 
 
 
National Survey of 
Pharmacist Supplementary 
Prescribers 
 
 
Please read the following three boxes and respond accordingly. 
 
If you are willing to complete the questionnaire 
 
Please answer all of the questions to the best of your knowledge. 
If there are any questions that you are unsure of, please leave them blank. 
 
If you are not willing to complete the questionnaire 
 
Please return the questionnaire in the enclosed FREEPOST envelope uncompleted 
 
If you are registered as a supplementary prescriber but are not prescribing 
I am a registered supplementary prescriber but am not currently prescribing 
 
Reasons why you are not prescribing 
………………………………………………………………………………………………………………………… 
 
Please also complete Section One and Section Two 
 
Section One: About you 
 
Firstly, we would like to ask you some questions about you, your background, your job and your prescribing.  
 
1. Are you: Male  • Female  • 
 
20-29  • 40-49 • 60-65 • 2. How old are you? 
30-39  • 50-59 • 66+ • 
 
3. In what year did you register as a pharmacist? . 
 
BPharm • PG Diploma/ Masters Degree • 
MPharm • Doctoral Degree • 
Bachelors Degree • Other • 
4. Which of the following 
qualifications do you have? 
Please tick all that apply. 
Other, please specify . 
 
5. What is your job title(s)? . 
 
Hospital • Walk in centre • 
GP practice  • Care homes • 
Community Pharmacy • Prison • 
6. Where do you prescribe?  
Please tick all that apply. 
Other, please specify. 
 
Less than £20,000 • £41,000-£50,000 • 
£21,000-£30,000 • £51,000-£60,000 • 
7. Please indicate your total income. 
£31,000-£40,000 • More than £60,000 • 
 
8. How many hours do you work per week? . 
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9. Are you prescribing as a supplementary prescriber? Yes • No • 
 
10. When did you register as a supplementary prescriber?  Month  Year 
 
11. When did you start supplementary prescribing?  Month  Year 
 
12. How many hours do you spend per week as a supplementary prescriber?  . 
 
I am prescribing as an independent prescriber • 
I am training as an independent prescriber • 
I am intending to train as an independent prescriber  • 
13. In relation to independent 
prescribing, please tick the box  
that best applies to you.  
I am not intending to train as an independent prescriber • 
 
Section Two: Training 
 
We would like to ask you some questions about the training you received in order to become a supplementary 
prescriber.  
 
14. For each statement below, please tick the box that best matches your current views: 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
My supplementary prescriber 
training was useful      
My supplementary prescriber 
training provided the 
knowledge I needed in order 
to prescribe appropriately 
     
My supplementary prescriber 
training provided the skills I 
needed in order to prescribe 
appropriately 
     
My Designated Medical 
Practitioner (DMP) fulfilled the 
role expected of them 
     
Independent and 
supplementary prescribers 
should be taught separately  
     
 
15. What were the most useful elements of your supplementary prescriber training? 
 
 
16. What were the least useful elements of your supplementary prescriber training? 
 
 
 
17. What areas would you have liked to cover in your supplementary prescriber training? 
 
 
 
Section Three: Support 
 
We would like to ask you some questions about the support you receive in your supplementary prescribing role.  
 
18. For each statement below, please tick the box that best matches your current views: 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
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I am satisfied with the advice and 
support I receive regarding my 
prescribing decisions 
     
I am satisfied with the overall level 
of support I receive from my 
organisation in my prescribing role 
     
My supplementary prescribing 
decisions are regularly monitored       
 
Once a week • 
Once a fortnight • 
Once a month • 
Once every three months • 
Once every six months • 
Once a year • 
19. How often do you have a session to 
review your supplementary prescribing 
practice with an independent prescriber? 
Never • 
 
20. How long do you spend reviewing your supplementary prescribing practice (per session)? 
 
 
 
21. Can you describe how your supplementary prescribing practice is reviewed?  
 
 
22. Overall, can you provide us with your views about the support you receive as a supplementary prescriber?  
 
 
 
Section Four: Your supplementary prescribing role 
 
We would now like to ask you about your supplementary prescribing role, in terms of what you do, your opinions 
about supplementary prescribing and what works well and what works less well for you as a supplementary 
prescriber.  
 
23. Which patient group(s) do you prescribe for? . 
 
24. In which BNF section(s) do you prescribe? 
    
Gastro-intestinal system  • Nutrition and blood  • 
Cardiovascular system • Central nervous system • 
Anaesthesia • Eye • 
Respiratory system • Ear, nose, and oropharynx • 
Infections • Skin  • 
Endocrine system • Musculoskeletal and joint diseases  • 
Obs, gynaecology and urinary-tract • Malignant disease and immunosuppression • 
Minor ailments • Wound management products  • 
Immunological products and vaccines  • Other  • 
    
If required, please give further details about the BNF sections in which you prescribe.  
  
 
25. Please list the three (drug and non drug) items that you most frequently prescribe.  
 
1.……………….………………    2.…………………………………    3.………………………………… 
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26. Do you have access to patients’ medical records when 
you prescribe for them?  Yes 
• No • 
     
If you do not have access to patients’ medical records, please explain the impact? 
 
 
27. When you prescribe, do you use a Clinical Management Plan?  Yes • No • 
 
All patients • 
Some patients • 
28. When you prescribe, are Clinical 
Management Plans used for?  
Please tick all that apply. No patients  • 
 
Individual patients • 
Groups of patients • 
29. Are the Clinical Management Plans you use developed for? 
Please tick all that apply.  
Specific conditions • 
Other, please specify   
 
Drug specific  • 
Guideline specific  • 
Protocol specific • 
30. Are the Clinical Management Plans that you prescribe 
from? 
Please tick all that apply 
Other, please 
specify…………………….…………. 
 
31. On average how many patients do you prescribe for on a recurring basis? . 
 
32. On average how many prescriptions do you issue per week? . 
 
33. On average how long do you spend with each patient for whom you are a supplementary prescriber? 
 
 
34. How many independent prescribers do you work with? . 
 
35. How many other supplementary prescribers operate in your work setting? . 
 
36. Do you prescribe instead of, or in addition to the 
independent prescriber for the same group of 
patients?  
Instead of  • In addition to  • 
 
37. As a result of your supplementary prescribing 
practice, do you think that doctors are prescribing 
… 
Less • The same amount • More • 
 
38. Do you undertake independent prescribing for 
any patient groups? Yes 
• No • 
     
If yes, which groups     
 
 
39. For each statement below, please tick the box that best matches your current views: 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
I am confident to prescribe the 
appropriate treatment for patients      
I am confident to prescribe the 
correct dosage for patients      
I am confident to identify drug 
related problems for patients      
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Clinical management plans are a 
useful aid to my decision making 
about supplementary prescribing 
     
 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
I am confident to identify drug 
interactions for patients      
I have sufficient knowledge of 
pharmacology and therapeutics to 
prescribe safely 
     
I am confident to prescribe for 
patients with co-morbidities       
Being a supplementary prescriber 
formalises the practice I was 
undertaking before I trained  
     
I have greater autonomy now I am 
a supplementary prescriber       
My pay has not increased as a 
result of being a supplementary 
prescriber 
     
As a supplementary prescriber I 
have higher status in my 
organisation 
     
Being a supplementary prescriber 
makes my job more satisfying      
I do not have the clinical 
examination skills to be a safe 
supplementary prescriber 
     
 
40. What do you think works well in terms of your supplementary prescribing?  
 
 
 
 
 
41. What difficulties have you experienced in supplementary prescribing? 
 
 
 
 
 
42. Please comment on the influence that supplementary prescribing has had on your relationships with 
colleagues?  
 
 
 
 
 
Section Five: Supplementary prescribing and safety 
 
The following questions look at the safety of supplementary prescribing and the safety of the wider environment in 
which you work. They include elements of the Safety Climate Questionnaire. 
 
43. For each statement below, please tick the box that best matches your current views about the area in which 
you work. 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
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The independent prescriber is 
available to discuss patients needs 
when required 
     
Clinical management plans are 
inappropriate for patients with short 
term conditions 
     
I have concerns about prescribing for 
patients who have co-morbidities      
I am asked by colleagues to prescribe 
in an area outside my competence      
I am asked by patients to prescribe in 
an area outside my competence       
I have concerns that I am prescribing 
outside my area of competence      
The levels of staffing in this area of the 
organisation are sufficient to handle 
the number of patients. 
     
I would feel safe being treated as a 
patient in this service.      
I am encouraged by my colleagues to 
report any patient safety concerns I 
may have. 
     
Staff frequently disregard rules or 
guidelines that are established for this 
area of the organisation. 
     
The culture in this area of the 
organisation makes it easy to learn 
from the errors of others. 
     
I receive appropriate feedback about 
my performance.      
Medical errors are handled 
appropriately here.      
I know the proper channels to which I 
should direct questions regarding 
patient safety. 
     
In this area of the organisation, it is 
difficult to discuss errors.      
Management does not knowingly 
compromise the safety of patients.      
This organisation is doing more for 
patient safety now than it did one year 
ago. 
     
Leadership is driving us to be a safety-
centred organisation.      
My suggestions about safety would 
be acted upon if I expressed them 
to management. 
     
 
 
 
 
Section Six: The impact of supplementary prescribing in your organisation 
 
44. For each statement below, please tick the box that best matches your current views: 
 Strongly 
Agree Agree 
Neither 
agree nor 
disagree 
Disagree Strongly disagree 
Patients are aware of what 
supplementary prescribing entails      
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I provide my patients with information 
about supplementary prescribing      
Patients are not involved in designing 
their own Clinical Management Plans      
I am satisfied that patients give their 
informed consent to being treated by a 
supplementary prescriber 
     
Patients have longer consultation 
times with supplementary prescribers 
as compared to independent 
prescribers 
     
Patients receive better quality care 
from supplementary prescribers as 
compared to independent prescribers 
     
Supplementary prescribing has 
improved my relationships with 
patients 
     
Supplementary prescribing has 
improved patients compliance with 
treatment 
     
I involve patients in prescribing 
decisions       
Patients are not aware of who is 
ultimately responsible for their care      
Patients are not aware of who is 
ultimately responsible for their 
prescribing 
     
Supplementary prescribing has led to 
patient care becoming fragmented       
Supplementary prescribing increases 
prescribing costs      
Supplementary prescribing increases 
non prescribing costs       
My organisation has been supportive 
of the supplementary prescribing role 
in general 
     
My organisation has facilitated the 
supplementary prescribing role in 
practice  
     
 
45. Do you have any other opinions about supplementary prescribing 
 
 
 
Case Studies of Pharmacist Supplementary Prescribers 
 
Following on from this national survey of supplementary prescribers in pharmacy, in depth case studies 
of supplementary prescribers will be undertaken. These will involve interviews and/or surveys with staff 
and patients and observation of supplementary prescribing consultations. 
If you are interested in taking part in an in depth case study, then please supply your contact details 
below. A member of the research team will contact you to discuss what participation will involve. If you 
supply your contact details this does not mean that you have to take part. You can withdraw from the 
study at any time. 
I am interested in taking part in a case study 
Name ……………………………………..Email, Telephone number………………………………………..  
Please return the questionnaire in the enclosed FREEPOST envelope 
 
__________________________________________________________________________________ 
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Distribution of nurse surveys  
Institution Number distributed Number returned Response rate 
A 132 60 45% 
B 282 138 49% 
C 170 44 26% 
D 77 54 70% 
E 70 18 26% 
F 100 36 36% 
G 150 3 2% 
H 87 23 26% 
I 45 10 22% 
J 58 15 26% 
K 60 29 47% 
L 125 42 34% 
M 147 38 26% 
 
 
 
11.4 Appendix D – Case Studies of Supplementary Prescribers 
 
Example of information sheets - to patients in case studies 
 
                                      
  
 
An evaluation of supplementary prescribing in nursing and pharmacy 
Information Sheet II – Patients – Observation and questionnaire 
Version 2 – 15.05.07 
 
Please read the following information carefully. It gives details on the overall evaluation of 
supplementary prescribing as well as the case studies which we are inviting you to participate in. If you 
have any questions then please contact Dr. Richard Cooper 0114 2220683. In this information sheet we 
are providing information regarding observation of appointments.  
 
What is the purpose of the study? 
The Department of Health have commissioned a team of researchers at the University of Sheffield and 
the University of Nottingham to undertake an evaluation of supplementary prescribing in nursing and 
pharmacy. The purpose is to examine the impact of supplementary prescribing on patients, health care 
professionals and the wider NHS. The study started in February 2006 and will last for two years.  
 
How is the study being undertaken? 
The study has three stages 
Stage One - An analysis of key literature in the area and a small number of interviews to look at some 
key issues in the development of supplementary prescribing.  
Stage Two - A national survey of nurse and pharmacist supplementary prescribers.  
Stage Three - In-depth case-studies of nurse and pharmacist supplementary prescribers. 
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What is involved in the case studies? 
We are undertaking 12 case studies of supplementary prescribers. These will involve observation, 
questionnaires and interviews. They will involve both nurse and pharmacist supplementary prescribers 
who prescribe for patients with different conditions.  
 
How will data be collected? 
We are using a number of different methods to collect data from both patients and NHS staff. We are 
observing the consultations between patients and supplementary prescribers and analysing the clinical 
management plans for these consultations. We are also asking patients to complete a questionnaire 
and asking some patients to be interviewed. In addition, we are interviewing the supplementary 
prescriber and the doctor that drew up the clinical management plan with the supplementary prescriber 
 
What will participation involve if I decide to take part? 
We would like to be present during your next appointment with the supplementary prescriber. We are 
interested in looking at how the supplementary prescriber works. We would like to tape record the 
appointment and make notes. We would not get involved in the appointment in any way. Following the 
appointment we would like to have a look at the clinical management plan that the supplementary 
prescriber uses during your appointment.  
 
We would ensure that none of the data that we collect could identify you as an individual. The data that 
we are collecting is about the supplementary prescriber only.  
Are there any other stages that you would like me to participate in? 
We would also like you to complete a short questionnaire about your views, experiences and 
satisfaction with supplementary prescribing. We would ensure that none of the data that we collect 
could identify you as an individual. The data that we are collecting is about the supplementary 
prescriber only.  
 
Will participation in this study be confidential? 
All information about participation in this study will be kept confidential.  Personal information will not be 
recorded as part of the observation. If your name is on the clinical management plan then this will be 
concealed. The procedures for handling, processing, storage and destruction of all data will comply with 
the Data Protection Act 1998. All data that could identify participants will be coded and used for this 
research study only. Access will be limited to trained researchers who are part of the research team.  
 
Who is organising and funding the research?   
The research is being funded by the Department of Health and is being carried out by researchers from 
the University of Sheffield and the University of Nottingham. 
 
What will happen to the results of the research study? 
The findings of this research will be written up and submitted to the Department of Health. The results 
may also be published in academic and professional journal articles. You will not be identified in any 
report/publication.  
 
Who has reviewed the study?  
This study was given a favourable ethical opinion for conduct in the NHS by Leeds Multi-Research 
Ethics Committee and has received local trust governance approval.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak with the study leader (Dr Paul 
Bissell 0114 2220831). If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure. 
 
What do I have to do? 
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If you are willing for the researcher to be present during your next appointment, please could you 
complete the attached details form and return it in the freepost envelope enclosed. When you attend 
your appointment you will be asked to sign a consent form to say that you are happy to have the 
researcher present. If you are not able to let us know that you agree to the researcher being present 
beforehand, please turn up to your appointment as planned. The researcher will not sit in on the 
appointment unless you agree to it.  
 
If you are willing for the researcher to be present at the appointment then we will give you a short 
questionnaire and if you are willing to take part then please complete the questionnaire and return it to 
us in the enclosed FREEPOST envelope. You do not require a stamp. If you are not willing to take part 
then this will not affect your medical care or legal rights.  
 
Thank you for your consideration of our study and for your time in reading this information 
sheet. If you have any additional questions then please do not hesitate to contact us, 
__________________________________________________________________________________ 
 
Example letter of invitation - to patients for case study 
 
Dear [insert name of patient] 
 
We are writing to you to ask you whether you would be willing to participate in a research study. The 
research study is looking at the role of supplementary nurse/ pharmacist prescribers and we are 
undertaking a case study with [insert name of supplementary prescriber]. This study is being funded by 
the Department of Health who have asked researchers from the University of Sheffield and the 
University of Nottingham to evaluate supplementary prescribers like [insert name of supplementary 
prescriber].  
 
We have asked [insert name of supplementary prescriber] to pass on this letter to you to ask whether 
you would be willing to have a researcher sit in on your next appointment with [insert name of 
supplementary prescriber]. The researcher would not be involved in the appointment. They would be 
observing the appointment, making notes and recording the conversation during the appointment. Also, 
we would like to have a look at the Clinical Management Plan which records the treatment and care that 
you receive from [insert name of supplementary prescriber]. Once you have attended your appointment 
we will give you a questionnaire about your views, experiences and satisfaction with the supplementary 
prescribing service. It is up to you whether you complete this or not. We will then be inviting some of the 
patients who have completed the questionnaire to be interviewed about supplementary prescribing.  
Please find included an information sheet which gives some additional details about the study. We 
would like to emphasise that it is up to you whether you take part and if you do then this will be 
confidential. 
If you are willing for the researcher to be present during your next appointment, please could you 
complete the attached details form and return it in the freepost envelope enclosed. When you attend 
your appointment you will be asked to sign a consent form to say that you are happy to have the 
researcher present. If you are not able to let us know that you agree to the researcher being present 
beforehand, please turn up to your appointment as planned. The researcher will not sit in on the 
appointment unless you agree to it.  
 
Please take time to read the information sheet to decide whether you would be prepared to have the 
researcher sit in on your next appointment. Please contact either the researcher or [insert name of 
supplementary prescriber] if you have any questions.  
 
Yours sincerely 
 
Paul Bissell 
Principal Investigator on behalf of the Research Team 
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Interview Schedule for Patients  
§ What do you understand by the term supplementary prescribing? 
§ What is your impression of nurse/pharmacist supplementary prescribing? 
§ What have been the positive or most beneficial aspects? 
§ What have been the negative aspects? 
§ Were you given the opportunity to consent to having a nurse/pharmacist provide 
supplementary prescribing? 
§ How does supplementary prescribing compare with your previous or usual medical 
encounters? 
§ Has your experience of supplementary prescribing had an effect upon how you take your 
medicines? If so, how? 
§ With supplementary prescribing, is it now easier to access medical care? 
§ Has supplementary prescribing had an effect upon your relationship with a) your doctor, b) 
your pharmacist/nurse c) anyone else? 
§ Why do you think supplementary prescribing has been introduced? 
§ What do you understand by the term 'clinical management plan'? 
§ Has supplementary prescribing had an effect on how long your consultations lasted or how 
long it took to obtain an appointment? Is so, how? 
§ What are your views on nurses/pharmacists having access to your medical record? 
§ What are your views on the safety of supplementary prescribing by nurses or pharmacists?  
§ What changes or improvements could be made to supplementary prescribing to make it better? 
 
Interview Schedule for Independent prescribers  
§ What do you understand by the term supplementary prescribing? 
§ What have been your experiences overall of supplementary prescribing? 
§ What have been the positive or most beneficial aspects? 
§ What have been the negative aspects? 
§ Has supplementary prescribing changed your relationships with either the pharmacist/nurse or 
patient? If so, how? 
§ In terms of your workload, has supplementary prescribing had any effect? Approximately how 
long do you spend in consultations and feedback sessions with the supplementary prescriber 
§ What changes or improvements could be made to supplementary prescribing to make it better? 
§ What are your experiences of the clinical management plan? 
§ Are there any safety issues in relation to supplementary prescribing? 
§ Why do you think supplementary prescribing has been introduced? 
§ Does supplementary prescribing interfere with any other area of your work? 
§ Is supplementary prescribing a threat to medical practice? If so, how? 
§ Where do you think supplementary prescribing consultations should be held and why? Are 
there situations/places where it would be inappropriate (such as community pharmacies)? 
§ Do you consider either nurses or pharmacists to be better suited to a supplementary 
prescribing role? Is so, why? 
§ How important are financial considerations in terms of doctor's participation in supplementary 
prescribing? 
§ What are your views on nurses/pharmacists having access to patients' medical record? 
 
Interview Schedule for Supplementary prescribers  
§ Check basic information that was included in the questionnaire (Their job title, caseload of 
patients, approximate number of prescriptions per week, length of time in post, length of time 
supplementary prescribing and history of their supplementary prescribing, involvement in 
independent prescribing 
§ Estimates of length of time spent in consultations and feedback sessions 
§ Why did you decide to become a supplementary prescriber?  
§ How did you find the training to become a supplementary prescriber – most and least useful 
aspects? 
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§ What are your CPD requirements in relation to supplementary prescribing?  
§ What have been your experiences overall of supplementary prescribing? 
§ What have been the positive or most beneficial aspects? 
§ What have been the negative aspects? 
§ Has supplementary prescribing changed your relationships with independent prescribers? 
§ Has supplementary prescribing changed your relationships with supplementary prescribers? 
§ In terms of your workload, has supplementary prescribing had any effect? Approximately how 
long do you spend in consultations and feedback sessions with the independent prescriber 
§ What changes or improvements could be made to supplementary prescribing to make it better? 
§ What are your experiences of the clinical management plan? 
§ Do you have any problems accessing patient’s medical records?  
§ Are there any safety issues in relation to supplementary prescribing? 
§ Why do you think supplementary prescribing has been introduced? 
§ Does supplementary prescribing interfere with any other area of your work? 
§ Is supplementary prescribing a threat to medical practice? If so, how? 
§ Where do you think supplementary prescribing consultations should be held and why? Are 
there situations/places where it would be inappropriate (such as community pharmacies)? 
§ Do you consider either nurses or pharmacists to be better suited to a supplementary 
prescribing role? If so, why? 
 
 
 
Nurses and pharmacists contacted but unable to participate in a case study  
 
Profession Pseudonym Reason 
Nurse Jayne Independent Prescriber only 
Nurse Gloria Independent Prescriber only 
Nurse Doris Independent Prescriber only 
Nurse Martha Independent Prescriber only 
Nurse Simon Did not respond to invitation to participate  
Nurse Sally Did not respond to invitation to participate 
Nurse Janice Independent Prescriber only 
Nurse Tina Independent Prescriber only 
Nurse Vanessa Independent Prescriber only 
Nurse Derek Did not respond to invitation to participate 
Nurse Carly Independent Prescriber only 
Nurse Janet Independent Prescriber only 
Nurse Sandra Independent Prescriber only 
Nurse  Chris Independent Prescriber only 
Nurse  Arthur Working in mental health 
Nurse Lois Governance obtained but withdrew due to work demands 
Pharmacist Carolyn Independent Prescriber only 
Pharmacist Phillipa  Independent Prescriber only 
Pharmacist Jack PCT did not give permission for him to take part in the research 
Pharmacist Carmel Governance obtained but withdrew as now independent prescriber 
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Case Study by data collected 
 
Case Study Prescriptions Items Consultations 
Patient 
questionnaire 
Patient 
interviews 
Doctor 
interviews 
Mark 3 4 7 5 3 0  
John 9 15 5 13 5 2  
Debbie 14 8 10 4 0 1  
Jane 1 1 7 2 0 0  
Natalie 0 0 4 1 0 1  
Anita 9 8 9 3 1 2 
Grace 10 10 10 5 3 1 
Sam 7 8 7 3 1 1 
Lara 3 3 6 0 5 2 
Kim 9 14 12 8 10 1 
Totals  65 71 77 44 28 11 
 
Case study descriptions 
 
Mark worked in a busy town in the North of England and was employed by, and worked full-time in, a 
medical practice in the town centre, along with a nurse prescriber. The pharmacist was qualified as a 
supplementary and independent prescriber, but considered the prescribing he undertook for patients 
with a number of clinical conditions to be supplementary. However, he used only one generic CMP that 
briefly listed a wide range of conditions (ranging from hypertension, cardiovascular disease, COPD to 
smoking cessation). This pharmacist also did not sign any prescriptions but, instead, initiated or 
changed medication, but then printed the prescription, which was given to the patient to hand to the 
receptionist for one of the doctors to sign. The pharmacist had his own permanent consultation room 
which was highly personalised, with qualification certificates, pictures and reference books.  
 
John worked across three surgeries in rural locations in the North of England as a practice support 
pharmacist. He was employed by the PCT.  He qualified as a supplementary prescriber in 2004 and 
intended to train as an independent prescriber. Before becoming a prescriber, he was already known to 
all three surgeries as a PCT employed practice support pharmacist. He specialised in cardio-vascular 
disease, hypertension and chronic obstructive airways disease using an individualised CMP.  He signed 
prescriptions for patients for conditions within his clinical competencies and he also printed repeat 
prescriptions for patients of medicines prescribed by doctors, which then had to be signed by the GP.  
He did not have a specific consultation room in either location and was observed using the office of the 
senior medical partner and the generic nurses' examination room. At both locations, he would go out 
into the waiting area and call patients in. it was apparent that the prescriber had developed long-term 
relationships with many of the patients whom he saw over the two days.  
 
Debbie worked across three surgeries in town and village locations in the North of England as a 
pharmacist supplementary prescriber and medicines management pharmacist. She was employed by 
the PCT. She qualified as a supplementary prescriber in 2004 and was, at the time of the consultation, 
undertaking her independent prescriber training. She had previously worked in some of the practices 
where she was a supplementary prescriber undertaking medicines review. Debbie specialised in 
cardiovascular conditions, but also undertook prescribing for osteoporosis and anti-depressant 
medication. She used a condition specific CMP which was personalised with patient details and an 
electronic copy was appended to patients’ records. She was able to print out and sign prescriptions in 
the surgery in which she was based for the case study, although much of the observed practice was 
altering medication records and ordering repeat prescriptions. She did not have a specific consultation 
room in the practice in which she was observed and was using the room of a doctor. She would collect 
patients from the waiting area.  
 
Jane, a pharmacist was based in a metabolic medicine department in a hospital in the North of England 
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She provided a 2.5hr session one day a week, working alongside a full-time independent prescribing 
nurse. The pharmacist qualified as a supplementary prescriber in 2005, and was intending to train as an 
independent prescriber. All the pharmacists' patient referrals came originally from the consultant. The 
pharmacist noted that it was trust policy encourage primary care rather than secondary care prescribing, 
thus of seven consultations observed, only one resulted in an act of prescribing. The pharmacist had 
developed one generic CMP which was used for all patients. These were usually only signed by the 
pharmacist and the consultant after the pharmacist-patient consultation and after any prescribing. The 
pharmacist was a lead clinical pharmacist and spent the remainder of their time as a manager in the 
pharmacy department and had previously provided supplementary prescribing in another therapeutic 
area, although the need for this service stopped some time ago. For almost all the observed 
consultations, the pharmacist and patient had not met before. The pharmacist used a generic 
examination room, which had computer access to diagnostic records but A4 paper based patient notes 
were used - the CMP was added to this. In the waiting area a sign alerted patients that they might not 
be prescribed for by the consultant.  
 
Kim worked in the primary care setting in a town centre surgery in the Midlands. The surgery had four 
GPs and a practice nurse, but no other non medical prescribers. She was a pharmacist, who qualified 
as a supplementary prescriber in 2005. She had recently completed the independent prescribing course 
and was awaiting accreditation and intended to use independent rather than supplementary prescribing 
in subsequent practice. She was employed by the PCT and had previously worked at the surgery as a 
practice support pharmacist. She was observed undertaking hypertension clinics. A sign in the reception 
area noted the names of the doctors and the nurse and whether they were present or not, but the name 
of the pharmacist prescriber was absent. The pharmacist used a generic examination room, which was 
located on an upper floor in the practice. The room had computer and medical records access. Most 
patients were known to the prescriber and vice versa. CMPs were produced for one generic 
hypertension template prior to the pharmacist consultation and uploaded subsequently onto the patient's 
electronic notes. Specific sensitivities were added at this stage and electronic signatures were used for 
the pharmacist and doctor. She printed out prescriptions using the computer in the consultation room, 
however this set up did not allow her to access the computer for ordering tests etc, so on one observed 
occasion she set up the computer to access test information and hand wrote her prescriptions.  
 
Anita was a nurse working in a hospital dermatology department, located in the Midlands. She was 
qualified as a supplementary and independent prescriber, but chose to work with a clinical management 
plan and defined herself as a supplementary prescriber. She undertook a weekly morning prescribing 
outpatient clinic, for which patients were booked in a month in advance. The remainder of her time was 
divided between ward managerial duties and clinical work and during the prescribing consultations, she 
was asked to assist with work related to dressings. Clinics were undertaken within the dermatology 
departments in a consultation room. She had a laminated sign which was placed on the door of the 
room in which she was consulting. Four separate CMPs had been prepared and kept on file in relation 
to the 4 medicines that the nurses prescribed. However, patient-specific CMPs were not made and no 
copies were added to patients' notes or signed by doctors. She issued prescriptions for dispensing at 
the hospital pharmacy which were handwritten.  
 
Sam was a nurse working in the primary care setting, in a substance misuse centre in a city in the North 
of England. She undertook a weekly afternoon prescribing session and the remainder of her full-time 
work was managerial in nature. She was qualified as an independent and supplementary prescriber, but 
due to the fact she was prescribing a controlled drug, she prescribed using a clinical management plan. 
The clinic the nurse undertook was mainly to oversee the titration and detoxification of substance 
misusers, following an initial diagnosis and consultation with the doctor, usually the week prior to the 
nurse's first contact with the patient/client. One standard CMP had been developed some months ago 
by the nurse in conjunction with one of the doctors, who worked full-time at the centre. At the start of a 
consultation with a new patient/client, the nurse discussed the CMP and both she and the patient/client 
signed it. It was subsequently signed by the doctor and added to the patient's paper records. Sam 
printed out controlled drug prescriptions which were checked and then returned to her for signing.  
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Grace was based in the primary care setting, and worked as a nurse substance misuse specialist, who 
had worked for many years in this area of practice, but who had begun a prescribing role in the last two 
years. She was employed full-time in a busy clinic located in a deprived area just outside the centre of a 
large city in the Midlands. Within the clinic, no member of staff had a permanent room in which they 
worked. There were no other nurse prescribers working at the clinic but several doctors- often GPs - 
who undertook sessional work. Other nurses performed wound management services at the site. She 
was qualified as an independent and supplementary prescriber, but due to the fact she was prescribing 
a controlled drug, she prescribed using a clinical management plan. Two generic CMPs had been 
developed - for buprenorphine and methadone -which were stored electronically and the patient's 
records annotated to reflect a doctor's agreement to let the patient be seen by a supplementary 
prescribing nurse. The nurse also prescribed independently, using antibiotics when running wound 
clinics and also when prescribing, although rarely, naltrexone. Patients were usually known to the nurse 
and either involved referrals from another doctor, or were initial consultations - therefore without an 
initial medical diagnosis. Prescriptions for controlled drugs were printed out in the room in which she 
worked and signed by her.  
 
Natalie worked in a hospital in the South of England as a consultant pharmacist. She qualified as a 
supplementary prescriber in 2004 and an independent prescriber in 2007. Her role is mostly managerial, 
but at the time of the case study she prescribed as a supplementary prescriber in once clinic per week 
and as an independent prescriber in another clinic. In the supplementary prescribing clinic observed, 
she had made a decision to prescribe in accordance with a clinical management plan due to the nature 
of the drug being prescribed. Within this clinic, there is a consultant, who prescribes for patients and a 
nurse who does not prescribe. Patients are not usually allocated to the pharmacist in advance of the 
clinic but allocation of patients is undertaken when the patient arrives. None of the staff who work within 
the clinic have a designated room in which they see patients. Clinical management plans are 
personalised for patients and a paper copy added to patients notes. During the consultation, Natalie 
makes notes in the medical records. Prescribing for patients is undertaken prospectively, therefore in 
the observed consultations; Natalie was ensuring that the patient could receive the medication that they 
had been prescribed in their previous consultation and prescribing for their next consultation. 
Prescribing is done electronically and patients collect their prescription from the hospital pharmacy.  
 
Lara is a Nurse Specialist, working in a hospital in a city in the North of England. She is part of a team 
of who run a specialist service for children with neuro-developmental conditions. She is qualified as an 
independent and supplementary prescriber in 2005, but prescribes according to a clinical management 
plan as she prescribes controlled drugs. She prescribes within three clinics a week, alongside the 
consultant clinics and was running these clinics, without prescribing, before she became qualified. She 
specialises in prescribing for a small number of conditions with a small number of drugs available. She 
uses a CMP which is signed by the consultant and is kept in the patients records. A copy is also kept for 
audit purposes. The majority of patients are prescribed for by their GP practice, rather than by the 
hospital, but for any changes in medication or initiation of new medicines, Lara issues handwritten 
controlled drug prescriptions.  
 
Data from patient questionnaires 
 
Variable Supplementary 
Prescriber 
Doctor Don’t know 
I can get an appointment quicker with the …  17 5 16 
I have longer appointments with the …  24 5 8 
I receive better quality care from the …  13 3 16 
I receive safer care from the …  9 3 18 
I am monitored better by the … 18 4 12 
I am better informed about my treatment by the  23 3 10 
My overall care is the responsibility of … 7 24 3 
 
 
 97 
Variable Agree Disagree Don’t 
know 
It was explained to me what having a supplementary prescriber would 
involve 
34 4 3 
I am involved in decisions about the treatment I receive from my 
supplementary prescriber 
37 2 0 
I have been given written information about having a supplementary 
prescriber 
22 14 4 
I have a written plan for my treatment by the supplementary prescriber 15 15 6 
I was involved in designing my written plan for my treatment by the 
supplementary prescriber 
14 18 2 
I understand my written plan for my treatment by the supplementary 
prescriber 
16 14 4 
I signed my written plan for my treatment by the supplementary prescriber 14 15 6 
I gave my consent to being treated by a supplementary prescriber 37 2 2 
I have a good relationship with my supplementary prescriber 41 1 0 
I have confidence in my supplementary prescriber 40 1 0 
 
 
MARS Always Often Sometimes Rarely Never 
I forget to take them 0 0 4 11 27 
I alter the dose 0 0 1 0 41 
I stop taking them for a while 0 1 1 1 39 
I decide to miss out a dose 0 0 2 1 39 
I take less than instructed 0 0 0 1 41 
MARS_5 RH2_022 Medication Adherence Report Scale _5 ©R Horne University of Brighton, 1999 
 
Information about your medicines Too 
much 
About 
right 
Too 
little 
None 
received 
None 
needed 
What your medicine is called 1 25 0 0 7 
What your medicine is for 0 30 0 0 4 
What it does 0 31 0 0 4 
How it works 0 26 4 0 4 
How long it will take to act 0 22 2 1 8 
How you can tell if it is working 0 19 2 2 8 
How long you will need to be on your medicine 0 21 3 1 5 
How to use your medicine 0 25 0 0 7 
How to get a further supply 0 25 0 0 7 
Whether the medicine has any unwanted effects 
(side effects) 0 22 3 2 5 
What are the risks of you getting side effects 0 23 4 2 3 
What you should do if you experience unwanted 
side effects 0 22 4 0 6 
Whether you can drink alcohol whilst taking this 
medicine 0 15 3 5 8 
Whether the medicine interferes with other 
medicines 0 19 3 4 5 
Whether the medication will make you feel drowsy 0 20 1 4 5 
Whether the medication will affect your sex life 0 13 2 4 11 
What you should do if you forget to take a dose 0 20 2 4 5 
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Types of CMPs Identified in Case Studies 
 
Case Study Site, Qualifications of Prescriber and Controlled Drug Prescribing 
CMP types/scenarios identified 
in case studies (Yes or No) 
Used 
for 
named 
patient? 
Used 
by SP? 
Used by 
SP, IP? 
Used for 
controlled 
drugs? 
Patient 
agreement 
confirmed in 
CMP? 
1 
Mark 
SP 
IP 
 
2 
John 
SP 
3 
Anita 
SP 
IP 
4 
Jane 
SP 
5 
Sarah 
SP 
IP 
CD 
6 
Grace 
SP 
IP 
CD 
7 
Kim* 
SP 
IP 
8 
Lara 
SP 
IP 
CD 
9 
Natali
e 
SP 
IP 
10 
Debbi
e 
SP 
 
1 Generic, non-patient specific paper copy No No Yes No No Yes  Yes        
2 
Patient specific paper 
copy signed or agreed 
by doctor & prescriber 
prior to, or during 
consultation ^ 
Yes Yes No Yes Yes  Yes   Yes Yes  Yes Yes Yes Yes 
3 
Patient specific physical 
paper copy signed by 
doctor & prescriber after 
consultation 
Yes Yes No No Yes  Yes  Yes Yes      
4 
Generic electronic form 
agreed ^ by doctor and 
prescriber 
No but 
linked 
to 
patient 
record 
No Yes Yes Yes      Yes     
5 
CMP lost or not 
attached to electronic 
patient record 
      Yes         
 
 Not assessed as transgression in accordance with Department of Health guidelines (Department of Health 2005 paragraphs 55-60) 
 Assessed as transgression in accordance Department of Health guidelines (Department of Health 2005 paragraphs 55-60) 
* Qualified as an independent prescriber after case studies 
^ Some CMPs were physically signed, whilst others permitted electronic signature agreement and were attached to electronic notes 
SP Qualified as supplementary prescriber 
IP Qualified as independent prescriber 
CD Controlled drugs prescribed 
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Prescribing assessment form  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEWER INITIALS………  DATE  ……… PRESCRIPTION REFERENCE……….. 
________________________________________________________________________________________________ 
 
APPROPRIATENESS 
 
 
The indication for the drug is recorded and upheld in the BNF 
 
Yes  No        Not Applicable  
  
The reason for prescribing a drug of limited value is recorded and valid Yes  No        Not Applicable  
  
Compared with alternative treatments in the same therapeutic class, 
which are just as safe and effective, the drug prescribed is either one 
of the cheapest or a valid reason is given for using an alternative 
Yes  No        Not Applicable  
  
A generic product is prescribed if one is available Yes  No        Not Applicable  
  
If a potentially hazardous drug-drug combination is prescribed, the 
prescriber shows knowledge of the hazard 
Yes  No        Not Applicable  
  
If the total daily dose is outside the range stated in the BNF, the 
prescriber gives a valid reason 
Yes  No        Not Applicable  
  
If the dosing frequency is outside the range stated in the BNF, the 
prescriber gives a valid reason 
Yes  No        Not Applicable  
  
If the duration of treatment is outside the ranges stated in the BNF, the 
prescriber gives a valid reason 
Yes  No        Not Applicable  
 
________________________________________________________________________________________________ 
 
PRESCRIBING ERROR 
 
Using the following definition, do you believe a prescribing error occurred  Yes  No  
for this prescribed medicine? 
 
“A clinically meaningful prescribing error occurs when, as a result of a prescribing decision or prescription writing 
process, there is an unintentional significant (1) reduction in the probability of treatment being timely and effective or (2) 
increase in the risk of harm when compared with generally accepted practice”. 
________________________________________________________________________________________________ 
 
SUPPLEMENTARY PRESCRIBING VIOLATIONS 
 
Is there a valid clinical management plan (CMP) for this patient………………………………Yes  No  
 
Is the medicine prescribed and the dose/duration used included in the CMP……………….Yes  No  
. 
 100
 
 
Patient questionnaire 
 
 
Survey for patients about 
pharmacist supplementary 
prescribing 
 
 
Please answer as many of the questions as possible and return the questionnaire in the FREEPOST envelope. 
More information, including definitions to help you answer the questionnaire is on the study information sheet. 
 
 Agree Disagree Don’t know 
It was explained to me what having a pharmacist 
supplementary prescriber would involve c c c 
I am involved in decisions about the treatment I receive from 
my pharmacist supplementary prescriber c c c 
I have been given written information about having a 
pharmacist supplementary prescriber c c c 
I have a written plan for my treatment by the pharmacist 
supplementary prescriber c c c 
I was involved in designing my written plan for my treatment 
by the pharmacist supplementary prescriber c c c 
I understand my written plan for my treatment by the 
pharmacist supplementary prescriber c c c 
I signed my written plan for my treatment by the pharmacist 
supplementary prescriber c c c 
I gave my consent to being treated by a pharmacist 
supplementary prescriber c c c 
I have a good relationship with my pharmacist supplementary 
prescriber c c c 
I have confidence in my pharmacist supplementary prescriber c c c 
    
 Pharmacist Doctor 
I can get an appointment quicker with the … c c 
I have longer appointments with the … c c 
I receive better quality care from the … c c 
I receive safer care from the … c c 
I am monitored better by the … c c 
I am better informed about my treatment by the … c c 
My overall care is the responsibility of …  c c 
My prescriptions are written by …  c c 
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Thinking about the appointment that we observed today, please answer the following 
 
Did you receive a prescription? 
Yes No  
c c 
 
 
 
 Yes No    Yes No  
Did you want this 
prescription? c c 
 Did you want a 
prescription? c c 
Was any advice given to 
you about the prescription? c c 
 Was any 
information 
given to you? 
c c 
Was any other advice given 
to you? c c 
 Was any advice 
given to you? c c 
 
 
 
 Yes No  Don’t know 
Not 
applicable 
Did you receive all of the information that you required c c c c 
Did you receive all of the reassurance/support you 
required c c c c 
Did you feel that the pharmacist understood you c c c c 
If you received a prescription today, will you have it 
dispensed? c c c c 
If the pharmacist gave you any advice, will you act on this 
advice? c c c c 
Have you reported any problems with this medication to 
the pharmacist?  c c c c 
 
Questions about using your medicines 
Many people find a way of using their medicines that suits them. This may differ from the instructions on the 
label or from what their prescriber has said. We would like to ask you a few questions about how you use your 
medicines. Here are some ways in which people have said that they use their medicines. For each of the 
statements, please tick the box which best applies to you 
 Always Often Sometimes Rarely Never 
I forget to take them c c c c c 
I alter the dose c c c c c 
I stop taking them for a while c c c c c 
I decide to miss out a dose c c c c c 
I take less than instructed c c c c c 
MARS_5 RH2_022 Medication Adherence Report Scale _5 ©R Horne University of Brighton, 1999 
 
Now, we would like to ask you about the information you have received about your medicines. Please rate the 
information you have received about each of the following aspects of your medicines. If you use more than one 
medicine, please give your overall feeling about information you have received about all your medicines 
Information about your medicines Too 
much 
About right Too 
little 
None 
received 
None 
needed 
What your medicine is called c c c c c 
What your medicine is for c c c c c 
What it does c c c c c 
How it works c c c c c 
How long it will take to act c c c c c 
How you can tell if it is working c c c c c 
How long you will need to be on your 
medicine 
c c c c c 
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medicine 
How to use your medicine c c c c c 
How to get a further supply c c c c c 
Whether the medicine has any 
unwanted effects (side effects) c c c c c 
What are the risks of you getting side 
effects c c c c c 
What you should do if you experience 
unwanted side effects c c c c c 
Whether you can drink alcohol whilst 
taking this medicine c c c c c 
Whether the medicine interferes with 
other medicines c c c c c 
Whether the medication will make you 
feel drowsy c c c c c 
Whether the medication will affect your 
sex life c c c c c 
What you should do if you forget to 
take a dose c c c c c 
Satisfaction with Information About Medicines Scale (SIMS) (Horne 2001) 
 
What do you consider is the best thing about having a supplementary prescriber? 
………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………… 
 
Telephone Interviews 
We are hoping to undertake some telephone interviews with patients about their experience of supplementary 
prescribing. If you are interested in taking part in an interview then please supply your contact details below. A 
member of the research team will telephone you to discuss what participation will involve. If you supply your contact 
details this does not mean that you have to take part. You can withdraw from the study at any time. 
 
 Name  ……………………………………………………………………………………… 
 Telephone number…………………………………………………………………………………… 
 
